|
PROSPECTUS
|
|
Filed pursuant to Rule 424(b)(4)
|
|
|
|
Registration No. 333-282932
|
|
|
Per Ordinary Share and
Accompanying Ordinary Warrant |
Per Pre-Funded
Warrant and Accompanying Ordinary Warrant
|
Total
|
|||||||||
|
Public offering price
|
$
|
1.35
|
$
|
1.3499
|
$ |
4,999,843
|
||||||
|
Placement agent fees (1)
|
$
|
0.0945
|
$
|
0.0945
|
$ |
350,000
|
||||||
|
Proceeds to us, before expenses (2) (3)
|
$
|
1.2555
|
$
|
1.2554
|
$ |
4,649,843
|
||||||
| (1) |
We have agreed to pay the Placement Agent cash fee equal to 7.0% of the gross proceeds raised in this offering. We have also agreed to reimburse the Placement
Agent for certain of its offering-related expenses, including a management fee of 1.0% of the gross proceeds raised in this offering, to reimburse the Placement Agent for its non-accountable expenses in the amount of $25,000, for its
legal fees and expenses and other out-of-pocket expenses in an amount up to $100,000, and for its clearing expenses in the amount of up to $15,950. In addition, we have agreed to issue to the Placement Agent 259,259 warrants to purchase
259,259 number of ordinary shares, equal to 7% of the aggregate number of our ordinary shares and pre-funded warrants sold in this offering, at an exercise price equal to 125% of the public offering price of our ordinary shares. See “Plan of Distribution” for additional information and a description of the compensation payable to the Placement Agent.
|
| (2) |
We estimate the total expenses of this offering payable by us, excluding the placement agent fee, will be approximately $200,000. Because there is no minimum
number of securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, Placement Agent fees, and proceeds to us, if any, are not presently determinable and may be
substantially less than the total maximum offering amounts set forth above.
|
| (3) |
Does not include proceeds from the cash exercise of the pre-funded warrants or ordinary warrants, if any.
|
|
|
●
|
the ability to maintain the listing of our ordinary shares and our warrants on Nasdaq;
|
|
|
|
|
|
|
●
|
our future performance, including our projected timeline for regulatory approvals of its product candidates;
|
|
|
●
|
our market opportunity;
|
|
|
●
|
our strategy, future operations, financial position, projected costs, prospects and plans;
|
|
|
●
|
expectations regarding the time during which we will be an emerging growth company under the JOBS Act;
|
|
|
●
|
our ability to retain or recruit officers, key employees and directors;
|
|
|
●
|
the impact of the regulatory environment and complexities with compliance related to such environment;
|
|
|
●
|
expectations regarding future partnerships or other relationships with third parties; and
|
|
|
●
|
our future capital requirements and sources and uses of cash, including the our ability to obtain additional capital in the future.
|
|
●
|
we are a development-stage company and have a limited operating history on which to assess our business;
|
|
●
|
we have never generated any revenue from product sales and may never be profitable;
|
|
●
|
we will need to raise substantial additional funding, which may not be available on acceptable terms, or at all, and which will cause dilution to our shareholders;
|
|
●
|
the approach we are taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products;
|
|
●
|
we do not have experience producing our product candidates at commercial levels, currently have no marketing and sales organization, have an uncertain market receptiveness to
our product candidates, and are uncertain as to whether there will be insurance coverage and reimbursement for our potential products;
|
|
●
|
we may be unable to attract, develop and/or retain our key personnel or additional employees required for our development and future success;
|
|
●
|
we may issue additional ordinary shares or other equity securities without your approval, including: (a) up to $15,337,500 of ordinary shares issuable under the Ordinary
Share Purchase Agreement, dated August 13, 2024 and effective as of August 15, 2024, by and between the Company and White Lion Capital, LLC (“White Lion”) (the “White Lion Purchase Agreement” or “ELOC Agreement”), which established an
equity line of credit for the Company; (b) ordinary shares underlying 660,001 outstanding warrants; and (c) ordinary shares underlying convertible promissory notes that the Company has issued to (i) Moringa’s sponsor, Moringa Sponsor,
LP, a Cayman Islands exempted limited partnership (the “Sponsor” or “Moringa Sponsor”), in a principal amount of $3,433,000 (the “A&R Sponsor Promissory Note”), in amendment and restatement of all promissory notes previously issued
by Moringa to the Sponsor for funds borrowed between Moringa’s initial public offering and the completion of the Business Combination, and (ii) EarlyBird Capital, Inc. (“EarlyBird”), which served as the representative of the
underwriters for Moringa’s initial public offering, in an amount of $1,250,000 (the “EarlyBird Convertible Note”), each of which would dilute your ownership interest and may depress the market price of our ordinary shares; and
|
|
●
|
those additional factors described or incorporated by reference under the heading “Risk Factors” below.
|
|
|
Page
|
| 1 |
|
| 7 | |
| 43 |
|
| 44 |
|
| 45 |
|
| 46 |
|
| 46 |
|
| 59 |
|
| 75 |
|
| 104 |
|
| 110 |
|
| 121 |
|
| 124 |
|
| 127 |
|
| 133 |
|
| 135 |
|
| 143 |
|
| 146 |
|
| 146 |
|
| 147 |
|
|
Index to Financial Statements
|
F-1 |
|
●
|
We are a development-stage company and have a limited operating history on which to assess our business. The approach we are taking to discover
and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
|
|
●
|
We have never generated any revenue from product sales and may never be profitable.
|
|
●
|
We will need to raise substantial additional funding, which may not be available on acceptable terms, or at all, and which will cause dilution to our shareholders.
|
|
●
|
Our independent registered public accounting firm’s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a
“going concern.”.
|
|
●
|
The approach we are taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
|
|
●
|
We are heavily dependent on the success of our product candidates, which are in the early stages of preclinical or clinical development. We
cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.
|
|
●
|
The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we
are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
|
|
●
|
Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of preclinical activity or earlier studies may not be
predictive of future study results.
|
|
●
|
We may find it difficult to enroll patients in our clinical studies, which could delay or prevent clinical studies of our product candidates.
|
|
●
|
Our product candidates and the administration of our product candidates may cause undesirable side effects or have other properties that could
delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
|
|
●
|
Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.
|
|
●
|
We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.
|
|
●
|
We rely on third parties to conduct our preclinical and clinical studies, and to manufacture the raw materials and products that we use to
create our product candidates and to supply us with the medical devices used to administer such products, which entails regulatory and trade secrets-related risks.
|
|
●
|
We do not have experience producing our product candidates at commercial levels, currently have no marketing and sales organization, have an
uncertain market receptiveness to our product candidates, and is uncertain as to whether there will be insurance coverage and reimbursement for our potential products.
|
|
●
|
We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar,
more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.
|
|
●
|
If we are unable to obtain and maintain effective patent rights for our product candidates or any future product candidates, we may not be
able to compete effectively in our markets.
|
|
●
|
Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.
|
|
●
|
We may be unable to attract, develop and/or retain our key personnel or additional employees required for our development and future success.
|
|
●
|
Conditions in the Middle East and in Israel may harm our operations.
|
|
| ● |
If we fail to maintain compliance with Nasdaq’s continued listing requirements, our securities may be delisted from the Nasdaq Global Market.
|
|
|
|
●
|
This offering is being made on a best efforts basis and we may sell fewer than all of the securities offered hereby and may receive significantly less in net
proceeds from this offering, which will provide us only limited working capital.
|
|
|
●
|
Our management team will have immediate and broad discretion over the use of the net proceeds from this offering and may not use them effectively.
|
|
●
|
You will experience immediate dilution in the book value per share of the ordinary shares purchased in the offering.
|
|
| ● |
Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase
without the benefit of a securities purchase agreement.
|
|
| ● |
Ordinary shares representing a substantial percentage of our outstanding shares may be sold in this offering, which could cause the price of our ordinary shares to
decline.
|
|
| ● |
There is no public market for the warrants being offered or pre-funded warrants in this offering.
|
|
| ● |
The pre-funded warrants are speculative in nature.
|
|
|
●
|
The ordinary warrants may not have any value.
|
|
●
|
Holders of the pre-funded warrants and ordinary warrants offered hereby will have no rights as our ordinary shareholders with respect to the ordinary shares
underlying those warrants until such holders exercise their warrants and acquire our ordinary shares, except as otherwise provided in the ordinary warrants.
|
|
|
●
|
The price of our ordinary shares and our warrants may be volatile.
|
|
|
●
|
A substantial number of our ordinary shares may be issued pursuant to the White Lion Purchase Agreement and/or the conversion terms of the A&R Sponsor Promissory
Note and the EarlyBird Convertible Note, which could cause (i) substantial dilution and (ii) the market price of the ordinary shares to decline.
|
|
| ● |
We have no current plans to pay cash dividends on our ordinary shares for the foreseeable future.
|
|
| ● |
Our reverse share split may negatively impact the market for our ordinary shares.
|
|
Ordinary shares
|
2,145,998 ordinary shares.
|
|
|
Pre-funded warrants
|
We are also offering to those purchasers, if any, whose purchase of our ordinary shares in this
offering would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ordinary
shares immediately following the consummation of this offering, the opportunity, in lieu of purchasing ordinary shares, to purchase 1,557,705 pre-funded warrants to purchase up to 1,557,705 ordinary shares. Each
pre-funded warrant will be immediately exercisable for one ordinary share at any time at the option of the holder until such pre-funded warrant is exercised in full, provided that the holder will be prohibited from
exercising pre-funded warrants for ordinary shares if, as a result of such exercise, the holder, together with its affiliates and certain related parties, would own more than 4.99% (or, at the election of the purchaser,
9.99%) of the total number of ordinary shares then issued and outstanding. The purchase price of each pre-funded warrant is $1.3499 (which is equal to the public offering price per ordinary share and ordinary warrant to
be sold in this offering minus $0.0001, the exercise price per ordinary share of each pre-funded warrant). This offering also relates to the ordinary shares issuable upon exercise of any pre-funded warrants sold in this
offering. See “Description of the Securities Offered” for more information.
|
|
|
Warrants
|
3,703,703 ordinary warrants. Each ordinary share and each pre-funded warrant will be sold together with one ordinary warrant. Each ordinary warrant will have an
exercise price of $1.35 per share (which is equal to 100% of the public offering price per ordinary share to be sold in this offering), will be exercisable upon issuance and will expire on the fifth anniversary of the
issuance date. Because we will issue an ordinary warrant for each ordinary share and for each pre-funded warrant sold in this offering, the number of ordinary warrants sold in this offering will not change as a result
of a change in the mix of ordinary shares and pre-funded warrants sold. This offering also relates to the ordinary shares issuable upon exercise of any ordinary warrants sold in this offering. See “Description of the Securities Offered” for more information.
|
|
|
Ordinary shares outstanding prior to this offering
|
1,849,132 ordinary shares
|
|
|
Ordinary shares outstanding after this offering
|
|
3,995,130 ordinary shares (assuming no sale of any pre-funded warrants and no exercise of the ordinary warrants).
Assuming all the pre-funded warrants were immediately exercised, there would be 5,552,835 ordinary shares outstanding after this offering.
|
|
Use of proceeds
|
|
Assuming no exercise of the ordinary warrants in connection with this offering, we estimate the net proceeds of the offering will be approximately $4.26 million, after
deducting the placement agent fees and estimated offering expenses payable by us.
We currently intend to use the net proceeds from this offering to advance our pre-clinical clinical studies, and for general corporate purposes. Pending such uses, we
intend to invest the net proceeds in bank deposits. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, our management will have broad discretion in the application
of the net proceeds of this offering. See “Use of Proceeds” for additional information.
|
|
|
|
|
|
Risk factors
|
|
Before investing in our securities, you should carefully read and consider the information set forth in “Risk Factors” beginning on page 7.
|
|
|
|
|
|
Nasdaq ticker symbols
|
|
Our ordinary shares and warrants are listed on the Nasdaq under the symbols “SLXN” and “SLXNW”, respectively. There is no
established public trading market for the pre-funded warrants being offered and we do not expect a market to develop. Without an active trading market, the liquidity of those warrants will be limited. In addition, we do not
intend to list the pre-funded warrants or the ordinary warrants on The Nasdaq Global Market, any other national securities exchange or any other trading system.
|
| ● |
up to 660,001 ordinary shares underlying an equivalent number of outstanding warrants at an exercise price of $103.50 per share;
|
| ● |
1,769,588 ordinary shares issuable pursuant to the A&R Sponsor Promissory Note (based on the conversion of the entire
$3,433,000 principal amount of that note into ordinary shares at an assumed conversion price of $1.94 per share, the closing price of our ordinary shares on the Nasdaq on January 10, 2025);
|
| ● |
568,947 ordinary shares potentially issuable (to the extent repaid in shares) pursuant to the EarlyBird Convertible Note (based
on the conversion of the remaining outstanding principal amount of the $1,250,000 original principal amount of that note into ordinary shares at an assumed conversion price of $1.94 per share, the closing price of our
ordinary shares on the Nasdaq on January 10, 2025);
|
| ● |
90,269 ordinary shares issuable upon exercise of outstanding share options under our equity incentive plan, at a weighted average exercise price of $57.97; and
|
| ● |
63,953 ordinary shares reserved for future awards under our equity incentive plan;
|
| ● |
no exercise of the options, conversion of the notes, or settlement of the RSUs described above;
|
|
|
●
|
no sale of pre-funded warrants in this offering;
|
|
|
|
|
|
|
●
|
no exercise of the ordinary warrants and the placement agent warrants; and
|
|
|
|
|
|
|
●
|
the reverse share split effected on November 27, 2024
|
|
●
|
continue and expand our research and preclinical and clinical development of our product candidates;
|
|
●
|
initiate additional preclinical, toxicology, clinical, or other studies for our product candidates;
|
|
●
|
continue to improve our quality standards and change or add additional manufacturers or suppliers;
|
|
●
|
seek regulatory and marketing approvals for our product candidates that successfully complete clinical studies;
|
|
●
|
establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval;
|
|
●
|
seek to identify, assess, acquire, license, and/or develop other product candidates;
|
|
●
|
enter into license agreements;
|
|
●
|
seek to maintain, protect, and expand our intellectual property portfolio;
|
|
●
|
seek to attract and retain skilled personnel;
|
|
●
|
create additional infrastructure to support our operations as a public company and our product development and planned future commercialization
efforts; and
|
|
●
|
experience any delays or encounter issues with any of the above, including but not limited to failed studies, complex results, safety issues, or other
regulatory challenges that require longer follow-up of existing studies, additional major studies, or additional supportive studies in order to pursue marketing approval.
|
|
●
|
completing research and preclinical and toxicology and clinical development of our product candidates;
|
|
●
|
obtaining regulatory and marketing approvals for our product candidates, if and when we complete clinical studies;
|
|
●
|
developing a sustainable and scalable in-house manufacturing process, meeting all regulatory standards for approved product candidates, and in some
instances, establishing and maintaining supply and manufacturing relationships with third parties that can conduct the process and provide adequate (in amount and quality) products to support clinical development and the market demand
for product candidates, if approved;
|
|
●
|
launching and commercializing product candidates, if and when we obtain regulatory and marketing approval, either directly or with a collaborator or
distributor;
|
|
●
|
exposing, educating and training physicians to use our products;
|
|
●
|
obtaining market acceptance of our product candidates as viable treatment options;
|
|
●
|
addressing any competing technological and market developments;
|
|
●
|
identifying, assessing, acquiring and/or developing new product candidates;
|
|
●
|
negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;
|
|
●
|
maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and
|
|
●
|
attracting, hiring, and retaining qualified personnel.
|
|
●
|
the scope, rate of progress, results and cost of our clinical studies, preclinical testing, toxicology studies, and other related activities;
|
|
●
|
the cost of manufacturing clinical supplies, and establishing commercial supplies of our product candidates and any future products;
|
|
●
|
the number and characteristics of product candidates that we pursue;
|
|
●
|
the cost, timing, and outcomes of regulatory approvals;
|
|
●
|
the cost and timing of establishing sales, marketing, and distribution capabilities; and
|
|
●
|
the terms and timing of any collaborative, licensing, and other arrangements that we may establish.
|
|
●
|
the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies;
|
|
●
|
We may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate’s benefit to risk ratio for our
proposed indication is acceptable;
|
|
●
|
the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek
approval;
|
|
●
|
the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical studies;
|
|
●
|
the data collected from clinical studies of our product candidates may not be sufficient to support the submission of a new drug application (NDA) or a
biologics license application (BLA) or other submission or to obtain regulatory approval in the United States or elsewhere;
|
|
●
|
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities
of third-party manufacturers with which we contract for clinical and commercial supplies; and
|
|
●
|
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical
data insufficient for approval.
|
|
●
|
inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to
support the initiation of human clinical studies;
|
|
●
|
delays in reaching a consensus with regulatory agencies on study design;
|
|
●
|
delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites, the terms of which can
be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;
|
|
●
|
delays in obtaining required Institutional Review Board (IRB) or Ethics Committee approval at each clinical study site;
|
|
●
|
imposition of a clinical hold by regulatory agencies, after review of an investigational new drug (IND) application, or equivalent application, or an
inspection of our clinical study operations or study sites;
|
|
●
|
difficulty collaborating with patient groups and investigators;
|
|
●
|
failure by our CROs, other third parties, or us to adhere to clinical study requirements;
|
|
●
|
failure to perform in accordance with the FDA’s good clinical practices requirements or applicable regulatory guidelines in other countries;
|
|
●
|
occurrence of serious adverse events associated with the product candidate that are viewed to outweigh our potential benefits;
|
|
●
|
the cost of clinical studies of our drug candidates being greater than we anticipate;
|
|
●
|
clinical studies of our drug candidates producing negative or inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional
clinical studies or abandon drug development programs; and
|
|
●
|
failures associated with data interpretation, data management and data storage of such studies.
|
|
●
|
regulatory authorities may withdraw approvals of such product;
|
|
●
|
regulatory authorities may require additional warnings on the label;
|
|
●
|
We may be required to create a Risk Evaluation and Mitigation Strategy (REMS) plan or similar plan in other jurisdictions, which could include a
medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;
|
|
●
|
We could be sued and held liable for harm caused to patients; and
|
|
●
|
Our reputation may suffer.
|
|
●
|
issue warning letters;
|
|
●
|
impose civil or criminal penalties;
|
|
●
|
suspend or withdraw regulatory approval;
|
|
●
|
suspend any of our ongoing clinical studies;
|
|
●
|
refuse to approve pending applications or supplements to approved applications submitted by Silexion; or
|
|
●
|
seize or detain products, or require a product recall.
|
|
●
|
the process of manufacturing RNAi-drugs, drug substances, and RNAi-delivery vehicles, such as our product candidates, is extremely susceptible to
product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes for any of our product candidates could
result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product
candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination; and
|
|
●
|
the manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, natural
disasters, power failures, and numerous other factors.
|
|
●
|
the timing of our receipt of any marketing and commercialization approvals;
|
|
●
|
the terms of any approvals and the countries in which approvals are obtained;
|
|
●
|
the safety and efficacy of our product candidates;
|
|
●
|
the prevalence and severity of any adverse side effects associated with our product candidates;
|
|
●
|
limitations or warnings contained in any labeling approved by the FDA or other regulatory authorities;
|
|
●
|
relative convenience and ease of administration of our product candidates;
|
|
●
|
the willingness of patients to accept any new methods of administration;
|
|
●
|
the success of our physician education programs;
|
|
●
|
the availability of adequate government and third-party payor reimbursement;
|
|
●
|
the pricing of our products, particularly as compared to alternative treatments; and
|
|
●
|
availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those
treatments.
|
|
●
|
much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products;
|
|
●
|
more extensive experience in pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling
pharmaceutical products;
|
|
●
|
product candidates that are based on previously tested or accepted technologies;
|
|
●
|
products that have been approved or are in late stages of development; and
|
|
●
|
collaborative arrangements in our target markets with leading companies and research institutions.
|
|
●
|
the safety and effectiveness of our product;
|
|
●
|
the ease with which our product can be administered and the extent to which patients accept relatively new routes of administration;
|
|
●
|
the timing and scope of regulatory approvals for our product;
|
|
●
|
the availability and cost of manufacturing, marketing and sales capabilities;
|
|
●
|
price;
|
|
●
|
reimbursement coverage; and
|
|
●
|
patent position.
|
|
●
|
decreased demand for any approved product;
|
|
●
|
injury to our reputation;
|
|
●
|
withdrawal of clinical trial participants;
|
|
●
|
initiation of investigations by regulators;
|
|
●
|
costs to defend the related litigation;
|
|
●
|
a diversion of management’s time and our resources;
|
|
●
|
substantial monetary awards to trial participants or patients;
|
|
●
|
product recalls, withdrawals or labeling, marketing or promotional restrictions;
|
|
●
|
exhaustion of any available insurance and our capital resources and potential increase in our insurance premiums and/or retention amounts; and
|
|
●
|
the inability to commercialize any product candidate.
|
|
●
|
the potential disruption of our ongoing business;
|
|
●
|
the distraction of management away from the ongoing oversight of our existing business activities;
|
|
●
|
incurring additional indebtedness;
|
|
●
|
the anticipated benefits and cost savings of those transactions not being realized fully, or at all, or taking longer to realize than anticipated;
|
|
●
|
an increase in the scope and complexity of our operations; and
|
|
●
|
the loss or reduction of control over certain of our assets.
|
|
●
|
actual or anticipated fluctuations in our financial condition or results of operations;
|
|
●
|
variance in the projected timeline for regulatory approvals of our product candidates from expectations of securities analysts;
|
|
●
|
changes in laws or regulations applicable to our business;
|
|
●
|
announcements by us or our competitors of significant business developments;
|
|
●
|
significant data breaches, disruptions to or other incidents involving our company;
|
|
●
|
conditions or developments affecting the biotechnology industry;
|
|
●
|
future sales of New Silexion ordinary shares by us or our shareholders, as well as the anticipation of lock-up releases;
|
|
●
|
changes in senior management or key personnel;
|
|
●
|
the trading volume of our securities;
|
|
●
|
changes in the anticipated future size and growth rate of our markets;
|
|
●
|
publication of research reports or news stories about us, our competitors or our industry, or positive or negative recommendations or withdrawal of
research coverage by securities analysts;
|
|
●
|
general economic and market conditions; and
|
|
●
|
other events or factors, including those resulting from war, incidents of terrorism, global pandemics or responses to those events.
|
|
●
|
limit our flexibility in planning the payment of expenditures that arise in our clinical program and our business and operations generally;
|
|
●
|
increase our vulnerability to general adverse economic conditions that hinder our ability to obtain equity financings; and
|
|
●
|
place us at a competitive disadvantage compared to our competitors.
|
|
●
|
the interest rate payable under the EarlyBird Convertible Note could be increased, and EarlyBird, as the holder of the EarlyBird Convertible Note, could declare all outstanding
principal and interest to be due and payable; and/or
|
|
●
|
we could be forced into bankruptcy or liquidation.
|
| • |
on an actual basis;
|
| • |
on a pro forma basis after giving effect to the sale of an aggregate of 606,444 ordinary shares for gross proceeds of approximately $2.4 million under the
ELOC Agreement; and
|
| • |
on a pro forma as adjusted basis to give further effect to reflect the sale by us of all 2,145,998 ordinary shares and accompanying 2,145,998
ordinary warrants offered by means of this prospectus at the public offering price of $1.35 per ordinary share and accompanying ordinary warrant and 1,557,705 pre-funded warrants and accompanying 1,557,705 ordinary
warrants offered by means of this prospectus at the public offering price of $1.3499 per pre-funded warrant and accompanying ordinary warrant, after deducting the Placement Agent’s fees and estimated offering expenses
payable by us, and without giving effect to the exercise of the ordinary warrants and pre-funded warrants issued in this offering.
|
|
As of September 30, 2024
(unaudited)
|
||||||||||||
|
(U.S. dollars in thousands)
|
Actual
|
Pro Forma
|
Pro Forma As Adjusted
|
|||||||||
|
Cash and cash equivalents
|
$
|
1,973
|
$
|
4,407
|
$
|
8,662
|
||||||
|
|
||||||||||||
|
Shareholders’ equity:
|
||||||||||||
|
Ordinary shares par value $0.0009 per share; authorized 22,222,222; issued and outstanding 1,242,267 ordinary shares
(actual),1,848,711 ordinary shares (pro forma) and 3,994,709* ordinary shares (pro forma as adjusted)
|
1
|
2
|
4
|
|||||||||
|
Additional paid in capital
|
37,003
|
39,436
|
43,689
|
|||||||||
|
Accumulated deficit
|
(41,583
|
)
|
(41,583
|
)
|
(41,583
|
)
|
||||||
|
|
||||||||||||
|
Total shareholders’ equity
|
(4,579
|
)
|
(2,145
|
)
|
2,110
|
|||||||
| ● |
up to 660,001 ordinary shares underlying an equivalent number of outstanding warrants at an exercise price of $103.50 per share;
|
| ● |
1,769,588 ordinary shares issuable pursuant to the A&R Sponsor Promissory Note (based on the conversion of the entire $3,433,000
principal amount of that note into ordinary shares at an assumed conversion price of $1.94 per share, the closing price of our ordinary shares on the Nasdaq on January 10, 2025):
|
| ● |
568,947 ordinary shares potentially issuable (to the extent repaid in shares) pursuant to the EarlyBird Convertible Note (based on
the conversion of the remaining outstanding principal amount of the $1,250,000 original principal amount of that note into ordinary shares at an assumed conversion price of $1.94 per share, the closing price of our ordinary
shares on the Nasdaq on January 10, 2025);
|
| ● |
26,316 ordinary shares issuable upon exercise of outstanding share options under our equity incentive plan, at a weighted average exercise price of $57.97; and
|
| ● |
63,953 ordinary shares reserved for future awards under our equity incentive plan
|
|
Public offering price per ordinary share and accompanying ordinary warrant
|
$
|
1.35
|
||
|
Net tangible book value per share as of September 30, 2024
|
$
|
(3.69
|
)
|
|
|
Increase in net tangible book value per ordinary share attributable to the pro forma adjustments described above
|
$
|
2.53
|
||
|
Pro forma net tangible book value per ordinary share as of September 30, 2024
|
(1.16
|
)
|
||
|
Increase in pro forma net tangible book value per ordinary share attributable to this offering
|
1.54
|
|||
|
Pro forma as adjusted net tangible book value per share as of September 30, 2024 after giving effect to this offering
|
$
|
0.38
|
||
|
Dilution in net tangible book value per share to new investors in this offering
|
$
|
0.97
|
| ● |
up to 660,001 ordinary shares underlying an equivalent number of outstanding warrants at an exercise price of $103.5 per share;
|
| ● |
1,769,588 ordinary shares issuable pursuant to the A&R Sponsor Promissory Note (based on the conversion of the entire $3,433,000
principal amount of that note into ordinary shares at an assumed conversion price of $1.94 per share, the closing price of our ordinary shares on the Nasdaq on January 10, 2025);
|
| ● |
568,947 ordinary shares potentially issuable (to the extent repaid in shares) pursuant to the EarlyBird Convertible Note (based on
the conversion of the remaining outstanding principal amount of the $1,250,000 original principal amount of that note into ordinary shares at an assumed conversion price of $1.94 per share, the closing price of our ordinary
shares on the Nasdaq on January 10, 2025);
|
| ● |
26,316 ordinary shares issuable upon exercise of outstanding share options under our equity incentive plan, at a weighted average exercise price of $57.97; and
|
| ● |
63,953 ordinary shares reserved for future awards under our equity incentive plan.
|
|
●
|
Silexion’s shareholders holding approximately 61.55% of the outstanding voting interests in New Silexion upon the Closing of the Transactions;
|
|
●
|
Silexion’s senior management comprise the senior management of New Silexion;
|
|
●
|
the directors nominated by Silexion constitute the majority of the board of directors of New Silexion (five out of seven of the initial directors); and
|
|
●
|
Silexion’s operations comprise the ongoing operations of New Silexion.
|
|
●
|
the accompanying notes to the unaudited pro forma condensed combined financial statements;
|
|
●
|
the historical unaudited financial statements of Moringa as of and for the six-months period ended June 30, 2024 and the related notes included elsewhere in this prospectus;
|
|
●
|
the historical unaudited financial statements of New Silexion as of and for the nine-months period ended September 30, 2024 and the related notes included elsewhere in this
prospectus;
|
|
●
|
the historical audited financial statements of Moringa as of and for the year ended December 31, 2023 and the related notes included elsewhere in this prospectus;
|
|
●
|
the historical audited financial statements of New Silexion as of and for the year ended December 31, 2023 and the related notes included elsewhere in this prospectus;
|
|
●
|
the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Moringa’s annual report on Form 10-K
for the year ended December 31, 2023 and quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on April 1, 2024 and August 13, 2024, respectively (the “Moringa 2023 Form
10-K” and “Moringa Q2 Form 10-Q,” respectively), and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in this prospectus;
|
|
●
|
the other financial information relating to Moringa and New Silexion included in this prospectus; and
|
|
●
|
factors detailed under the section entitled “Risk Factors” in this prospectus.
|
|
|
Historical
|
Historical
|
Actual Redemption
|
||||||||||||||||
|
|
Moringa Acquisition
Corp (Period between January 1 and August 14, 2024)
|
New Silexion
|
Business Combination
Adjustments
|
|
Pro Forma Statement of Operations
|
||||||||||||||
|
Research and development expenses, net
|
$
|
—
|
$
|
4,944
|
A
|
$
|
(2,424
|
)
|
|
$
|
2,520
|
||||||||
|
|
|
||||||||||||||||||
|
General and administrative expenses
|
551
|
5,727
|
A
|
(3,438
|
)
|
2,449
|
|||||||||||||
|
|
—
|
—
|
B
|
75
|
|
||||||||||||||
|
|
—
|
—
|
C
|
(466
|
)
|
|
|||||||||||||
|
OPERATING LOSS
|
551
|
10,671
|
(6,253
|
)
|
4,969
|
||||||||||||||
|
Financial expenses (income), net
|
(155
|
)
|
4,092
|
D
|
(134
|
)
|
(740
|
)
|
|||||||||||
|
|
—
|
—
|
E
|
(4,783
|
)
|
|
|||||||||||||
|
|
F
|
123
|
|
||||||||||||||||
|
|
G
|
(337
|
)
|
|
|||||||||||||||
|
|
H
|
454
|
|
||||||||||||||||
|
Loss before income tax
|
396
|
14,763
|
(10,930
|
)
|
4,229
|
||||||||||||||
|
Tax on Income
|
—
|
9
|
—
|
9
|
|||||||||||||||
|
LOSS FOR THE PERIOD
|
$
|
396
|
$
|
14,772
|
$
|
(10,930
|
)
|
|
$
|
4,238
|
|||||||||
|
|
|
||||||||||||||||||
|
Attributable to:
|
|
||||||||||||||||||
|
Equity holders of the Company
|
—
|
14,696
|
I
|
76
|
4,238
|
||||||||||||||
|
Non-controlling interests
|
—
|
76
|
I
|
(76
|
)
|
—
|
|||||||||||||
|
|
|
||||||||||||||||||
|
PROFIT (LOSS) PER SHARE, BASIC AND DILUTED
|
|
||||||||||||||||||
|
Ordinary share subject to possible redemption
|
$
|
0.39
|
$
|
—
|
$
|
(0.39
|
)
|
|
$
|
—
|
|||||||||
|
Non-redeemable ordinary shares
|
$
|
(0.18
|
)
|
$
|
(50.43
|
)
|
$
|
46.85
|
|
$
|
(3.76
|
)
|
|||||||
|
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN
COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
|
|
||||||||||||||||||
|
Ordinary shares subject to possible redemption
|
87,722
|
—
|
(87,722
|
)
|
|
||||||||||||||
|
Non-redeemable ordinary shares
|
3,355,000
|
291,407
|
(2,519,042
|
)
|
J
|
1,127,365
|
|||||||||||||
|
|
Moringa Acquisition
Corp
|
New Silexion
|
Business Combination
Adjustments
|
|
Pro Forma Statement
of Operations
|
|||||||||||||||||
|
Research and development expenses, net
|
$
|
—
|
$
|
3,708
|
A |
$
|
2,424
|
|
$
|
6,132
|
||||||||||||
|
|
—
|
—
|
-
|
|
||||||||||||||||||
|
General and administrative expenses
|
1,122
|
973
|
A |
3,438
|
|
6,119
|
||||||||||||||||
|
|
—
|
—
|
-
|
|
||||||||||||||||||
|
|
—
|
—
|
B |
120
|
|
|||||||||||||||||
|
|
—
|
—
|
C |
466
|
|
|||||||||||||||||
|
|
—
|
—
|
-
|
|
||||||||||||||||||
|
OPERATING LOSS
|
1,122
|
4,681
|
6,448
|
|
12,251
|
|||||||||||||||||
|
Financial expenses (income), net
|
(1,385
|
)
|
395
|
D |
(86
|
)
|
|
6,047
|
||||||||||||||
|
|
E |
4,783
|
|
|||||||||||||||||||
|
|
F |
1,364
|
|
|||||||||||||||||||
|
|
G |
337
|
|
|||||||||||||||||||
|
|
H |
639
|
|
|||||||||||||||||||
|
Loss before income tax
|
(263
|
)
|
5,076
|
13,485
|
|
18,298
|
||||||||||||||||
|
Tax on Income
|
—
|
32
|
—
|
|
32
|
|||||||||||||||||
|
LOSS FOR THE PERIOD
|
$
|
(263
|
)
|
$
|
5,108
|
$
|
13,485
|
|
$
|
18,330
|
||||||||||||
|
|
|
|||||||||||||||||||||
|
Attributable to:
|
|
|||||||||||||||||||||
|
Equity holders of the Company
|
—
|
4,942
|
I |
166
|
|
18,330
|
||||||||||||||||
|
Non-controlling interests
|
—
|
166
|
I |
(166
|
)
|
|
—
|
|||||||||||||||
|
|
|
|||||||||||||||||||||
|
PROFIT (LOSS) PER SHARE, BASIC AND DILUTED
|
|
|||||||||||||||||||||
|
Ordinary share subject to possible redemption
|
$
|
0.51
|
$
|
—
|
$
|
(0.51
|
)
|
|
$
|
—
|
||||||||||||
|
Non-redeemable ordinary shares
|
$
|
(0.34
|
)
|
$
|
(44.23
|
)
|
$
|
28.30
|
|
$
|
(16.27
|
)
|
||||||||||
|
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
|
|
|||||||||||||||||||||
|
Ordinary shares subject to possible redemption
|
2,774,850
|
—
|
(2,774,850
|
)
|
|
—
|
||||||||||||||||
|
Non-redeemable ordinary shares
|
3,355,000
|
111,726
|
(2,340,293
|
)
|
J |
1,126,433
|
||||||||||||||||
|
●
|
Moringa Sponsor forfeited for retirement 1,308,000 of the Moringa founders shares held by it, while 1,567,000 of the Moringa founders shares were transferred to
non-affiliated third-party investors (including 316,750 founders shares to certain security holders) as Backstop Shares (as defined in the Business Combination Agreement);
|
|
●
|
New Silexion issued to the Moringa Sponsor the A&R Sponsor Promissory Note in an amount of $3,433,000, in replacement of all promissory notes that Moringa had issued to the
Moringa Sponsor for amounts owed by Moringa to the Moringa Sponsor prior to the Closing;
|
|
●
|
New Silexion, Moringa Sponsor, the investor in the PIPE financing (described below) and certain additional shareholders of New Silexion entered into an Amended
and Restated Registration Rights and Lock-Up Agreement granting them registration rights with respect to the ordinary shares of New Silexion issued to them; and
|
|
●
|
Guangzhou Sino-Israel Bio-Industry Investment Fund I (“GIBF”), a shareholder of Silexion, transferred its noncontrolling interest in
Silexion’s Chinese subsidiary, Silenseed (China) Ltd., directly to New Silexion, such that the subsidiary became a wholly-owned subsidiary of New Silexion, and was issued 203,971 ordinary shares of New Silexion as consideration for that
transfer (the “Chinese Subsidiary Transfer”) (in addition to the 16,817 New Silexion ordinary shares that GIBF received upon the accelerated vesting of RSUs granted to it).
|
|
●
|
the redemption of the 427,297 Moringa public shares described above;
|
|
●
|
the separation of each former Moringa unit into one Moringa Class A ordinary share and one-half of a Moringa warrant;
|
|
●
|
t1he Sponsor Founder Shares Forfeiture (as defined in the Business Combination Agreement) of 1,308,000 Moringa founders shares, and the transfer of the remaining 1,567,000 Moringa founders shares to
third parties (including 316,750 Moringa founders shares to certain securityholders) as Backstop Shares, which resulted in the issuance of 174,112 ordinary shares of New Silexion;
|
|
●
|
the issuance of 9,747 New Silexion ordinary shares in exchange for 87,722 Moringa public shares that remained outstanding immediately prior to the Closing (following the
redemptions described above);
|
|
●
|
the issuance of 42,223 New Silexion ordinary shares in exchange for 380,000 Moringa private shares;
|
|
●
|
the issuance of 11,112 New Silexion ordinary shares to EarlyBird in exchange for 100,000 Moringa representative shares;
|
|
●
|
the issuance by New Silexion to the Sponsor and/or its limited partners to whom the Sponsor distributed such shares of the 153,592 Sponsor Investment Shares
(as defined in the Business Combination Agreement);
|
|
●
|
the issuance of 22,223 New Silexion ordinary shares to Greenstar, L.P. in exchange for 200,000 Moringa shares that were purchased in the $2.0 million PIPE financing, as
described above;
|
|
●
|
the issuance of 446,835 New Silexion ordinary shares as the Silexion Merger Consideration (as defined in the Business Combination Agreement) to security
holders of Silexion;
|
|
●
|
the issuance of 203,971 New Silexion ordinary shares to GIBF in respect of the Chinese Subsidiary Transfer (in addition to 16,817 New Silexion ordinary shares issued to GIBF
upon the accelerated vesting of RSUs granted to it), as described above; and
|
|
●
|
the issuance of 4,370 New Silexion ordinary shares to a non-employee director of New Silexion upon acceleration of vesting, and settlement, of an equivalent number of New
Silexion RSUs granted to the director.
|
|
Equity Holders
|
Shares
|
Percentage of
Outstanding
Shares
|
||||||
|
Moringa Public Shareholders(1)
|
9,747
|
0.88
|
%
|
|||||
|
Silexion Shareholders(2)
|
694,491
|
62.46
|
%
|
|||||
|
Moringa Sponsor Shares(3)
|
187,798
|
16.89
|
%
|
|||||
|
Distributees of Sponsor Investment Shares
|
5,000
|
0.45
|
%
|
|||||
|
PIPE investor
|
22,223
|
2.00
|
%
|
|||||
|
Founders Shares/ Backstop Shares
|
174,112
|
15.66
|
%
|
|||||
|
EarlyBird(3)
|
14,127
|
1.27
|
%
|
|||||
|
Director receiving RSU grant upon Closing
|
4,370
|
0.39
|
%
|
|||||
|
Total
|
1,111,868
|
100
|
%
|
|||||
|
(1)
|
Excludes 638,889 public warrants held by Moringa’s public shareholders, which will be exercisable for New Silexion ordinary shares at an exercise price of
$103.50 per share beginning 30 days after the Closing of the Business Combination.
|
|
(2)
|
Includes all securities issuable to security holders of Silexion on a fully-diluted basis, including New Silexion ordinary shares, New Silexion warrants, New Silexion options
and New Silexion RSUs, and also includes 203,971 New Silexion ordinary shares issued directly to GIBF in respect of the Chinese Subsidiary Transfer, as well as 16,817 New Silexion ordinary shares issued to GIBF upon the accelerated
vesting of RSUs granted to it.
|
|
(3)
|
Excludes 21,112 private warrants held, in the aggregate, by the Moringa Sponsor and EarlyBird, which will be exercisable for New Silexion ordinary shares at
an exercise price of $103.50 per share beginning 30 days after the Closing of the Business Combination.
|
|
|
|
Moringa Acquisition Corp (Period between January 1 and August 14, 2024)
(Historical) |
|
|
|
|
|
|
|
|||||||
|
For the nine-months period ended September 30, 2024
|
|
Class A
subject to Possible Redemption |
|
|
Non-
redeemable Class A and Class B |
|
|
New Silexion
(Historical) |
|
|
Pro Forma
Combined (Actual Redemption) |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Weighted average shares outstanding – basic and diluted
|
|
|
87,722
|
|
|
|
3,355,000
|
|
|
|
291,407
|
|
|
|
1,127,365
|
|
|
Net profit (loss) per share – basic
|
|
$
|
0.39
|
|
|
$
|
(0.18
|
)
|
|
$
|
(50.43
|
)
|
|
$
|
(3.76
|
)
|
|
|
|
Moringa Acquisition Corp
(Historical) |
|
|
|
|
|
|
||||||||
|
For the year ended December 31, 2023
|
|
Class A
subject to Possible Redemption |
|
|
Non-
redeemable Class A and Class B |
|
|
New Silexion
(Historical) |
|
|
Pro Forma
Combined
(Actual Redemption) |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Weighted average shares outstanding – basic and diluted
|
|
|
2,774,850
|
|
|
|
3,355,000
|
|
|
|
111,726
|
|
|
|
1,126,433
|
|
|
Net profit (loss) per share – basic
|
|
$
|
0.51
|
|
|
$
|
(0.34
|
)
|
|
$
|
(44.23
|
)
|
|
$
|
(16.27
|
)
|
|
●
|
apply for Orphan Drug Designation in both the U.S. and EU for its SIL-204B product;
|
|
●
|
initiate a clinical trial powered for statistical significance with respect to SIL-204B;
|
|
●
|
initiate toxicological studies with respect to SIL-204B;
|
|
●
|
seek marketing approvals for SIL-204B in various territories;
|
|
●
|
maintain, expand and protect our intellectual property portfolio;
|
|
●
|
hire additional operational, clinical, quality control and scientific personnel;
|
|
●
|
add operational, financial and management information systems and personnel, including personnel to support our product development, any future commercialization efforts
and our prospective transition to a public company; and
|
|
●
|
invest in research and development and regulatory approval efforts in order to utilize our technology as a platform focused on the silencing of the KRAS oncogene using
RNA-interference therapeutics.
|
|
Nine-month period ended
September 30, |
||||||||
| 2024 |
2023
|
|||||||
|
(U.S. dollars, in thousands)
|
||||||||
|
Operating expenses:
|
||||||||
|
Research and development, net
|
$
|
4,944
|
$
|
2,451
|
||||
|
General and administrative
|
5,727
|
502
|
||||||
|
Total operating expenses
|
10,671
|
2,953
|
||||||
|
Operating loss
|
10,671
|
2,953
|
||||||
|
Financial expenses, net
|
4,092
|
449
|
||||||
|
Loss before income tax
|
14,763
|
3,402
|
||||||
|
Income tax
|
9
|
26
|
||||||
|
Net loss for the nine-month period
|
$
|
14,772
|
$
|
3,428
|
||||
|
|
Nine-month period ended
September 30, |
|||||||
|
|
2024
|
2023
|
||||||
|
|
(U.S. dollars, in thousands)
|
|||||||
|
Payroll and related expenses
|
$
|
928
|
$
|
729
|
||||
|
Share-based compensation expenses
|
2,424
|
57
|
||||||
|
Subcontractors and consultants
|
1,425
|
1,444
|
||||||
|
Materials
|
3
|
16
|
||||||
|
Rent and maintenance
|
106
|
124
|
||||||
|
Travel expenses
|
13
|
27
|
||||||
|
Other
|
45
|
54
|
||||||
|
Total research and development expenses
|
$
|
4,944
|
$
|
2,451
|
||||
|
|
|
Nine-month periods ended
September 30, |
|
|||||
|
|
|
2024
|
|
|
2023
|
|
||
|
|
|
(U.S. dollars, in thousands)
|
|
|||||
|
Payroll and related expenses
|
|
$
|
856
|
|
|
$
|
190
|
|
|
Share-based compensation expenses
|
|
|
3,438
|
|
|
|
39
|
|
|
Professional services
|
|
|
1,053
|
|
|
|
79
|
|
|
Depreciation
|
|
|
37
|
|
|
|
39
|
|
|
Rent and maintenance
|
|
|
90
|
|
|
|
67
|
|
|
Patent registration
|
|
|
25
|
|
|
|
18
|
|
|
Travel expenses
|
|
|
72
|
|
|
|
31
|
|
|
Other
|
|
|
156
|
|
|
|
39
|
|
|
Total general and administrative expenses
|
|
$
|
5,727
|
|
|
$
|
502
|
|
|
|
Three-month period ended
September 30, |
|||||||
|
|
2024
|
2023
|
||||||
|
Operating expenses:
|
(U.S. dollars, in thousands)
|
|||||||
|
Research and development, net
|
$
|
3,217
|
$
|
535
|
||||
|
General and administrative
|
4,819
|
196
|
||||||
|
Total operating expenses
|
8,036
|
731
|
||||||
|
Operating loss
|
8,036
|
731
|
||||||
|
Financial expenses, net
|
3,822
|
72
|
||||||
|
Loss before income tax
|
11,858
|
803
|
||||||
|
Income tax
|
2
|
6
|
||||||
|
Net loss for the three-month period
|
$
|
11,860
|
$
|
809
|
||||
|
|
Three-month period ended
September 30, |
|||||||
|
|
2024
|
2023
|
||||||
|
|
(U.S. dollars, in thousands)
|
|||||||
|
Payroll and related expenses
|
$
|
453
|
$
|
198
|
||||
|
Share-based compensation expenses
|
2,385
|
19
|
||||||
|
Subcontractors and consultants
|
297
|
236
|
||||||
|
Materials
|
-
|
-
|
||||||
|
Rent and maintenance
|
57
|
46
|
||||||
|
Travel expenses
|
-
|
-
|
||||||
|
Other
|
25
|
36
|
||||||
|
Total research and development expenses
|
$
|
3,217
|
$
|
535
|
||||
|
Three-month period ended
September 30, |
||||||||
| 2024 |
2023
|
|||||||
|
|
(U.S. dollars, in thousands)
|
|||||||
|
Payroll and related expenses
|
$
|
575
|
$
|
71
|
||||
|
Share-based compensation expenses
|
3,413
|
13
|
||||||
|
Professional services
|
605
|
51
|
||||||
|
Depreciation
|
22
|
10
|
||||||
|
Rent and maintenance
|
18
|
25
|
||||||
|
Patent registration
|
-
|
2
|
||||||
|
Travel expenses
|
56
|
15
|
||||||
|
Other
|
130
|
9
|
||||||
|
Total general and administrative expenses
|
$
|
4,819
|
$
|
196
|
||||
|
Comparison of Years ended December 31, 2023 and 2022
|
|
Years ended December 31,
|
||||||||
|
2023
|
2022
|
|||||||
|
Operating expenses:
|
||||||||
|
Research and development, net
|
$
|
3,708
|
$
|
3,226
|
||||
|
General and administrative
|
973
|
634
|
||||||
|
Total operating expenses
|
4,681
|
3,860
|
||||||
|
Operating loss
|
4,681
|
3,860
|
||||||
|
Financial expenses (income), net
|
395
|
(396
|
)
|
|||||
|
Loss before income tax
|
5,076
|
3,464
|
||||||
|
Income tax
|
32
|
24
|
||||||
|
Net loss for the year
|
$
|
5,108
|
$
|
3,488
|
||||
|
Research and Development Expenses
|
|
Years ended December 31,
|
||||||||
| 2023 | 2022 | |||||||
|
Payroll and related expenses
|
$
|
973
|
$
|
1,192
|
||||
|
Subcontractors and consultants
|
2,467
|
1,595
|
||||||
|
Materials
|
13
|
191
|
||||||
|
Rent and maintenance
|
160
|
175
|
||||||
|
Travel expenses
|
37
|
42
|
||||||
|
Other
|
58
|
31
|
||||||
|
Total research and development expenses
|
$
|
3,708
|
$
|
3,226
|
||||
|
Years ended December 31,
|
||||||||
|
2023
|
2022
|
|||||||
|
Payroll and related expenses
|
$
|
356
|
$
|
219
|
||||
|
Professional Services
|
386
|
197
|
||||||
|
Depreciation
|
45
|
57
|
||||||
|
Rent and maintenance
|
86
|
71
|
||||||
|
Patent registration
|
22
|
32
|
||||||
|
Travel expenses
|
31
|
—
|
||||||
|
Other
|
47
|
58
|
||||||
|
Total general and administrative expenses
|
$
|
973
|
$
|
634
|
||||
|
Financial expenses, net
|
|
Net loss
|
|
|
Nine-month period ended
September 30, |
|||||||
|
|
2024
|
2023
|
||||||
|
(U.S. dollars, in thousands)
|
||||||||
|
Cash and cash equivalents and restricted cash at beginning of the period
|
$
|
4,645
|
$
|
8,309
|
||||
|
Net cash used in operating activities
|
(5,470
|
)
|
(3,272
|
)
|
||||
|
Net cash provided by (used in) investing activities
|
(22
|
)
|
577
|
|||||
|
Net cash provided by financing activities
|
2,920
|
522
|
||||||
|
Net decrease in cash and cash equivalents and restricted cash
|
$
|
(2,572
|
)
|
$
|
(2,173
|
)
|
||
|
Translation adjustments on cash and cash equivalents and restricted cash
|
(50
|
)
|
(324
|
)
|
||||
|
Cash and cash equivalents and restricted cash at end of the period
|
$
|
2,023
|
$
|
5,812
|
||||
|
|
Three-month period ended
September 30, |
|||||||
|
|
2024
|
2023
|
||||||
|
(U.S. dollars, in thousands)
|
||||||||
|
Cash and cash equivalents and restricted cash at the beginning of the period
|
$
|
1,747
|
$
|
6,491
|
||||
|
Net cash used in operating activities
|
(2,653
|
)
|
(685
|
)
|
||||
|
Net cash provided by (used in) investing activities
|
(16
|
)
|
72
|
|||||
|
Net cash provided by financing activities
|
2,920
|
-
|
||||||
|
Net decrease in cash and cash equivalents and restricted cash
|
$
|
251
|
$
|
(613
|
)
|
|||
|
Translation adjustments on cash and cash equivalents and restricted cash
|
25
|
(66
|
)
|
|||||
|
Cash and cash equivalents and restricted cash at the end of the period
|
$
|
2,023
|
$
|
5,812
|
||||
|
|
Year ended December 31,
|
|||||||
|
|
2023
|
2022
|
||||||
|
Cash and cash equivalents and restricted cash at beginning of the period
|
$
|
8,309
|
$
|
10,083
|
||||
|
Net cash used in operating activities
|
(4,529
|
)
|
(3,335
|
)
|
||||
|
Net cash provided by (used in) investing activities
|
573
|
(524
|
)
|
|||||
|
Net cash provided by financing activities
|
522
|
2,752
|
||||||
|
Net decrease in cash and cash equivalents and restricted cash
|
$
|
(3,434
|
)
|
$
|
(1,107
|
)
|
||
|
Translation adjustments on cash and cash equivalents and restricted cash
|
(230
|
)
|
(667
|
)
|
||||
|
Cash and cash equivalents and restricted cash at the end of the period
|
$
|
4,645
|
$
|
8,309
|
||||
|
●
|
Material cost.
|
|
●
|
Regulatory pathway; and
|
|
●
|
Human clinical trial costs.
|
| ● |
significant dilution to the equity interests of our current shareholders;
|
| ● |
a deemed change of control of our company due to the issuance of a substantial number of ordinary shares, which may affect, among other things, our ability to use our net operating loss carry
forwards, if any, and could result in a change in the officers and directors of our company relative to our current officers and directors, to the extent any shareholders build up significant beneficial ownership from ordinary shares
issued pursuant to the ELOC;
|
| ● |
may have the effect of delaying or preventing a change of control of our company by diluting the share ownership or voting rights of a person seeking to obtain control; and
|
| ● |
may adversely affect prevailing market prices for our ordinary shares or warrants.
|
|
●
|
History of transactions in our preferred shares;
|
|
●
|
Probability of an IPO scenario (including de SPAC transaction);
|
|
●
|
Probability of other liquidation events;
|
|
|
|
|
|
|
●
|
Expected time to liquidation; and
|
|
●
|
Expected return on equity.
|
|
KRAS
G12x Mutation |
|
Cohort 1
Arm 2 (Control) |
|
Cohort 1
Arm 1 (Treatment) |
|
Cohort 1
% Arm 1 Tx |
|
Cohort 2
(Treatment) |
|
All
Treated % |
|
R
|
|
5/10
|
|
1/12
|
|
8
|
|
2/9
|
|
26 (8/31)
|
|
D
|
|
2/10
|
|
3/12
|
|
25
|
|
2/9
|
|
23 (7/31)
|
|
V
|
|
3/10
|
|
8/12
|
|
67
|
|
5/9
|
|
52 (16/31)
|
|
●
|
Advancing the clinical development of SIL-204B for the treatment of LAPC. Our Phase 2 trial with our first-generation siRNA product, Loder in LAPC patients acts as a validation of approach and foundation for our continued development efforts. As further described in “Future Development Plans”,
Silexion plans to initiate toxicology studies of SIL-204B in 2025 followed by the regulatory submission in late 2025 to initiate a Phase 2/3 trial of SIL-204B powered for statistical significance. At this time, Silexion is focused on
the further development of the core siRNA technology underlying the Loder and SIL-204B as well as the clinical development of SIL-204B as the most optimized version of the technology.
|
|
●
|
Leveraging our platform to other oncological indications harboring
the KRASG12D/V mutation.
|
|
●
|
Advancing SIL-204B to commercialization. We have assembled a
world class clinical advisory board for better understanding the market in the U.S. and EU.
|
|
●
|
Forming strategic alliances and collaborating with partners to augment our capabilities. We may pursue strategic alliances with other biopharmaceutical companies with well-established presences in the specialties we aim to target for our indications. This may include co-marketing, co-promotion,
and co-development relationships, or a partnership with a diagnostics company to help improve availability of rapid testing. We also intend to explore options to work with partners to augment the study and treatment of patients and
the impact of our product candidates, including medical professionals, healthcare professional networks, pharmacy benefit managers, insurance companies, and artificial intelligence companies.
|
|
●
|
completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the GLP regulations;
|
|
●
|
submission to the FDA of an investigational new drug application, or IND, Clinical Trial Application (CTA) for Europe which must become effective or approved before human
clinical studies may begin and must be updated on a regular basis;
|
|
●
|
approval by an independent institutional review board, or IRB, or ethics committee representing each clinical site before each clinical study may be initiated;
|
|
●
|
performance of adequate and well-controlled human clinical studies to establish the safety and efficacy of the product candidate for each proposed indication;
|
|
●
|
preparation of and submission to the FDA of a new drug application, or NDA, or biologics license application, or BLA, or for Europe a Marketing Authorization Application
(MAA) after completion of all pivotal clinical studies;
|
|
●
|
potential review of the product application by an FDA advisory committee, where appropriate and if applicable. In the EU, the Committee for Medicinal Products for Human Use
(CHMP) issues a scientific opinion to the European Commission which issues the marketing authorization;
|
|
●
|
a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;
|
|
●
|
satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities where the proposed product drug substance is produced to assess compliance with
cGMP; and
|
|
●
|
FDA review and approval of an NDA or BLA or marketing authorization in the European Union (EU) in all European Union Member States plus Norway, Iceland and Liechtenstein,
prior to any commercial marketing or sale of the drug in the United States. Note that if the centralized procedure is used, which is mandatory for all new anticancer products, a marketing authorization is issued centrally by the EU
commission, which is valid immediately in all member states of the EEA (EU plus Iceland, Norway, and Liechtenstein).
|
|
●
|
obtaining regulatory approval to commence a study;
|
|
●
|
reaching agreement with third-party clinical trial sites and their subsequent performance in conducting accurate and reliable studies on a timely basis;
|
|
●
|
obtaining institutional review board approval or an Ethics Committee approval to conduct a study at a prospective site;
|
|
●
|
recruiting patients to participate in a study; and
|
|
●
|
supply of the drug.
|
|
●
|
Phase 1. The drug is initially introduced into healthy human subjects and tested for
safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to
healthy volunteers, the initial human testing is often conducted in patients.
|
|
●
|
Phase 2. This phase involves trials in a limited patient population to identify
possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.
|
|
●
|
Phase 3. This phase involves trials undertaken to further evaluate dosage, clinical
efficacy and safety in an expanded patient population, often at geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for
product labeling.
|
|
●
|
Phase 4. In some cases, the FDA or the EMA may condition approval of an NDA or BLA
or MAA for a product candidate on the Sponsor’s agreement to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after approval to gain more information
about the drug. Such post-approval studies are typically referred to as Phase 4 clinical studies.
|
|
●
|
restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
|
|
●
|
fines, warning letters or holds on post-approval clinical studies;
|
|
●
|
refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;
|
|
●
|
injunctions or the imposition of civil or criminal penalties; or
|
|
●
|
product seizure or detention, or refusal to permit the import or export of products.
|
|
●
|
the required patent information has not been filed;
|
|
●
|
the listed patent has expired;
|
|
●
|
the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or
|
|
●
|
the listed patent is invalid, unenforceable or will not be infringed by the new product.
|
|
●
|
Decentralized procedure. Using the decentralized procedure, an applicant may apply
for simultaneous authorization in more than one European Union country of medicinal products that have not yet been authorized in any European Union country and that do not fall within the mandatory scope of the centralized procedure.
|
|
●
|
Mutual recognition procedure. In the mutual recognition procedure, a medicine is
first authorized in one European Union Member State, in accordance with the national procedures of that country. Following this, further marketing authorizations can be sought from other European Union countries in a procedure whereby
the countries concerned agree to recognize the validity of the original, national marketing authorization.
|
|
●
|
the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly
or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;
|
|
●
|
federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or
causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent;
|
|
●
|
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any
healthcare benefit program and making false statements relating to healthcare matters;
|
|
●
|
the federal transparency laws, including the federal Physician Payment Sunshine Act, that requires drug manufacturers to disclose payments and other transfers of value
provided to physicians and teaching hospitals;
|
|
●
|
HIPAA, as amended by HITECH and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually
identifiable health information; and
|
|
●
|
state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer,
including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus
complicating compliance efforts.
|
|
Name
|
|
Age
|
|
Position(s)
|
|
Directors
|
|
|
|
|
|
Ilan Hadar
|
|
55
|
|
Chairman and Chief Executive Officer
|
|
Dror J. Abramov
|
|
63
|
|
Director
|
|
Ruth Alon
|
|
72
|
|
Director
|
|
Ilan Levin
|
|
58
|
|
Director
|
|
Avner Lushi
|
|
57
|
|
Director
|
|
Shlomo Noy
|
|
71
|
|
Director
|
|
Amnon Peled
|
65 |
Director | ||
|
Executive Officers (who are not also directors)
|
|
|
|
|
|
Dr. Mitchell Shirvan
|
|
70
|
|
Chief Scientific and Development Officer
|
|
Mirit Horenshtein Hadar, CPA
|
|
40
|
|
EVP of Finance Affairs, Chief Financial Officer and Secretary
|
|
●
|
helping the New Silexion Board oversee our corporate accounting and financial reporting processes;
|
|
●
|
managing the selection, engagement, qualifications, independence, and performance of a qualified firm to serve as the independent registered public accounting firm to audit
our financial statements;
|
|
●
|
reviewing and discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent
accountants, our interim and year-end operating results;
|
|
●
|
obtaining and reviewing a report by the independent registered public accounting firm at least annually that describes our internal quality control procedures, any material
issues with such procedures and any steps taken to deal with such issues when required by applicable law;
|
|
●
|
establishing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;
|
|
●
|
overseeing our policies on risk assessment and risk management;
|
|
●
|
overseeing compliance with our code of business conduct and ethics;
|
|
●
|
reviewing related person transactions; and
|
|
●
|
approving or, as required, pre-approving audit and permissible non-audit services to be performed by the independent registered public accounting firm.
|
|
●
|
reviewing, approving and determining, or making recommendations to the New Silexion Board regarding the compensation of our chief executive officer, other executive officers
and senior management;
|
|
●
|
reviewing, evaluating and recommending to the New Silexion Board succession plans for our executive officers;
|
|
●
|
reviewing and recommending to the New Silexion Board the compensation paid to our non-employee directors;
|
|
●
|
administering our equity incentive plans and other benefit programs;
|
|
●
|
reviewing, adopting, amending and terminating incentive compensation and equity plans, severance agreements, profit sharing plans, bonus plans, change-of-control protections
and any other compensatory arrangements for our executive officers and other senior management; and
|
|
●
|
reviewing and establishing general policies relating to compensation and benefits of our employees, including our overall compensation philosophy.
|
|
●
|
identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by shareholders, to serve on the New Silexion
Board;
|
|
●
|
considering and making recommendations to the New Silexion Board regarding the composition and chairmanship of the committees of the New Silexion Board;
|
|
●
|
instituting plans or programs for the continuing education of the New Silexion Board and the orientation of new directors;
|
|
●
|
developing and making recommendations to the New Silexion Board regarding corporate governance guidelines and matters;
|
|
●
|
overseeing our corporate governance practices;
|
|
●
|
overseeing periodic evaluations of the New Silexion Board’s performance, including committees of the New Silexion Board; and
|
|
●
|
contributing to succession planning.
|
|
Name and Principal Position
|
Year
|
Base Gross
Salary ($)(1) |
Stock
Awards ($) |
All Other
Compensation ($)(1)(2) |
Total
($)(1) |
|||||||||||||
|
Ilan Hadar
Chief Executive Officer (formerly Managing Director of Silexion)(3) |
2024
|
240,560
|
1,192,785
|
107,283
|
1,540,628
|
|||||||||||||
|
2023
|
182,976
|
-
|
70,638
|
253,614
|
||||||||||||||
|
Mirit Horenshtein Hadar
Chief Financial Officer (formerly EVP Finance of Silexion)(4) |
2024
|
233,532
|
447,291
|
89,267
|
770,090
|
|||||||||||||
|
2023
|
26,238
|
-
|
-
|
26,238
|
||||||||||||||
|
Dr. Mitchell Shirvan
Chief Scientific and Development Officer(5) |
2024
|
190,286
|
1,043,699
|
67,505
|
1,301,490
|
|||||||||||||
|
2023
|
156,140
|
-
|
50,660
|
206,800
|
||||||||||||||
|
(1)
|
Amounts reported for the named executive officer and paid in New Israeli Shekels are converted from New Israeli Shekels to U.S. dollars using the 2024 and 2023 (as applicable) average exchange rates as
published by Bank of Israel of 3.699 and 3.689 New Israeli Shekels, respectively, to 1 U.S. Dollar.
|
|
(2)
|
The amounts in this column include payments for a leased car or car maintenance, contributions to a pension fund, compensation fund, and continuing education fund, or payments in lieu of a continuing
education fund.
|
|
(3)
|
This was for a part-time (75%) position prior to, and a full-time position following, completion of the Business Combination.
|
|
(4)
|
For 2023, Ms. Horenshtein Hadar’s compensation was for a period of 4.5 months during which she served as a part-time consultant in a Strategy & Corporate Finance Advisory capacity.
|
|
(5)
|
This was for a part-time (80%) position prior to, and a full-time position following, completion of the Business Combination.
|
|
Option awards
|
||||||||||||||||||||
|
Name
|
Number of securities underlying unexercised options
(#) exercisable |
Number of securities
underlying unexercised options (#) unexercisable |
Equity
incentive plan awards: Number of securities underlying unexercised unearned options (#) |
Option
exercise price ($) |
Option expiration date
|
|||||||||||||||
|
Ilan Hadar
Chief Executive Officer (formerly Managing Director of Silexion |
14,339
|
- | - |
60.51
|
24/03/2032
|
|||||||||||||||
|
Mirit Horenshtein Hadar
Chief Financial Officer (formerly EVP Finance of Silexion |
--
|
-
|
- |
-
|
-
|
|||||||||||||||
|
Dr. Mitchell Shirvan
Chief Scientific and Development Officer( |
7,170
|
- | - |
60.51
|
07/06/2032
|
|||||||||||||||
|
Name
|
Fees earned or paid in cash
($) |
Stock awards
($) |
Option awards
($) |
All other compensation
($) |
Total
($) |
|||||||||||||||
|
Ilan Hadar
|
See Summary Compensation Table above
|
See Summary Compensation Table above
|
See Summary Compensation Table above
|
See Summary Compensation Table above
|
See Summary Compensation Table above
|
|||||||||||||||
|
Dror Abramov
|
-
|
313,800
|
-
|
-
|
313,800
|
|||||||||||||||
|
Ruth Alon
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
|
Ilan Levin
|
-
|
-
|
-
|
45,000
|
45,000
|
|||||||||||||||
|
Avner Lushi
|
-
|
313,800
|
-
|
-
|
313,800
|
|||||||||||||||
|
Shlomo Noy
|
-
|
313,800
|
-
|
-
|
313,800
|
|||||||||||||||
|
Amnon Peled
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
|
Ilan Shiloah (former director)
|
-
|
313,800
|
-
|
-
|
313,800
|
|||||||||||||||
|
(a)
|
entitle a grantee to exercise an award, or to otherwise provide for the acceleration of such award’s vesting schedule, as to all or part of its underlying shares, including
with respect to awards that would not otherwise be exercisable or vested, under such terms and conditions as the Administrator shall determine, including the cancellation of all unexercised awards upon or immediately prior to the
closing of a transaction or as of such other date (the “Cut-Off Date”), and/or the termination of all awards (whether vested but un-exercised or un-vested) as of the relevant Cut-Off Date, as of
which they shall no longer be exercisable by the applicable grantees; and/or
|
|
(b)
|
provide for the cancellation of outstanding awards at or immediately prior to the closing of a transaction, and payment to the applicable grantee of a consideration
determined by the Administrator to be fair in the circumstances (whether in shares, cash, other securities, property, or any combination thereof), taking into account the value of each underlying share of any such award’s vested portion
as reflected by the terms of such transaction, and the exercise price of each such underlying share, and subject to such terms and conditions as determined by the Administrator.
|
|
|
●
|
The Share Pool will be reduced by one share for each share made subject to an award granted under the 2024 Plan;
|
|
|
|
|
|
|
●
|
The Share Pool will be increased by the number of unissued shares underlying or used as a reference measure for any award or portion of an award granted under the 2024 Plan
that is cancelled, forfeited, expired, terminated unearned or settled in cash, in any such case without the issuance of shares;
|
|
●
|
The Share Pool will be increased by the number of shares that are forfeited back or surrendered for no consideration to us after issuance due to a failure to meet an award
contingency or condition with respect to any award or portion of an award granted under the 2024 Plan;
|
|
●
|
The Share Pool shall be increased, on the exercise date, by the number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment
of the exercise price of any award granted under the 2024 Plan; and
|
|
●
|
The Share Pool shall be increased, on the relevant date, by the number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment
of any tax withholding obligation that arises in connection with any award granted under the 2024 Plan.
|
|
|
●
|
the aggregate number and kind of shares or other securities that may be granted to eligible individuals under the 2024 Plan;
|
|
|
●
|
the maximum number of shares or other securities that may be issued with respect to incentive share options granted under the 2024 Plan;
|
|
|
●
|
the number of shares or other securities covered by each outstanding award and the exercise price, base price or other price per share, if any, and other relevant terms of
each outstanding award; and
|
|
|
●
|
all other numerical limitations relating to awards, whether contained in the 2024 Plan or in award agreements.
|
|
●
|
the amounts involved exceeded or will exceed $120,000; and
|
|
●
|
any of our directors, executive officers or holders of more than 5% of our share capital, or any member of the immediate family of, or person sharing the household with, the
foregoing persons, had or will have a direct or indirect material interest.
|
|
●
|
Sponsor Investment Shares and securities held by former Silexion shareholders: (A) 50% of the Sponsor Investment Shares held by the Sponsor and its
distributees and 50% of the New Silexion securities held by the former Silexion shareholders who are party to the agreement, in each case, upon the Closing, are subject to a lock-up period ending on the earlier of (i) six (6)
months after the completion of the Business Combination, and (ii) the date on which New Silexion will consummate a liquidation, merger, amalgamation, share exchange, reorganization, or other similar transaction after the Business
Combination that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (B) the other 50% of the Sponsor Investment Shares held by the Sponsor and its
distributees and 50% of the our securities held by the former Silexion shareholders party to the agreement, in each case, upon the Closing, will be subject to a lock-up period that will end on the earliest of (x) six (6) months
after the date of the consummation of the Business Combination, (y) the date on which we consummate a liquidation, merger, amalgamation, share exchange, reorganization, or other similar transaction after the Business Combination
that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property, or (z) the date on which the closing price of our ordinary shares equals or exceeds $12.00 per
share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period.
|
|
●
|
Private Shares and Private Warrants: The lock-up period on all New Silexion ordinary
shares issued pursuant to the SPAC Merger in exchange for private placement shares and private placement warrants purchased by or issued to the Sponsor and EarlyBird concurrently with Moringa’s initial public offering will remain (as
provided in the documentation for Moringa’s initial public offering) 30 days after the Closing.
|
|
●
|
Representative Shares. The lock-up period on all Representative Shares (as defined in
the Amended and Restated Registration Rights and Lock-Up Agreement) that are held by EarlyBird will remain (as provided in the documentation for Moringa’s initial public offering) three months after the Closing.
|
|
●
|
Note Shares and PIPE Shares. Note Shares issued to the Sponsor upon conversion of
amounts due under the A&R Sponsor Promissory Note and PIPE Shares issued to the PIPE Investor will not be subject to any lock-up periods following the Closing.
|
|
●
|
each person who is the beneficial owner of more than 5% of the outstanding New Silexion ordinary shares;
|
|
●
|
our named executive officer and directors; and
|
|
●
|
all of our executive officers and directors as a group.
|
|
Name and Address of Beneficial Owner(1)
|
|
Number of Shares
Beneficially Owned
|
|
|
Approximate
Percentage of Outstanding
Ordinary Shares
|
|
||
|
Directors and Executive Officers of New Silexion:
|
|
|
|
|
|
|
||
|
Ilan Hadar
|
|
|
31,160
|
(2)
|
|
|
1.7
|
%
|
|
Dror Abramov
|
|
|
4,425
|
|
|
|
*
|
|
|
Ruth Alon
|
|
|
6,037
|
|
|
|
*
|
|
|
Ilan Levin(3)
|
|
|
229,624
|
(4)
|
|
|
12.3
|
%
|
|
Avner Lushi(5)
|
|
|
220,788
|
(6)
|
|
|
11.9
|
%
|
|
Shlomo Noy(7)
|
|
|
220,788
|
(6)
|
|
|
11.9
|
%
|
|
Amnon Peled
|
-
|
-
|
||||||
|
Dr. Mitchell Shirvan
|
|
|
21,888
|
(8)
|
|
|
1.2
|
%
|
|
Mirit Horenshtein Hadar, CPA
|
|
|
6,308
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
All executive officers and directors as a group (8 individuals)
|
|
|
520,230
|
|
|
|
27.5
|
%
|
|
Five Percent Holders:
|
|
|
|
|
|
|
|
|
|
Moringa Sponsor, LP and affiliated entities (3)
|
|
|
229,624
|
(4)
|
|
|
12.3
|
%
|
|
Guangzhou Sino-Israel Biotech Fund(9)
|
|
|
220,788
|
(6)
|
|
|
11.9
|
%
|
|
Wildcat Partner Holdings LP(10)
|
|
|
113,428
|
|
|
|
6.1
|
%
|
|
*
|
Less than 1%.
|
|
(1)
|
Unless otherwise noted, the business address of each beneficial owner listed in the above table is c/o Silexion Therapeutics Corp, 12 Abba Hillel Road, Ramat Gan, Israel
5250606.
|
|
(2)
|
Includes 14,339 New Silexion ordinary shares issuable upon exercise of options, at an exercise price of $60.48 per share, all of which are vested and currently exercisable.
|
|
|
|
|
(3)
|
The shares reported in this row are held of record by the Sponsor, Moringa Sponsor, LP, and/or by the PIPE Investor, Greenstar, L.P., each a Cayman Islands exempted limited
partnership, as described in footnote (4) below. Moringa Partners Ltd., an Israeli company that is wholly-owned by Mr. Ilan Levin, serves as the sole general partner of each of the Sponsor and the PIPE Investor. Mr. Levin, a director of
New Silexion, is the sole director of that general partner. As a result of his ownership of that general partner, Mr. Levin possesses sole voting and investment authority with respect to the shares indirectly held by the Sponsor and the
PIPE Investor. The limited partnership interests of the Sponsor and the PIPE Investor are held by various individuals and entities, including Mr. Levin. Mr. Levin disclaims beneficial ownership of the securities held by the Sponsor and
the PIPE Investor other than to the extent of his direct or indirect pecuniary interest in such securities. The address of each of the entities beneficially owning the shares that are reported in this row is c/o Moringa Acquisition
Corp, 250 Park Avenue, 7th floor, New York, NY 10177.
|
|
(4)
|
Consists of the total of: (i) 148,592 New Silexion ordinary shares issued to the Sponsor as Sponsor Investment Shares (as defined under the Business Combination
Agreement); (ii) 39,206 New Silexion ordinary shares issued to the Sponsor upon the Closing of the Business Combination due to the conversion, on a one-for-one basis, of the 352,857 Moringa private shares held by it; (iii) 19,603
New Silexion ordinary shares underlying New Silexion warrants issued to the Sponsor upon the Closing of the Business Combination due to the conversion, on a one-for-one basis, of the 176,429 Moringa private warrants held by the
Sponsor (which New Silexion warrants will be exercisable beginning 30 days after the Closing Date); and (iv) 22,223 New Silexion ordinary shares issued to Greenstar, L.P., the PIPE Investor, as PIPE Shares in respect of the PIPE
Financing. The foregoing beneficial ownership of New Silexion ordinary shares by the Sponsor does not include any Note Shares that may be issued to the Sponsor following the Closing upon conversion of amounts owed by New Silexion to
the Sponsor under the A&R Sponsor Promissory Note, as the potential number of Note Shares, and the timing of issuance of Note Shares, cannot be determined in advance.
|
|
(5)
|
The shares reported in this row consist entirely of New Silexion ordinary shares held of record by Guangzhou Sino-Israel Biotech Fund (“GIBF”),
with respect to which Mr. Lushi possesses shared voting and investment authority as a result of his serving as a Managing Partner and CEO of GIBF.
|
|
(6)
|
Includes 203,971 New Silexion ordinary shares issued to GIBF at the Closing in respect of its transfer of its noncontrolling interest in our Chinese subsidiary, Silenseed
(China) Ltd., to New Silexion pursuant to the Chinese Subsidiary Transfer.
|
|
(7)
|
The shares reported in this row consist entirely of New Silexion ordinary shares held of record by GIBF, with respect to which Mr. Noy possesses shared voting and investment
authority as a result of his serving as Chief Medical Officer of GIBF.
|
|
|
|
|
(8)
|
Includes 7,170 New Silexion ordinary shares issuable upon exercise of options, at an exercise price of $60.48 per share, all of which are vested and currently exercisable.
|
|
|
|
|
(9)
|
The address of this shareholder is 34 Ha’Barzel St., Tel-Aviv 6971052 Israel. Each of Avner Lushi and Shlomo Noy may be deemed to share voting and investment power over the
securities beneficially owned by GIBF.
|
|
(10)
|
The address of this shareholder is 301 Commerce Street, Suite 3150, Fort Worth, Texas 76102. Len Porter may be deemed to have sole voting and investment power over the
securities beneficially owned by Wildcat Partner Holdings LP.
|
|
●
|
the reported last sale price of the ordinary shares equals or exceeds $162.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations and
recapitalizations), for any 20 trading days within a 30 trading day period commencing after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders; and
|
|
●
|
a registration statement is then in effect with respect to the New Silexion ordinary shares underlying such warrants.
|
|
●
|
the U.S. Holder’s gain or excess distribution will be allocated ratably over the U.S. Holder’s holding period for our securities;
|
|
●
|
the amount allocated to the U.S. Holder’s taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the
period in the U.S. Holder’s holding period before the first day of our first taxable year in which we are a PFIC, will be taxed as ordinary income;
|
|
●
|
the amount allocated to other taxable years (or portions thereof) of the U.S. Holder and included in its holding period will be taxed at the highest
tax rate in effect for that year and applicable to the U.S. Holder without regard to the U.S. Holder’s other items of income and loss for such year; and
|
|
●
|
an additional amount equal to the interest charge generally applicable to underpayments of tax will be imposed on the U.S. Holder with respect to the
tax attributable to each such other taxable year of the U.S. Holder.
|
| • |
standard issuer representations and warranties on matters such as organization, qualification, authorization, no conflict, no governmental filings required, current in SEC filings, no
litigation, labor or other compliance issues, environmental, intellectual property and title matters and compliance with various laws such as the Foreign Corrupt Practices Act; and
|
| • |
covenants regarding matters such as registration of warrant shares, no integration with other offerings, no stockholder rights plans, no material nonpublic
information, use of proceeds, indemnification of purchasers, reservation and listing of shares of common stock, no subsequent equity sales for 60 days, subject to certain exceptions, and an agreement to not enter into variable rate
financings for one (1) year from closing, subject to certain exceptions.
|
|
|
Per Ordinary Share and
Accompanying Ordinary Warrant |
Per Pre-Funded
Warrant and Accompanying Ordinary Warrant
|
Total
|
|||||||||
|
Public offering price
|
$
|
1.35
|
$
|
1.3499
|
$ |
4,999,843
|
||||||
|
Placement agent fees
|
$
|
0.0945
|
$
|
0.0945
|
$ |
350,000
|
||||||
|
Proceeds to us, before expenses
|
$
|
1.2555
|
$
|
1.2554
|
$ |
4,649,843
|
||||||
INDEX TO FINANCIAL STATEMENTS
TABLE OF CONTENTS
MORINGA ACQUISITION CORP
| Page | ||
| Moringa Acquisition Corp Condensed Consolidated Financial Statements | ||
| Condensed Consolidated Balance Sheets | F-2 | |
| Condensed Consolidated Statements of Operations | F-3 | |
| Condensed Consolidated Statements of Changes in Capital Deficiency | F-4 | |
| Condensed Consolidated Statements of Cash Flows | F-5 | |
| Notes to the Condensed Consolidated Financial Statements | F-6 - F-21 |
|
| Moringa Acquisition Corp Audited Financial Statements | ||
| Report of Independent Registered Public Accounting Firm (PCAOB ID # 1309) | F-22 | |
| Balance Sheets | F-23 | |
| Statements of Operations | F-24 | |
| Statements of Changes in Capital Deficiency | F-25 | |
| Statements of Cash Flows | F-26 | |
| Notes to Financial Statements | F-27 - F-39 |
SILEXION THERAPEUTICS CORP
CONSOLIDATED FINANCIAL STATEMENTS
| Page | ||
| Silexion Therapeutics Corp Condensed Consolidated Financial Statements | ||
| Condensed Consolidated Balance Sheets (unaudited) | F-42 - F-44 |
|
| Condensed Consolidated Statements of Operations (unaudited) | F-45 | |
| Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency (unaudited) | F-46 - F-47 |
|
| Condensed Consolidated Statements of Cash Flows (unaudited) | F-48 -F-49 |
|
| Notes to Condensed Consolidated Financial Statements (unaudited) | F-50 - F64 |
| Silexion Therapeutics Corp Audited Financial Statements | ||
| Report of Independent Registered Public Accounting Firm | F-67 | |
| CONSOLIDATED FINANCIAL STATEMENTS: | ||
| Consolidated Balance Sheets | F-68 -F-69 |
|
| Consolidated Statements of Operations | F-70 | |
| Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency | F-71 | |
| Consolidated Statements of Cash Flows | F-72 - F-73 |
|
| Notes to Consolidated Financial Statements | F-74 |
F-1
MORINGA ACQUISITION CORP
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, | December 31, | |||||||||
| Note | 2024 | 2023 | ||||||||
| U.S. Dollars | ||||||||||
| Assets | ||||||||||
| ASSETS: | ||||||||||
| Cash and cash equivalents | 17,880 | 108,278 | ||||||||
| Investments held in Trust Account | 5,924,118 | 5,697,632 | ||||||||
| Prepaid expenses | 24,808 | 28,305 | ||||||||
| TOTAL ASSETS | 5,966,806 | 5,834,215 | ||||||||
| Liabilities and shares subject to possible redemption net of capital deficiency | ||||||||||
| LIABILITIES: | ||||||||||
| Accrued expenses | 55,191 | 115,560 | ||||||||
| Related party | 4 | 3,346,000 | 2,861,000 | |||||||
| Private warrant liability | 27,284 | 8,531 | ||||||||
| TOTAL LIABILITIES | 3,428,475 | 2,985,091 | ||||||||
| COMMITMENTS AND CONTINGENCIES | 5 |
-
|
-
|
|||||||
| CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION: 515,019 shares at redemption value of $11.50 and $11.06 as of June 30, 2024 and December 31, 2023, respectively | 5,924,118 | 5,697,632 | ||||||||
| CAPITAL DEFICIENCY: | 7 | |||||||||
| Class A Ordinary Shares, $0.0001 par value; 500,000,000 shares authorized, 3,354,999 issued and outstanding (excluding 515,019 shares subject to possible redemption) as of June 30, 2024 and December 31, 2023; | 336 | 336 | ||||||||
| Class B Ordinary Shares, $0.0001 par value; 50,000,000 shares authorized, 1 issued and outstanding as of June 30, 2024 and December 31, 2023; | * | * | ||||||||
| Preferred Shares, $0.0001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2024 and December 31, 2023. |
-
|
-
|
||||||||
| Accumulated deficit | (3,386,123 | ) | (2,848,844 | ) | ||||||
| TOTAL CAPITAL DEFICIENCY | (3,385,787 | ) | (2,848,508 | ) | ||||||
| TOTAL LIABILITIES AND SHARES SUBJECT TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY | 5,966,806 | 5,834,215 | ||||||||
| * | Less than one US dollar |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-2
MORINGA ACQUISITION CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Note | Six months ended June 30, |
Three months ended June 30, |
||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||||
| U.S. Dollars | U.S. Dollars | |||||||||||||||||
| Except share data | Except share data | |||||||||||||||||
| INTEREST EARNED ON INVESTMENTS HELD IN TRUST ACCOUNT | 149,236 | 1,063,043 | 75,305 | 318,002 | ||||||||||||||
| GENERAL AND ADMINISTRATIVE | (441,276 | ) | (592,201 | ) | (179,135 | ) | (155,472 | ) | ||||||||||
| CHANGE IN FAIR VALUE OF WARRANT LIABILITY | (18,753 | ) | 5,301 | (6,745 | ) | 418 | ||||||||||||
| NET PROFIT (LOSS) FOR THE PERIOD | (310,793 | ) | 476,143 | (110,575 | ) | 162,948 | ||||||||||||
| WEIGHTED AVERAGE NUMBER OF CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION | 8 | 515,019 | 5,015,185 | 515,019 | 2,589,567 | |||||||||||||
|
NET PROFIT PER CLASS A ORDINARY SHARE SUBJECT TO POSSIBLE REDEMPTION – BASIC AND DILUTED
|
0.32 | $ | 0.22 | 0.17 | $ | 0.19 | ||||||||||||
| WEIGHTED AVERAGE NUMBER OF NON-REDEEMABLE CLASS A AND CLASS B ORDINARY SHARES | 8 | 3,355,000 | 3,355,000 | 3,355,000 | 3,355,000 | |||||||||||||
|
NET LOSS PER NON-REDEEMABLE CLASS A AND CLASS B ORDINARY SHARES – BASIC AND DILUTED
|
(0.14 | ) | $ | (0.19 | ) | (0.06 | ) | $ | (0.10 | ) | ||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-3
MORINGA ACQUISITION CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY
| Class A ordinary shares |
Class B ordinary shares |
Total | ||||||||||||||||||||||
| Number of shares |
Par value | Number of shares |
Par value | Accumulated deficit |
capital deficiency | |||||||||||||||||||
| BALANCE AT December 31, 2022 | 480,000 | 48 | 2,875,000 | 288 | (1,203,097 | ) | (1,202,761 | ) | ||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of March 31, 2023 | (905,040 | ) | (905,040 | ) | ||||||||||||||||||||
| Net profit for the period | 313,195 | 313,195 | ||||||||||||||||||||||
| BALANCE AT March 31, 2023 | 480,000 | 48 | 2,875,000 | 288 | (1,794,942 | ) | (1,794,606 | ) | ||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of June 30, 2023 | (558,002 | ) | (558,002 | ) | ||||||||||||||||||||
| Net profit for the period | 162,948 | 162,948 | ||||||||||||||||||||||
| BALANCE AT June 30, 2023 | 480,000 | 48 | 2,875,000 | 288 | (2,189,996 | ) | (2,189,660 | ) | ||||||||||||||||
| BALANCE AT December 31, 2023 | 3,354,999 | 336 | 1 | * | (2,848,844 | ) | (2,848,508 | ) | ||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of March 31, 2024 | (112,558 | ) | (112,558 | ) | ||||||||||||||||||||
| Net loss for the period | (200,218 | ) | (200,218 | ) | ||||||||||||||||||||
| BALANCE AT March 31, 2024 | 3,354,999 | 336 | 1 | * | (3,161,620 | ) | (3,161,284 | ) | ||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of June 30, 2024 | (113,928 | ) | (113,928 | ) | ||||||||||||||||||||
| Net loss for the period | (110,575 | ) | (110,575 | ) | ||||||||||||||||||||
| BALANCE AT June 30, 2024 | 3,354,999 | 336 | 1 | * | (3,386,123 | ) | (3,385,787 | ) | ||||||||||||||||
| * | Less than one US dollar |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-4
MORINGA ACQUISITION CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Six months ended June 30, |
||||||||
| 2024 | 2023 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net profit (loss) for the period | (310,793 | ) | 476,143 | |||||
| Adjustments to reconcile net profit (loss) to net cash provided by (used in) operating activities: | ||||||||
| Change in the fair value of the private warrant liability | 18,753 | (5,301 | ) | |||||
| Changes in operating assets and liabilities: | ||||||||
| Decrease in prepaid expenses | 3,497 | 2,023 | ||||||
| Increase (decrease) in related party | (20,000 | ) | 30,000 | |||||
| Increase (decrease) in accrued expenses | (60,369 | ) | 14,993 | |||||
| Net cash provided by (used in) operating activities | (368,912 | ) | 517,858 | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Partial redemption of Class A ordinary shares subject to possible redemption |
-
|
(90,750,217 | ) | |||||
| Proceeds from promissory notes – related party | 505,000 | 920,000 | ||||||
| Net cash provided by (used in) financing activities | 505,000 | (89,830,217 | ) | |||||
| INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT | 136,088 | (89,312,359 | ) | |||||
| CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT BEGINNING OF PERIOD | 5,805,910 | 116,751,752 | ||||||
| CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT END OF PERIOD | 5,941,998 | 27,439,393 | ||||||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT: | ||||||||
| Cash and cash equivalents | 17,880 | 34,530 | ||||||
| Investments held in trust account | 5,924,118 | 27,404,863 | ||||||
| Total cash, cash equivalents and investments held in a trust account | 5,941,998 | 27,439,393 | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-5
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
| a. | Organization and General |
Moringa Acquisition Corp (hereafter – the Company) is a blank check company, incorporated on September 24, 2020 as a Cayman Islands exempted company, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination (hereafter – the Business Combination). The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).
The Company has selected December 31 as its fiscal year end.
| b. | Sponsor and Financing |
The Company’s sponsor is Moringa Sponsor, L.P., a Cayman exempted limited partnership (which is referred to herein, together with its wholly-owned subsidiary, Moringa Sponsor (US) LP, a Delaware limited partnership, as the “Sponsor”).
Refer to Note 7(a) for information regarding the aggregate withdrawals of approximately $113 million, due to partial redemptions.
| c. | The Trust Account |
The proceeds held in the Trust Account are invested in money market funds registered under the Investment Company Act and compliant with Rule 2a-7 thereof that maintain a stable net asset value of $1.00.
The Company complies with the provisions of ASU 2016-18, under which changes in Investments held in the Trust Account are accounted for as Changes in Cash, Cash Equivalents and Investments Held in a Trust Account in the Company’s Statements of Cash Flows.
Refer to Note 4(a) for information regarding proceeds received from the Sponsor under the Sixth and Eighth Promissory Notes, deposited into the Trust Account.
F-6
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (continued):
| d. | Initial Business Combination |
The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds of the Public Offering and the Private Placement are intended to be generally applied toward consummating an initial Business Combination. The initial Business Combination must occur with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding taxes payable on the income accrued in the Trust Account). There is no assurance that the Company will be able to successfully consummate an initial Business Combination.
The Company, after signing a definitive agreement for an Initial Business Combination, will provide its public shareholders the opportunity to redeem all or a portion of their shares upon the completion of the initial Business Combination, either (i) in connection with a shareholder meeting called to approve the business combination or (ii) by means of a tender offer.
If the Company holds a shareholder vote or there is a tender offer for shares in connection with an initial Business Combination, a public shareholder will have the right to redeem its shares for an amount in cash equal to its pro rata share of the aggregate amount then on deposit in the Trust Account, calculated as of two days prior to the general meeting or commencement of the Company’s tender offer, including interest but less taxes payable. As a result, the Company’s Public Class A ordinary shares are classified as temporary equity upon the completion of the Public Offering, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity.”
Pursuant to the Company’s amended and restated memorandum and articles of association, as amended, if the Company is unable to complete the initial Business Combination within 42 months from the Closing of the Public Offering, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable, and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
The Sponsor and the Company’s officers and directors have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to any Class B ordinary share (as described in Note 7) held by them if the Company fails to complete the initial Business Combination within 24 months of the Closing of the Public Offering or during any extended time that the Company has to consummate an initial Business Combination beyond 24 months as a result of a shareholder vote to amend its amended and restated memorandum and articles of association. However, if the Sponsor or any of the Company’s directors or officers acquire any Class A ordinary shares, they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete the Initial Business Combination within the prescribed time period.
F-7
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (continued):
In the event of a liquidation, dissolution or winding up of the Company after an initial Business Combination, the Company’s shareholders are entitled to share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of stock, if any, having preference over the ordinary shares. The Company’s shareholders have no preemptive or other subscription rights. There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide its shareholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account, under the circumstances, and, subject to the limitations, described herein.
On February 9, 2023 the Company held an extraordinary general meeting in lieu of the 2022 annual general meeting of the Company (hereafter – the First Extension Meeting). At the First Extension Meeting, the Company’s shareholders approved the proposal to adopt, by way of special resolution, an amendment to the Amended and Restated Articles to extend the date by which the Company has to consummate a business combination from the 24 month anniversary of the Closing of the Public Offering – i.e., February 19, 2023 to August 19, 2023 (hereafter – the Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.
On August 18, 2023 the Company held an extraordinary general meeting in lieu of the 2023 annual general meeting of the Company (hereafter – the Second Extension Meeting). At the Second Extension Meeting, the Company’s shareholders approved, among other proposals, an amendment to the Amended and Restated Memorandum and Articles of Association to further extend the date by which the Company has to consummate a business combination from the Extended Mandatory Liquidation Date to August 19, 2024 (hereafter – the Second Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.
Refer to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions, and for information regarding the conversion of Class B ordinary shares into Class A ordinary shares, following the Second Extension Meeting.
| e. | Substantial Doubt about the Company’s Ability to Continue as a Going Concern |
As of June 30, 2024, the Company had approximately $18 thousand of cash and an accumulated deficit of $3,386 thousand. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standard Codification 205-40, “Going Concern”, the Company will need to obtain additional funds in order to satisfy its liquidity needs in its current endeavors to consummate the Proposed Silexion Merger, as detailed in Note 1(f), or a different Initial Business Combination, if the former does not occur.
F-8
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (continued):
Since its inception date and through the issuance date of these unaudited condensed consolidated financial statements, the Company’s liquidity needs were satisfied through an initial capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor promissory notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and future promissory notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following the Second Extension Meeting, the Company has until August 19, 2024 to consummate an Initial Business Combination. If a business combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can be no assurance that the Company will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation Date, nor will it be able to raise sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt about the Company’s ability to continue as a going concern, for the subsequent twelve months following the issuance date of these unaudited condensed consolidated financial statements.
In February 2024, the Company entered into a Business Combination Agreement with Silexion Therapeutics Ltd. (hereafter – Silexion), an Israeli company which is in its developmental stage, dedicated to the development of innovative treatments for pancreatic cancer. Refer to Note 1(f) for further information regarding the Proposed Silexion Merger.
No adjustments have been made to the carrying amounts of assets or liabilities should the company fail to obtain financial support in its pursuit to consummate an Initial Business Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation Date.
| f. | Proposed Business Combination |
On February 21, 2024, the Company, together with its wholly-owned Israeli subsidiary April M.G. Ltd. – which was incorporated due to the original business combination structure, entered into a business combination agreement with Silexion (hereafter – the Proposed Silexion Merger).
The Proposed Silexion Merger is expected to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the Business Combination Agreement, including the approval of the business combination by Silexion’s and the Company’s shareholders, as well as Nasdaq’s approval of the initial listing of the combined company’s securities.
The Proposed Silexion Merger have been unanimously approved by the boards of directors of the Company and Silexion.
On April 3, 2024, the Proposed Silexion Merger contemplated under the original Proposed Silexion Merger agreement was restructured pursuant to the Business Combination Agreement, by and among New Pubco (a newly formed Cayman Islands exempted company), its two newly-formed subsidiaries – Merger Sub 1 and Merger Sub 2 – the Company and Silexion.
F-9
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (continued):
As contemplated under the Business Combination Agreement, Merger Sub 2 will merge with and into the Company, with the Company continuing as the surviving company and a wholly-owned subsidiary of New Pubco, and Merger Sub 1 will merge with and into Silexion, with Silexion continuing as the surviving company and a wholly-owned subsidiary of New Pubco. The shareholders and other equity holders of each of the Company and Silexion will receive corresponding securities of New Pubco as consideration in the Prospective Business Combination at set ratios in exchange for their securities of Company and Silexion, respectively. New Pubco will serve as the public company upon completion of the Proposed Business Combination, with its ordinary shares and warrants listed for trading on Nasdaq.
The foregoing description of the Proposed Business Combination, as amended, does not purport to be complete. For further information and access to the full agreement and all other related agreements, refer to the Company’s Current Report on Form 8-K filed with the SEC on April 3, 2024.
In connection with the Proposed Silexion Merger, on May 9, 2024, New Pubco filed with the SEC a Registration Statement on Form S-4, and has subsequently filed amendments on June 24, 2024, July 7, 2024 and July 12, 2024, that include a document that will serve as both a prospectus for the securities to be issued by New Pubco in the Prospective Business Combination to security holders of the Company and Silexion, as well as a proxy statement of the Company for the Company’s extraordinary general meeting at which the Prospective Business Combination and the Business Combination Agreement (among other matters) was presented for approval (see note 9). The SEC staff declared the New Pubco Registration Statement effective on July 16, 2024.
| g. | Impact of War in Israel |
Israel’s current war against the terrorist organization Hamas continued to rage during the second quarter of 2024. The intensity and duration of the war has varied since it began on October 7, 2023. Up to the balance sheet date and subsequently, the war has not had a material effect on the Company. However, the war may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company’s ability to effectively complete the Proposed Business Combination.
F-10
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:
| a. | Basis of Presentation |
The condensed consolidated financial statements herein are unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in the opinion of the management, necessary for a fair statement of results for the interim period. The results of the operation for the six and three-month periods ended June 30, 2024, are not necessarily indicative of the results to be expected for the full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements for the year ended December 31, 2023 as filed on April 1, 2024, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S. GAAP”). These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto of Moringa Acquisition Corp.
| b. | Emerging Growth Company |
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company’s unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible, because of the potential differences in accounting standards used.
F-11
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| c. | Cash and cash equivalents |
The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use by nature of the account and are readily convertible to known amounts of cash.
| d. | Class A Ordinary Shares subject to possible redemption |
As discussed in Note 1, all of the 11,500,000 shares of Class A ordinary shares sold as parts of the Units in the Public Offering contain a redemption feature. In accordance with the Accounting Standards Codification 480-10-S99-3A “Classification and Measurement of Redeemable Securities”, redemption provisions not solely within the control of the Company require the security to be classified outside of permanent equity. The Company has classified all of the shares sold under the Public Units as subject to possible redemption.
Refer to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions. Also, refer to Note 9(c) regarding an additional redemption after the balance sheet date.
| e. | Net profit (loss) per share |
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share. Net profit (loss) per share is computed by dividing net profit (loss) by the weighted average number of shares outstanding during the period. The Company applies the two-class method in calculating net profit (loss) per each class of shares: the non-redeemable shares, which include the Private Class A Ordinary Shares, as defined in Note 7, and the Class B ordinary shares (hereafter and collectively – Non-Redeemable class A and B ordinary shares); and the Class A ordinary shares subject to possible redemption.
In order to determine the net profit (loss) attributable to each class, the Company first considered the total profit (loss) allocable to both sets of shares. This is calculated using the total net profit (loss) less any interest earned on investments held in trust account. Then, the accretion is fully allocated to the Class A ordinary shares subject to redemption.
| f. | Concentration of credit risk |
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. From the Company’s incorporation and through June 30, 2024, the Company has not experienced any losses on these accounts.
As of June 30, 2024, the Company held its cash and cash equivalents in an SVB bank account, and its investments Held in Trust Account in Goldman Sachs money market funds. Money market funds are characterized as Level 1 investments within the fair value hierarchy under ASC 820.
F-12
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| g. | Public Warrants |
The Company applied the provisions of ASC 815-40 and classified its public warrants, issued as part of the Public Units as detailed in Note 3, as equity securities.
| h. | Private Warrant liability |
The Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 (“ASC 815”), “Derivatives and Hedging”, under which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company classifies the private warrants as liabilities at their fair value and adjusts the private warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the private warrants are exercised or expire, and any change in fair value is recognized in the Company’s statements of operations. Refer to Note 6 for information regarding the model used to estimate the fair value of the Private Warrants (as defined in Note 3).
| i. | Financial instruments |
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures”, approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.
| j. | Use of estimates in the preparation of financial statements |
The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company’s financial statements.
| m. | Income tax |
The Company accounts for income taxes in accordance with ASC 740, “Income Taxes (hereafter – ASC 740). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015-17.
F-13
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| n. | Recent accounting pronouncements |
Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted would have a material effect on the Company’s financial statements.
NOTE 3 - PUBLIC OFFERING AND PRIVATE PLACEMENTS:
In the Initial Public Offering, the Company issued and sold 11,500,000 units (including 1,500,000 units sold at a second closing pursuant to the underwriters’ exercise of their over-allotment option in full) at an offering price of $10.00 per unit (hereafter – the Units). The Sponsor and EarlyBirdCapital, Inc. (the representative of the underwriters) purchased, in a private placement that occurred simultaneously with the two closings of the initial Public Offering (hereafter – the Private Placement), an aggregate of 352,857 and 27,143 Units, respectively, at a price of $10.00 per Unit.
Once the Public Warrants become exercisable, the Company may redeem them in whole and not in part at a price of $0.01 per Warrant upon a minimum of 30 days’ prior written notice of redemption, if and only if the last reported sale price of the Company’s Class A ordinary shares equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the Public Warrant holders.
The Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc. or their respective affiliates: (1) will not be redeemable by the Company; (2) may not (including the Class A ordinary shares issuable upon exercise thereof), subject to certain limited exceptions, be transferred, assigned or sold by the holders thereof until 30 days after the completion of the Company’s Initial Business Combination; (3) may be exercised by the holders thereof on a cashless basis; and (4) they (including the Class A ordinary shares issuable upon exercise thereof) are entitled to registration rights.
The Company paid an underwriting commission of 2.0% of the gross proceeds of the Public Offering and the full exercise of the underwriters’ over-allotment, or $2,300,000, in the aggregate, to the underwriters at the two closings of the Public Offering. Refer to Notes 5(a) and 9(a) for more information regarding an additional fee payable to the underwriters upon the consummation of an Initial Business Combination, and an amendment to the agreement.
F-14
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 4 - RELATED PARTY TRANSACTIONS:
| a. | Promissory Notes |
The Company has issued several promissory note agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational needs or preparations towards an Initial Business Combination. All outstanding promissory notes bear no interest and are repayable in full upon the earlier of (a) the date of the consummation of the Company’s Initial Business Combination, or (b) Second Extended Mandatory Liquidation Date (hereafter and collectively – the Maturity Date).
Second to Fifth Promissory Notes
On August 9, 2021 the Company issued its Second Promissory Note to the Sponsor, according to which the former may withdraw up to $1 million – which has been withdrawn in full in several installments up until June 2022.
In December 2022 the Company issued its Third and Fourth Promissory Notes, according to which the Company may withdraw up to an aggregate amount of $190 thousand – which were withdrawn in full on the same month.
On February 8, 2023 the Company issued its Fifth Promissory Note to the Sponsor, in an amount of up to $310 thousand, which were withdrawn in full in several installments between February and June 2023.
According to the terms of the outstanding Second, Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $1.5 million, the Sponsor may elect to convert any portion of the amounts outstanding into private warrants to purchase Class A ordinary shares at a conversion price of $1 per private warrant on the Maturity Date. Such private warrants will have an exercise price of $11.5 and shall be identical to the private warrants included in the private units.
Sixth Promissory Note
On February 9, 2023 the Company issued its Sixth Promissory Note to the Sponsor, in an amount of $480 thousand – under which the funds that were loaned by the Sponsor were deposited into the Company’s Trust Account, in connection with the First Extension. The Sponsor provided six monthly injections of $80 thousand into the Company’s Trust Account under the Sixth Promissory Note, starting February 19, 2023.
Seventh Promissory Note
On June 14, 2023 the Company issued its Seventh Promissory Note to the Sponsor in an amount of up to $1 million, which were withdrawn in full in several installments between June 2023 and March 2024.
F-15
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 4 - RELATED PARTY TRANSACTIONS (continued):
Eighth Promissory Note
On August 18, 2023 the Company issued its Eighth Promissory Note to the Sponsor, in an amount of approximately $154 thousand – under which the funds that were loaned by the Sponsor were deposited into the Company’s Trust Account, in connection with the Second Extension. The Sponsor shall make monthly injections of approximately $13 thousand into the Company’s Trust Account, starting August 19, 2023 and up until the earlier of the Second Extended Mandatory Liquidation Date (or such earlier date that the Board determines to liquidate the Company) or the date on which an Initial Business Combination is completed. During the six months ended June 30, 2024, approximately $77 thousand have been injected into the trust account in six monthly installments.
Ninth Promissory Note
On March 27, 2024, the Company issued its Ninth Promissory Note, according to which the Company may withdraw up to an aggregate amount of $180 thousand. As of June 30, 2024 the Ninth Promissory Note has been fully withdrawn.
Tenth Promissory Note
On June 27, 2024, the Company issued its Tenth Promissory Note, according to which the Company may withdraw up to an aggregate amount of $250 thousand. The Company has made partial withdrawals in June and July 2024.
A&R Promissory Note
Upon the closing of the proposed business combination, and according to the terms of the amended Silexion Business Combination agreement, all promissory notes shall be converted into one sponsor promissory note – the A&R Sponsor Promissory Note, which will be subject to a cap of (i) $5.5 million, minus (ii) any fee that may be paid or owed under the amended Business Marketing Agreement (See Notes 5(a) and 9(a)). Any outstanding amount loaned by the sponsor to the Company in excess of the cap, will be attributed to the conversion shares issuable under the A&R Sponsor Promissory Note as additional paid-in capital.
| b. | Administrative Services Agreement |
On December 16, 2020, the Company signed an agreement with the Sponsor, under which the Company shall pay the Sponsor a fixed $10 thousand per month for office space, utilities and other administrative expenses. The monthly payments under this administrative services agreement commenced on the effective date of the registration statement for the initial Public Offering and will continue until the earlier of (i) the consummation of the Company’s initial Business Combination, or (ii) the Company’s liquidation.
The composition of the Related Party balance as of June 30, 2024 and December 31, 2023 is as follows:
| June 30, 2024 |
December 31, 2023 |
|||||||
| In U.S. dollars | ||||||||
| Promissory notes | 3,346,000 | 2,841,000 | ||||||
| Accrual for Administrative Services Agreement |
-
|
20,000 | ||||||
| 3,346,000 | 2,861,000 | |||||||
F-16
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 5 - COMMITMENTS AND CONTINGENCIES:
| a. | Underwriters’ deferred discount |
Under the Business Combination Marketing Agreement, the Company shall pay an additional fee (hereafter – the Deferred Commission) of 3.5% of the gross proceeds of the Public Offering (or $4,025,000) payable upon the Company’s completion of the Initial Business Combination. The Deferred Commission will become payable to the underwriters from the amounts held in the Trust Account solely in the event the Company completes an Initial Business Combination.
| b. | Advisory and Placement Agent Agreement with Cohen & Company |
Refer to Note 9(d) for information regarding the agreement entered into after the balance sheet date.
| c. | Nasdaq Deficiency Notice |
Third Deficiency Notice
On February 20, 2024, the Company received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that unless the Company timely requests a hearing before the Nasdaq Hearings Panel (hereafter - the Panel), trading of the Company’s securities on The Nasdaq Capital Market would be suspended at the opening of business on February 29, 2024, due to the Company’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement.
The Company timely requested a hearing before the Panel to request sufficient time to complete its previously disclosed proposed business combination with Silexion. The hearing request has resulted in a stay of any suspension or delisting action pending the hearing, which was held on April 23, 2024.
On April 23, 2024, the Company participated in a hearing with Nasdaq in which the Company presented its request that Nasdaq provide the Company an additional six months to remedy the Company’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement. The Company’s plan for regaining compliance focused on the Company’s efforts to complete its previously disclosed Proposed Business Combination with Silexion. On May 10, 2024, the Company received the results of the hearing, under which Nasdaq approved the Company’s request for a six-month extension— until the Second Extension Date— to remain listed on Nasdaq and complete its proposed business combination.
F-17
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 6 - FAIR VALUE MEASUREMENTS:
The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., the exit price).
The fair value hierarchy under ASC 820 prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
Basis for Fair Value Measurement
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices in markets that are not active or financial instruments for which significant inputs to models are observable (including but not limited to quoted prices for similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly or indirectly;
Level 3: Prices or valuations that require significant unobservable inputs (including the Management’s assumptions in determining fair value measurement).
The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023 by level within the fair value hierarchy:
| Level | June 30, 2024 |
December 31, 2023 |
||||||||
| Assets: | ||||||||||
| Money market funds held in Trust Account | 1 | 5,924,118 | 5,697,632 | |||||||
| Liabilities: | ||||||||||
| Private Warrant Liability | 3 | 27,284 | 8,531 | |||||||
The estimated fair value of the Private Placement Warrants was determined using a binomial model to extract the market’s implied probability for an Initial Business Combination, using the Public Warrant’s market price. Once probability was extracted, a Black-Scholes-Merton model with Level 3 inputs was used to calculate the Private Warrants’ fair value. Inherent in a Black-Scholes-Merton model are assumptions related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants based on implied volatility from the Company’s traded warrants and from historical volatility of selected peer companies’ Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.
The following table provides quantitative information regarding Level 3 fair value measurements inputs:
| As of June 30, 2024 |
As of December 31, 2023 |
|||||||
| Share price | $ | 10.0 | $ | 10.0 | ||||
| Strike price | $ | 11.5 | $ | 11.5 | ||||
| Volatility | 60 | % | 60 | % | ||||
| Risk-free interest rate | 4.34 | % | 4.78 | % | ||||
| Dividend yield | 0.00 | % | 0.00 | % | ||||
| Public warrant market price | $ | 0.08 | $ | 0.03 | ||||
| In U.S dollars | ||||
| Value of warrant liability measured with Level 3 inputs at December 31, 2023 | 8,531 | |||
| Change in fair value of private warrant liability measured with Level 3 inputs | 18,753 | |||
| Value of warrant liability measured with Level 3 inputs at June 30, 2024 | 27,284 | |||
F-18
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 7 - CAPITAL DEFICIENCY:
| a. | Ordinary Shares |
Class A Ordinary Shares
On November 20, 2020 the Company issued 100,000 Class A ordinary shares of $0.0001 par value each to designees of the Representative (hereafter – the Representative Shares) for a consideration equal to the par value of the shares. The Representative Shares are deemed to be underwriters’ compensation by FINRA pursuant to Rule 5110 of the FINRA Manual.
The Company accounted for the issuance of the Representative Shares as compensation expenses amounting to $860, with a corresponding credit to Additional Paid-In Capital, for the excess value over the consideration paid. The Company estimated the fair value of the issuance based upon the price of Class B Ordinary Shares that were issued to the Sponsor.
Pursuant to the initial Public Offering and the concurrent Private Placement that were each effected in two closings – on February 19, 2021 and March 3, 2021 – the Company issued and sold an aggregate of 11,500,000 and 380,000 Class A ordinary shares as part of the Units sold in those respective transactions. The Units (which also included Warrants) were sold at a price of $10 per Unit, and for an aggregate consideration of $115 million and $3.8 million in the Public Offering and Private Placement, respectively. See Note 3 above for further information regarding those share issuances.
The Company classified its 11,500,000 Public Class A ordinary shares as temporary equity. The remaining 480,000 Private Class A ordinary shares were classified as permanent equity.
In conjunction with the First and Second Extensions, 8,910,433 and 2,074,548 Class A Ordinary Shares subject to possible redemption were redeemed, respectively, for their redemption value, including accrued interest. As part of the partial redemptions approximately $113 million has been withdrawn from the Investments held in Trust Account.
Class B Ordinary Shares
On November 20, 2020, the Company issued 2,875,000 Class B ordinary shares of $0.0001 par value each for a total consideration of $25 thousand to the Sponsor’s wholly-owned Delaware subsidiary.
Class B ordinary shares are convertible into non-redeemable Class A ordinary shares, on a one-for-one basis, automatically on the day of the Business Combination or at the election of the holder thereof at any time prior to the Business Combination. Class B ordinary shares also possess the sole right to vote for the election or removal of directors, until the consummation of an Initial Business Combination.
Following the Second Extension Meeting, the Sponsor converted 2,874,999 of its Class B ordinary shares into Class A ordinary shares on a one to one basis.
| b. | Preferred shares |
The Company is authorized to issue up to 5,000,000 Preferred Shares of $0.0001 par value each. As of June 30, 2024, the Company has no preferred shares issued and outstanding.
F-19
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 8 - NET PROFIT (LOSS) PER SHARE:
The following table reflects the calculation of basic and diluted net profit (loss) per share (in dollars, except share amounts):
| Six months ended June 30, |
Three months ended June 30, |
|||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net profit (loss) for the period | $ | (310,793 | ) | $ | 476,143 | $ | (110,575 | ) | $ | 162,948 | ||||||
| Less – interest earned on Investment held in Trust Account | (149,236 | ) | (1,063,043 | ) | (75,305 | ) | (318,002 | ) | ||||||||
| Net loss excluding interest | $ | (460,029 | ) | $ | (586,900 | ) | $ | (185,880 | ) | $ | (155,054 | ) | ||||
| Class A ordinary shares subject to possible redemption: | ||||||||||||||||
| Numerator: | ||||||||||||||||
| Net loss excluding interest | $ | (61,220 | ) | $ | (351,654 | ) | $ | (24,737 | ) | $ | (67,544 | ) | ||||
| Accretion to Class A ordinary shares subject to possible redemption to redemption amount (“Accretion”) | 226,486 | 1,463,043 | 113,930 | 558,002 | ||||||||||||
| $ | 165,266 | $ | 1,111,389 | $ | 89,193 | $ | 490,458 | |||||||||
| Denominator: | ||||||||||||||||
| weighted average number of shares | 515,019 | 5,015,185 | 515,019 | 2,589,567 | ||||||||||||
|
Net profit per Class A ordinary share subject to possible redemption – basic and diluted
|
$ | 0.32 | $ | 0.22 | $ | 0.17 | $ | 0.19 | ||||||||
| Non-redeemable Class A and B ordinary shares: | ||||||||||||||||
| Numerator: | ||||||||||||||||
| Net loss excluding interest | $ | (398,809 | ) | $ | (235,246 | ) | $ | (161,143 | ) | $ | (87,510 | ) | ||||
| Accretion | (77,250 | ) | (400,000 | ) | (38,625 | ) | (240,000 | ) | ||||||||
| (476,059 | ) | (635,246 | ) | (199,768 | ) | (327,510 | ) | |||||||||
| Denominator: | ||||||||||||||||
| weighted average number of shares | 3,355,000 | 3,355,000 | 3,355,000 | 3,355,000 | ||||||||||||
|
Net loss per non-redeemable Class A and B ordinary share – basic and diluted
|
$ | (0.14 | ) | $ | (0.19 | ) | $ | (0.06 | ) | $ | (0.10 | ) | ||||
The potential exercise of 5,750,000 Public Warrants and 190,000 Private Warrants sold in the Public Offering and Private Placements as detailed in Note 3 into 5,940,000 shares has not been included in the calculation of diluted net profit (loss) per share, since the exercise of the warrants is contingent upon the occurrence of a future event.
Additionally, the effect of the conversion of the Second, Third, Fourth and Fifth Promissory Notes into an aggregate amount of 1,500,000 private warrants (exercisable into 1,500,000 shares) as detailed in Note 4, has not been included in the calculation of diluted net profit (loss) per share, since the conversion of the abovementioned promissory notes is contingent upon the occurrence of a future event.
As a result, diluted net profit (loss) per share is the same as basic net profit (loss) per share for each of the periods presented, and for each class.
F-20
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 9 - SUBSEQUENT EVENTS:
| a. | Additional withdrawals under the Promissory Notes |
Since the balance sheet date and up until the filing date of these financial statements, an aggregate amount of $62 thousand has been withdrawn under the Tenth Promissory Note, and a final injection into the trust account of approximately $13 thousand has been withdrawn under the Eighth Promissory Note – rendering the latter fully withdrawn.
| b. | Extraordinary General Meeting and redemption of Class A ordinary shares subject to possible redemption |
On August 6, 2024 the Extraordinary General Meeting has approved the proposed business combination with Silexion. In connection with the meeting, an additional 427,297 Class A ordinary shares subject to possible redemption have been redeemed. Consequently, $4.8 million has been withdrawn from the trust account.
| c. | Advisory and Placement Agent Agreement with Cohen & Company |
On July 29, 2024 the Company has entered into agreement with Cohen & Company, for providing capital markets advisory and placement agent services, in connection with both (i) the completion of the proposed business combination with Silexion, and (ii) a private placement of equity, equity-linked, convertible and / or debt securities to be consummated with the business combination.
F-21
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of Moringa Acquisition Corp
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Moringa Acquisition Corp (the “Company”) as of December 31, 2023 and 2022, and the related statements of operations, changes in capital deficiency and cash flows for each of the two years in the period ended December 31, 2023, including the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.
Substantial Doubt about the Company’s Ability to Continue as a Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1(e) to the financial statements, the Company has limited cash and has incurred losses since inception. Moreover, if the Company is unable to complete a business combination by August 19, 2024 then the Company will cease all operations except for the purpose of liquidating. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1(e). The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Kesselman & Kesselman
Certified Public Accountants (Isr.)
A member firm of PricewaterhouseCoopers International Limited
Tel-Aviv, Israel
April 1, 2024
We have served as the Company’s auditor since 2020.
F-22
MORINGA ACQUISITION CORP
BALANCE SHEETS
| Note | December 31, 2023 |
December 31, 2022 |
||||||||
| U.S. Dollars | ||||||||||
| Assets | ||||||||||
| ASSETS: | ||||||||||
| Cash and cash equivalents | 108,278 | 59,714 | ||||||||
| Investments held in Trust Account | 5,697,632 | 116,692,038 | ||||||||
| Prepaid expenses | 28,305 | 43,853 | ||||||||
| TOTAL ASSETS | 5,834,215 | 116,795,605 | ||||||||
| Liabilities and shares subject to possible redemption net of capital deficiency |
||||||||||
| LIABILITIES: | ||||||||||
| Accrued expenses | 115,560 | 86,688 | ||||||||
| Related party | 4 | 2,861,000 | 1,190,000 | |||||||
| Private warrant liability | 8,531 | 29,640 | ||||||||
| TOTAL LIABILITIES | 2,985,091 | 1,306,328 | ||||||||
| COMMITMENTS AND CONTINGENCIES | 5 |
—
|
—
|
|||||||
| CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION: 515,019 and 11,500,000 shares at redemption value $11.06 and $10.15 as of December 31, 2023 and 2022, respectively | 5,697,632 | 116,692,038 | ||||||||
| CAPITAL DEFICIENCY: | 7 | |||||||||
| Class A Ordinary Shares, $0.0001 par value; 500,000,000 shares authorized, 3,354,999 and 480,000 issued and outstanding (excluding 515,019 and 11,500,000 shares subject to possible redemption) as of December 31, 2023 and 2022, respectively; | 336 | 48 | ||||||||
| Class B Ordinary Shares, $0.0001 par value; 50,000,000 shares authorized, 1 and 2,875,000 issued and outstanding as of December 31, 2023 and 2022, respectively; | * | 288 | ||||||||
| Preferred Shares, $0.0001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022. |
—
|
—
|
||||||||
| Additional paid-in capital |
—
|
—
|
||||||||
| Accumulated deficit | (2,848,844 | ) | (1,203,097 | ) | ||||||
| TOTAL CAPITAL DEFICIENCY | (2,848,508 | ) | (1,202,761 | ) | ||||||
| TOTAL LIABILITIES AND SHARES SUBJECT TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY | 5,834,215 | 116,795,605 | ||||||||
| * | Less than one US dollar. |
The accompanying notes are an integral part of these financial statements.
F-23
MORINGA ACQUISITION CORP
STATEMENTS OF OPERATIONS
| Note | Year ended December 31, 2023 |
Year ended December 31, 2022 |
||||||||||
| U.S. Dollars | ||||||||||||
| Except share data | ||||||||||||
| Interest earned on investments held in trust account | 1,364,444 | 1,685,666 | ||||||||||
| General and administrative | 9 | (1,122,480 | ) | (1,232,342 | ) | |||||||
| Change in fair value of Private Warrant liability | 21,109 | 130,701 | ||||||||||
| Net profit for the year | 263,073 | 584,025 | ||||||||||
| Weighted average number of Class A Ordinary Shares subject to Possible Redemption | 8 | 2,774,850 | 11,500,000 | |||||||||
|
Basic and diluted net profit per Class A Ordinary Shares subject to Possible Redemption
|
$ | 0.51 | 0.07 | |||||||||
| Weighted average number of non-redeemable Class A and Class B Ordinary shares | 3,355,000 | 3,355,000 | ||||||||||
|
Basic and diluted net loss per non-redeemable Class A and Class B Ordinary shares
|
$ | (0.34 | ) | (0.07 | ) | |||||||
The accompanying notes are an integral part of these financial statements.
F-24
MORINGA ACQUISITION CORP
STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY
| Class A ordinary shares |
Class B ordinary shares |
Additional | ||||||||||||||||||||||||||
| Number of shares |
Par value |
Number of shares |
Par value |
paid-in capital |
Accumulated deficit |
Total | ||||||||||||||||||||||
| U.S. Dollars (except share data) | ||||||||||||||||||||||||||||
| BALANCE AT December 31, 2021 | 480,000 | 48 | 2,875,000 | 288 | 855,994 | (951,078 | ) | (94,748 | ) | |||||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of December 31, 2022 | — |
—
|
— |
—
|
(855,994 | ) | (836,044 | ) | (1,692,038 | ) | ||||||||||||||||||
| Net profit for the year | — |
—
|
— |
—
|
—
|
584,025 | 584,025 | |||||||||||||||||||||
| BALANCE AT December 31, 2022 | 480,000 | 48 | 2,875,000 | 288 |
—
|
(1,203,097 | ) | (1,202,761 | ) | |||||||||||||||||||
| Subsequent accretion of Class A Ordinary Shares subject to possible redemption to amount as of December 31, 2023 | — |
—
|
— |
—
|
—
|
(1,908,820 | ) | (1,908,820 | ) | |||||||||||||||||||
| Conversion of Class B ordinary shares into Class A ordinary shares | 2,874,999 | 288 | (2,874,999 | ) | (288 | ) |
—
|
—
|
—
|
|||||||||||||||||||
| Net profit for the year | — |
—
|
— |
—
|
—
|
263,073 | 263,073 | |||||||||||||||||||||
| BALANCE AT December 31, 2023 | 3,354,999 | 336 | 1 | * |
—
|
(2,848,844 | ) | (2,848,508 | ) | |||||||||||||||||||
| * | Less than one US dollar. |
The accompanying notes are an integral part of these financial statements.
F-25
MORINGA ACQUISITION CORP
STATEMENTS OF CASH FLOWS
| Year ended December 31, 2023 |
Year ended December 31, 2022 |
|||||||
| U.S. Dollars | ||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net profit for the year | 263,073 | 584,025 | ||||||
| Adjustments to reconcile net profit to net cash provided by operating activities: | ||||||||
| Changes in the fair value of the private warrant liability | (21,109 | ) | (130,701 | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Decrease in prepaid expenses | 15,548 | 325,000 | ||||||
| Increase (decrease) in related party | 20,000 | (10,000 | ) | |||||
| Increase in accrued expenses | 28,872 | 48,112 | ||||||
| Net cash provided by operating activities | 306,384 | 816,436 | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Partial redemption of Class A ordinary shares subject to possible redemption | (112,903,226 | ) |
—
|
|||||
| Proceeds from a promissory note – related party | 1,651,000 | 890,000 | ||||||
| Net cash provided by (used in) financing activities | (111,252,226 | ) | 890,000 | |||||
| INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT | (110,945,842 | ) | 1,706,436 | |||||
| CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT BEGINNING OF YEAR | 116,751,752 | 115,045,316 | ||||||
| CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT END OF YEAR | 5,805,910 | 116,751,752 | ||||||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT: | ||||||||
| Cash and cash equivalents | 108,278 | 59,714 | ||||||
| Investments held in trust account | 5,697,632 | 116,692,038 | ||||||
| Total cash, cash equivalents and investments held in a trust account | 5,805,910 | 116,751,752 | ||||||
| SUPPLEMENTARY INFORMATION REGARDING NON-CASH ACTIVITIES: | ||||||||
| Conversion of Class B ordinary shares into Class A ordinary shares | 288 |
—
|
||||||
The accompanying notes are an integral part of these financial statements.
F-26
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
| a. | Organization and General |
Moringa Acquisition Corp (hereafter — the Company) is a blank check company, incorporated on September 24, 2020 as a Cayman Islands exempted company, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination (hereafter — the Business Combination). The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).
All activity for the year ended December 31, 2023 relates to the Company’s search for a target company, as well as attempts to consummate the Proposed Holisto Merger which was terminated on August 8, 2023 as detailed in Note 1(f).
In February 2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note 10(b) for further information regarding the Proposed Business Combination.
The Company has selected December 31 as its fiscal year end.
| b. | Sponsor and Financing |
The Company’s sponsor is Moringa Sponsor, L.P., a Cayman exempted limited partnership (which is referred to herein, together with its wholly-owned subsidiary, Moringa Sponsor (US) LP, a Delaware limited partnership, as the “Sponsor”).
The registration statement relating to the Company’s Public Offering was declared effective by the United States Securities and Exchange Commission (the “SEC”) on February 16, 2021. The initial stage of the Company’s Public Offering — the sale of 10,000,000 Units — closed on February 19, 2021 (hereafter — the Closing of the Public Offering). Upon that closing and the concurrent closing of the initial stage of the Private Placement (as defined below in Note 3). $100,000,000 was placed in a trust account (the “Trust Account”) (discussed in Note 1(c) below). On March 3, 2021 upon the full exercise by the underwriters of their over-allotment option for the Public Offering, the second stage of the Public Offering — the sale of 1,500,000 Units — closed. Upon that closing and the concurrent closing of the second stage of the Private Placement, an additional $15,000,000 was placed in the Trust Account. As part of the partial redemptions in conjunction with the First and Second Extensions, approximately $113 million have been withdrawn from the Investments held in Trust Account. The Company intends to finance its Initial Business Combination with the net proceeds from the Public Offering and the Private Placement.
| c. | The Trust Account |
The proceeds held in the Trust Account are invested in money market funds registered under the Investment Company Act and compliant with Rule 2a-7 thereof that maintain a stable net asset value of $1.00.
The Company’s complies with the provisions of ASU 2016-18, under which changes in proceeds held in the Trust Account are accounted for as Changes in Cash, Cash Equivalents and Investments Held in a Trust Account in the Company’s Statements of Cash Flows.
Refer to Note 4(a) for information regarding proceeds loaned by the Sponsor under the Sixth and Eighth Promissory Notes, deposited into the Trust Account.
| d. | Initial Business Combination |
The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds of the Public Offering and the Private Placement are intended to be generally applied toward consummating an Initial Business Combination. The Initial Business Combination must occur with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding taxes payable on the income accrued in the Trust Account) as of the time of entry into the related definitive agreement for the Initial Business Combination. There is no assurance that the Company will be able to successfully consummate an Initial Business Combination.
F-27
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS: (cont.)
The Company, after signing a definitive agreement for an Initial Business Combination, will provide its public shareholders the opportunity to redeem all or a portion of their shares upon the completion of the Initial Business Combination, either (i) in connection with a shareholder meeting called to approve the business combination or (ii) by means of a tender offer.
If the Company holds a shareholder vote or there is a tender offer for shares in connection with an Initial Business Combination, a public shareholder will have the right to redeem its shares for an amount in cash equal to its pro rata share of the aggregate amount then on deposit in the Trust Account, calculated as of two days prior to the general meeting or commencement of the Company’s tender offer, including interest but less taxes payable. As a result, the Company’s Class A ordinary shares subject to possible redemption are classified as temporary equity upon the completion of the Public Offering, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity”.
Pursuant to the Company’s amended and restated memorandum and articles of association, if the Company is unable to complete the Initial Business Combination within 24 months (as was subsequently extended, as described below) from the Closing of the Public Offering, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable, and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
The Sponsor and the Company’s officers and directors have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to any Class B ordinary share, including any Class A ordinary share issuable upon conversion of such Class B ordinary shares, and Class A ordinary share (as described in Note 7) held by them if the Company fails to complete the Initial Business Combination within 24 months (as was subsequently extended) of the Closing of the Public Offering or during any extended time that the Company has to consummate an Initial Business Combination beyond 24 months as a result of a shareholder vote to amend its amended and restated memorandum and articles of association. However, if the Sponsor or any of the Company’s directors or officers acquire any Class A ordinary shares subject to possible redemption, they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete the Initial Business Combination within the prescribed time period.
In the event of a liquidation, dissolution or winding up of the Company after an Initial Business Combination, the Company’s shareholders are entitled to share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of stock, if any, having preference over the ordinary shares. The Company’s shareholders have no preemptive or other subscription rights. There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide its shareholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account, under the circumstances, and, subject to the limitations, described herein.
F-28
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS: (cont.)
On February 9, 2023 the Company held an extraordinary general meeting in lieu of the 2022 annual general meeting of the Company (hereafter — the First Extension Meeting). At the First Extension Meeting, the Company’s shareholders approved the proposal to adopt, by way of special resolution, an amendment to the Amended and Restated Articles to extend the date by which the Company has to consummate a business combination from the 24 month anniversary of the Closing of the Public Offering — i.e., February 19, 2023 to August 19, 2023 (hereafter — the Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.
On August 18, 2023 the Company held an extraordinary general meeting in lieu of the 2023 annual general meeting of the Company (hereafter — the Second Extension Meeting). At the Second Extension Meeting, the Company’s shareholders approved, among other proposals, an amendment to the Amended and Restated Memorandum and Articles of Association to further extend the date by which the Company has to consummate a business combination from the Extended Mandatory Liquidation Date to August 19, 2024 (hereafter — the Second Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.
Refer to Note 4(a) for information regarding proceeds received by the Company from the Sponsor under the Sixth and Eighth Promissory Notes, which were deposited into the Trust Account.
Refer to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extension Meetings.
Refer to Note 5(b) for information regarding the conversion of Class B ordinary shares into Class A ordinary shares, following the Second Extension Meeting.
| e. | Substantial Doubt about the Company’s Ability to Continue as a Going Concern |
As of December 31, 2023 the Company had approximately $108 thousand of cash and an accumulated deficit of approximately $2,848 thousand. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standard Codification 205-40, “Going Concern”, the Company will need to obtain additional funds in order to satisfy its liquidity needs in its endeavors to consummate a business combination.
Since its inception date and through the issuance date of these financial statements, the Company’s liquidity needs were satisfied through an initial capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor promissory notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and future promissory notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following the Second Extension Meeting, the Company has until August 19, 2024 to consummate an Initial Business Combination. If a business combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can be no assurance that the Company will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation Date, nor will it be able to raise sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt about the Company’s ability to continue as a going concern, for the subsequent twelve months following the issuance date of these financial statements. In February 2024, the Company entered into a Business Combination Agreement with Silexion Therapeutics Ltd. (hereafter — Silexion). Refer to Note 10(b) for further information regarding the Proposed Business Combination.
No adjustments have been made to the carrying amounts of assets or liabilities should the company fail to obtain financial support in its pursuit to consummate an Initial Business Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation Date.
F-29
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS: (cont.)
| f. | Proposed Business Combination |
On June 9, 2022 the Company entered into a Business Combination Agreement for a proposed business combination (hereafter — the Proposed Holisto Merger) with Holisto Ltd., a company organized under the laws of the State of Israel (hereafter — Holisto) and Holisto MergerSub, Inc., a Cayman Islands exempted company and wholly-owned subsidiary of Holisto.
On August 7, 2023 Holisto notified the Company that it was terminating the Proposed Holisto Merger agreement. The termination became effective as of August 8, 2023. Upon termination of the Proposed Holisto Merger, all rights and obligations of each party to the agreement ceased, except for those obligations of the parties that are intended to survive such termination and which remain in effect in accordance with their respective terms. Neither the Company nor Holisto has any remaining substantive obligation to one another following the above-mentioned termination, as of date of these financial statements.
In February 2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note 10(b) for further information regarding the Proposed Business Combination.
| g. | Impact of War in Israel |
On October 7, 2023 Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks.
The intensity and duration of Israel’s current war against Hamas is difficult to predict, as are such war’s economic implications on the business and operations on any target company with which the Company may combine, and on Israel’s economy in general. These events may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company’s ability to effectively complete an Initial Business Combination, or on the operations of an Israel-centered target company with which the Company may combine.
Refer to Note 10(b) for further information regarding the Proposed Business Combination.
NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES:
| a. | Basis of Presentation |
The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the SEC.
| b. | Emerging Growth Company |
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
F-30
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES: (cont.)
This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible, because of the potential differences in accounting standards used.
| c. | Cash and cash equivalents |
The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use by nature of the account and are readily convertible to known amounts of cash.
| d. | Class A Ordinary Shares subject to possible redemption |
As discussed in Note 1(b), all of the 11,500,000 Class A ordinary shares sold as part of the Units in the Public Offering contained a redemption feature. In accordance with the Accounting Standards Codification 480-10-S99-3A “Classification and Measurement of Redeemable Securities”, redemption provisions not solely within the control of the Company require the security to be classified outside of permanent equity. The Company has classified all of the shares sold under the Public Units as subject to possible redemption.
Refer to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption, following the First Extension Meeting and the Second Extension Meeting.
| e. | Net profit (loss) per share |
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share. Net profit (loss) per share is computed by dividing net profit (loss) by the weighted average number of shares outstanding during the period. The Company applies the two-class method in calculating net profit (loss) per each class of shares: the non-redeemable shares, which include the Private Class A Ordinary Shares, as defined in Note 7(a), and the Class B ordinary shares (hereafter and collectively — Non-Redeemable class A and B ordinary shares); and the Class A ordinary shares subject to possible redemption.
In order to determine the net profit (loss) attributable to each class, the Company first considered the total profit (loss) allocable to both sets of shares. This is calculated using the total net profit (loss) less any interest earned on investments held in the Trust Account. Then, any accretion is fully allocated to the Class A ordinary shares subject to redemption.
| f. | Concentration of credit risk |
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. From the Company’s incorporation and through December 31, 2023 the Company has not experienced any losses on these accounts.
As of December 31, 2023 the Company held its cash and cash equivalents in an SVB bank account, and its investments Held in Trust Account in Goldman Sachs money market funds. Money market funds are characterized as Level 1 investments within the fair value hierarchy under ASC 820.
F-31
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES: (cont.)
| g. | Public Warrants |
The Company applied the provisions of ASC 815-40 and classified its public warrants, issued as part of the Public Units as detailed in Note 3, as equity securities.
| h. | Private Warrant liability |
The Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 (“ASC 815”), “Derivatives and Hedging”, under which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company classifies the warrants as liabilities at their fair value and adjusts the warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value is recognized in the Company’s statement of operations. Refer to Note 6 for information regarding the model used to estimate the fair value of the Private Warrants (as defined in Note 3).
| i. | Financial instruments |
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures”, approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.
| j. | Use of estimates in the preparation of financial statements |
The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company’s financial statements.
| k. | Income tax |
The Company accounts for income taxes in accordance with ASC 740, “Income Taxes (hereafter — ASC 740). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015-17.
| l. | Recent accounting pronouncements |
Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted would have a material effect on the Company’s financial statements.
NOTE 3 — PUBLIC OFFERING AND PRIVATE PLACEMENTS:
In the initial Public Offering, the Company issued and sold 11,500,000 units (including 1,500,000 units sold at a second closing pursuant to the underwriters’ exercise of their over-allotment option in full) at an offering price of $10.00 per unit (hereafter — the Units). The Sponsor and EarlyBirdCapital, Inc. (the representative of the underwriters) purchased, in a private placement that occurred simultaneously with the two closings of the initial Public Offering (hereafter — the Private Placement), an aggregate of 352,857 and 27,143 Units, respectively, at a price of $10.00 per Unit.
F-32
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 3 — PUBLIC OFFERING AND PRIVATE PLACEMENTS: (cont.)
Each Unit (both those sold in the initial Public Offering and in the Private Placement) consists of one Class A ordinary share, $0.0001 par value, and one-half of one warrant, with each whole warrant exercisable for one Class A ordinary share (hereafter — each, a Public Warrant and a Private Warrant, and collectively, the Warrants). Each Warrant entitles the holder thereof to purchase one whole Class A ordinary share at a price of $11.50 per share, subject to adjustment. No fractional shares will be issued upon exercise of the Warrants and only whole Warrants trade. Each Warrant will become exercisable 30 days after the completion of the Company’s Initial Business Combination and will expire at 5:00 p.m., New York City time, five years after the completion of the Initial Business Combination or earlier upon redemption (only in the case of the Public Warrants) or liquidation.
Once the Public Warrants become exercisable, the Company may redeem them in whole and not in part at a price of $0.01 per Warrant upon a minimum of 30 days’ prior written notice of redemption, if and only if the last reported sale price of the Company’s Class A ordinary shares equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the Public Warrant holders.
The Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc. or their respective affiliates: (1) will not be redeemable by the Company; (2) may not (including the Class A ordinary shares issuable upon exercise thereof), subject to certain limited exceptions, be transferred, assigned or sold by the holders thereof until 30 days after the completion of the Company’s Initial Business Combination; (3) may be exercised by the holders thereof on a cashless basis; and (4) they (including the Class A ordinary shares issuable upon exercise thereof) are entitled to registration rights.
The Company paid an underwriting commission of 2.0% of the gross proceeds of the Public Offering and the full exercise of the underwriters’ over-allotment, or $2,300,000, in the aggregate, to the underwriters at the two closings of the Public Offering. Refer to Note 5(a) for more information regarding an additional fee payable to the underwriters upon the consummation of an Initial Business Combination.
NOTE 4 — RELATED PARTY TRANSACTIONS:
| a. | Promissory Notes |
The Company has issued several promissory note agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational needs or preparations towards an Initial Business Combination. All outstanding promissory notes bear no interest and are repayable in full upon the earlier of (a) the date of the consummation of the Company’s Initial Business Combination, or (b) Second Extended Mandatory Liquidation Date (hereafter and collectively — the Maturity Date).
First Promissory Note
The First Promissory Note withdrawn was borrowed and repaid in full in early 2021 and has subsequently expired.
Second to Fifth Promissory Notes
On August 9, 2021 the Company issued its Second Promissory Note to the Sponsor, according to which the former may withdraw up to $1 million — which has been withdrawn in full in several installments up until June 2022.
In December 2022 the Company issued its Third and Fourth Promissory Notes (hereafter — the Third and Fourth Promissory Notes), according to which the Company may withdraw up to an aggregate amount of $190 thousand — which were withdrawn in full on the same month.
F-33
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 4 — RELATED PARTY TRANSACTIONS: (cont.)
On February 8, 2023 the Company issued its Fifth Promissory Note to the Sponsor, in an amount of up to $310 thousand, which were withdrawn in full in several installments between February and June 2023.
According to the terms of the outstanding Second, Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $1.5 million, the Sponsor may elect to convert any portion of the amounts outstanding into private warrants to purchase Class A ordinary shares at a conversion price of $1 per private warrant on the Maturity Date. Such private warrants will have an exercise price of $11.5 and shall be identical to the private warrants included in the private units.
Sixth Promissory Note
On February 9, 2023 the Company issued its Sixth Promissory Note to the Sponsor, in an amount of $480 thousand — under which the funds that were loaned by the Sponsor were deposited into the Company’s Trust Account, in connection with the First Extension. The Sponsor provided six monthly injections of $80 thousand into the Company’s Trust Account under the Sixth Promissory Note, starting February 19, 2023.
Seventh Promissory Note
On June 14, 2023 the Company issued its Seventh Promissory Note to the Sponsor in an amount of up to $1 million, of which $210 thousand were withdrawn at the same date; and approximately $586 thousand were withdrawn up until December 31, 2023.
Eighth Promissory Note
On August 18, 2023 the Company issued its Eighth Promissory Note to the Sponsor, in an amount of approximately $154 thousand — under which the funds that were loaned by the Sponsor were deposited into the Company’s Trust Account, in connection with the Second Extension. The Sponsor shall make monthly injections of approximately $13 thousand into the Company’s Trust Account, starting August 19, 2023 and up until the earlier of the Second Extended Mandatory Liquidation Date (or such earlier date that the Board determines to liquidate the Company) or the date on which an Initial Business Combination is completed.
| b. | Administrative Services Agreement |
On December 16, 2020 the Company signed an agreement with the Sponsor, under which the Company shall pay the Sponsor a fixed $10 thousand per month for office space, utilities and other administrative expenses. The monthly payments under this administrative services agreement commenced on the effective date of the registration statement for the initial Public Offering and will continue until the earlier of (i) the consummation of the Company’s Initial Business Combination, or (ii) the Company’s liquidation.
The composition of the Related Party balance as of December 31, 2023 and 2022 is as follows:
| December 31, 2023 |
December 31, 2022 |
|||||||
| U.S. dollars | ||||||||
| Promissory notes | 2,841,000 | 1,190,000 | ||||||
| Accrual for Administrative Services Agreement | 20,000 |
—
|
||||||
| 2,861,000 | 1,190,000 | |||||||
F-34
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 5 — COMMITMENTS AND CONTINGENCIES:
| a. | Underwriters’ Deferred Discount |
Under the Business Combination Marketing Agreement, the Company shall pay an additional fee (hereafter — the Deferred Commission) of 3.5% of the gross proceeds of the Public Offering (or $4,025,000) payable upon the Company’s completion of the Initial Business Combination. The Deferred Commission will become payable to the underwriters from the amounts held in the Trust Account solely in the event the Company completes an Initial Business Combination.
| b. | Nasdaq Deficiency Notices |
First Deficiency Notice
On March 28, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it is not in compliance with Nasdaq Listing Rule 5550(a)(3) (hereafter — the First Deficiency), according to which the Company must satisfy the Minimum Public Holders Rule which requires listed companies to have at least 300 public holders. The Company has submitted its compliance plan on May 11, 2023 which was accepted by Nasdaq, which has then granted an extension of up to 180 calendar days from the date of the notice — until September 24, 2023 — to evidence compliance with the rule.
On September 27, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained compliance with the First Deficiency.
Second Deficiency Notice
On June 15, 2023 the Company received another notice from Nasdaq Listing Qualifications Department indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(2) (hereafter — the Second Deficiency), according to which the Company must sustain a market value of listed securities of at least $35 million, for continued listing on the Nasdaq Capital Market. The notice was only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market.
NOTE 6 — FAIR VALUE MEASUREMENTS:
Following the Second Extension Meeting, the Sponsor converted 2,874,999 of its Class B ordinary shares on a one to one basis into Class A ordinary shares, in an effort to regain compliance with the Second Deficiency.
On November 24, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained compliance with the Second Deficiency.
The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., the exit price).
The fair value hierarchy under ASC 820 prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
F-35
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 6 — FAIR VALUE MEASUREMENTS: (cont.)
Level 2: Quoted prices in markets that are not active or financial instruments for which significant inputs to models are observable (including but not limited to quoted prices for similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly or indirectly;
Level 3: Prices or valuations that require significant unobservable inputs (including the Management’s assumptions in determining fair value measurement).
Basis for Fair Value Measurement
The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2023 by level within the fair value hierarchy:
| Level | December 31, 2023 |
December 31, 2022 |
||||||||||
| Assets: | ||||||||||||
| Money market funds held in Trust Account | 1 | 5,697,632 | 116,692,038 | |||||||||
| Liabilities: | ||||||||||||
| Private warrant liability | 3 | 8,531 | 29,640 | |||||||||
The estimated fair value of the Private Placement Warrants was determined using a binomial model to extract the market’s implied probability for an Initial Business Combination, using the Public Warrant’s market price. Once probability was extracted, a Black-Scholes-Merton model with Level 3 inputs was used to calculate the Private Warrants’ fair value. Inherent in a Black-Scholes-Merton model are assumptions related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants based on implied volatility from the Company’s traded warrants and from historical volatility of selected peer companies’ Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.
The following table provides quantitative information regarding Level 3 fair value measurements inputs:
| As of December 31, 2023 |
As of December 31, 2022 |
|||||||
| Share price | $ | 10.0 | $ | 10.0 | ||||
| Strike price | $ | 11.5 | $ | 11.5 | ||||
| Volatility | 60 | % | 50 | % | ||||
| Risk-free interest rate | 4.78 | % | 4.00 | % | ||||
| Dividend yield | 0.00 | % | 0.00 | % | ||||
| U.S. dollars | ||||
| Value of warrant liability measured with Level 3 inputs at December 31, 2022 | 29,640 | |||
| Change in fair value of private warrant liability measured with Level 3 inputs | (21,109 | ) | ||
| Value of warrant liability measured with Level 3 inputs at December 31, 2023 | 8,531 | |||
F-36
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 7 — CAPITAL DEFICIENCY:
| a. | Ordinary Shares |
Class A Ordinary Shares
On November 20, 2020 the Company issued 100,000 Class A ordinary shares of $0.0001 par value each to designees of the Representative (hereafter — the Representative Shares) for a consideration equal to the par value of the shares. The Representative Shares are deemed to be underwriters’ compensation by FINRA pursuant to Rule 5110 of the FINRA Manual.
The Company accounted for the issuance of the Representative Shares as compensation expenses amounting to $860, with a corresponding credit to Additional Paid-In Capital, for the excess value over the consideration paid. The Company estimated the fair value of the issuance based upon the price of Class B Ordinary Shares that were issued to the Sponsor.
Pursuant to the initial Public Offering and the concurrent Private Placement that were each effected in two closings — on February 19, 2021 and March 3, 2021 — the Company issued and sold an aggregate of 11,500,000 and 380,000 Class A ordinary shares as part of the Units sold in those respective transactions. The Units (which also included Warrants) were sold at a price of $10 per Unit, and for an aggregate consideration of $115 million and $3.8 million in the Public Offering and Private Placement, respectively. See Note 3 above for further information regarding those share issuances.
The Company classified its 11,500,000 Class A ordinary shares subject to possible redemption as temporary equity. The remaining 480,000 Private Class A ordinary shares were classified as permanent equity.
In conjunction with the First and Second Extensions, 8,910,433 and 2,074,548 Class A Ordinary Shares subject to possible redemption were redeemed, respectively, for their redemption value, including accrued interest. As part of the partial redemptions approximately $113 million has been withdrawn from the Investments held in Trust Account.
Class B Ordinary Shares
On November 20, 2020 the Company issued 2,875,000 Class B ordinary shares of $0.0001 par value each for a total consideration of $25 thousand to the Sponsor’s wholly-owned Delaware subsidiary. Out of the 2,875,000 Class B ordinary shares, up to 375,000 were subject to forfeiture if the underwriters were to not exercise their over-allotment in full or in part. Because the underwriters exercised their over-allotment option in full on March 3, 2021 that potential forfeiture did not occur.
Class B ordinary shares are convertible into non-redeemable Class A ordinary shares, on a one-for-one basis, automatically on the day of the Business Combination or at the election of the holder thereof at any time prior to the Business Combination. Class B ordinary shares also possess the sole right to vote for the election or removal of directors, until the consummation of an Initial Business Combination.
Refer to Note 5(b) for information regarding the conversion of Class B ordinary shares into Class A ordinary shares following the Second Extension Meeting.
| b. | Preferred shares |
The Company is authorized to issue up to 5,000,000 Preferred Shares of $0.0001 par value each. As of December 31, 2023 the Company has no preferred shares issued and outstanding.
F-37
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 8 — NET PROFIT (LOSS) PER SHARE:
The following table reflects the calculation of basic and diluted net profit (loss) per share (in dollars, except share amounts):
| Year ended December 31, |
||||||||
| 2023 | 2022 | |||||||
| Net profit for the year | $ | 263,073 | $ | 584,025 | ||||
| Less – interest earned on Investment held in Trust Account | (1,364,444 | ) | (1,685,666 | ) | ||||
| Net loss excluding interest | $ | (1,101,371 | ) | $ | (1,101,641 | ) | ||
| Class A ordinary shares subject to possible redemption: | ||||||||
| Numerator: | ||||||||
| Net loss excluding interest | $ | (498,567 | ) | $ | (852,835 | ) | ||
| Accretion to Class A ordinary shares subject to possible redemption to redemption amount (“Accretion”) | 1,908,820 | 1,685,666 | ||||||
| $ | 1,410,253 | $ | 832,831 | |||||
| Denominator: | ||||||||
| Weighted average number of shares | 2,774,850 | 11,500,000 | ||||||
|
Basic and diluted net profit per Class A ordinary share subject to possible redemption
|
$ | 0.51 | $ | 0.07 | ||||
| Non-redeemable Class A and B ordinary shares: | ||||||||
| Numerator: | ||||||||
| Net loss excluding interest | $ | (602,804 | ) | $ | (248,806 | ) | ||
| Accretion | (544,376 | ) |
—
|
|||||
| (1,147,180 | ) | (248,806 | ) | |||||
| Denominator: | ||||||||
| Weighted average number of shares | 3,355,000 | 3,355,000 | ||||||
|
Basic and diluted net loss per non-redeemable Class A and B ordinary share
|
$ | (0.34 | ) | $ | (0.07 | ) | ||
The potential exercise of 5,750,000 Public Warrants and 190,000 Private Warrants sold in the Public Offering and Private Placements as detailed in Note 3 into 5,940,000 shares has not been included in the calculation of diluted net profit (loss) per share, since the exercise of the warrants is contingent upon the occurrence of a future event.
Additionally, the effect of the conversion of the Second, Third, Forth and Fifth Promissory Notes into an aggregate amount of 1,500,000 private warrants (exercisable into 1,500,000 shares) as detailed in Note 4, has not been included in the calculation of diluted net profit (loss) per share, since the conversion of the abovementioned promissory notes is contingent upon the occurrence of a future event.
As a result, diluted net profit (loss) per share is the same as basic net profit (loss) per share for each of the periods presented, and for each class.
F-38
MORINGA ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE 9 — GENERAL AND ADMINISTRATIVE:
The formation and other operating expenses for the years ended December 31, 2023 and 2022 are as follows:
| December 31, 2023 |
December 31, 2022 |
|||||||
| U.S. dollars | ||||||||
| Legal expenses | 259,000 | 398,903 | ||||||
| Audit, bookkeeping and accounting | 146,600 | 143,101 | ||||||
| Professional services | 245,538 | 115,651 | ||||||
| Management fees | 120,000 | 120,000 | ||||||
| Insurance | 281,044 | 325,000 | ||||||
| Nasdaq fees | 70,000 | 129,500 | ||||||
| Other | 298 | 187 | ||||||
| 1,122,480 | 1,232,342 | |||||||
NOTE 10 — SUBSEQUENT EVENTS:
| a. | Nasdaq Deficiency Note |
On February 20, 2024, the Company received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that unless the Company timely requests a hearing before the Nasdaq Hearings Panel (hereafter — the Panel), trading of the Company’s securities on The Nasdaq Capital Market would be suspended at the opening of business on February 29, 2024, due to the Company’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement.
The Company timely requested a hearing before the Panel to request sufficient time to complete its previously disclosed proposed business combination with Silexion. The hearing request has resulted in a stay of any suspension or delisting action pending the hearing, which is scheduled to take place on April 23, 2024.
| b. | Proposed Business Combination |
On February 21, 2024, the Company, together with its wholly-owned Israeli subsidiary (hereafter — the Merger Sub), entered into a business combination agreement (hereafter — the BCA) with Silexion Therapeutics Ltd., an Israeli company (hereafter — Silexion).
The Business Combination is expected to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the BCA, including the approval of the Business Combination by Silexion’s and the Company’s shareholders, and Nasdaq approval of the initial listing of the combined company’s securities.
Headquartered in Israel, Silexion is a clinical-stage, oncology-focused biotechnology company that develops innovative treatments for unsatisfactorily treated solid tumor cancers which have a mutated KRAS oncogene. The Business Combination values Silexion at a pre-transaction equity value of $62.5 million, based on a $10 price per share.
The BCA and the Business Combination have been unanimously approved by the boards of directors of the Company and Silexion.
F-39
|
Page
|
|
|
CONSOLIDATED FINANCIAL STATEMENTS:
|
|
|
F-42 - F-44
|
|
|
F-45
|
|
|
F-46 - F-47
|
|
|
F-48 - F-49
|
|
|
F-50 - F-64
|
|
September 30,
|
December 31
|
|||||||
|
2024
|
2023
|
|||||||
|
U.S. dollars in thousands
|
||||||||
|
Assets
|
||||||||
|
CURRENT ASSETS:
|
||||||||
|
Cash and cash equivalents
|
$
|
1,973
|
$
|
4,595
|
||||
|
Restricted cash
|
50
|
25
|
||||||
|
Prepaid expenses
|
944
|
335
|
||||||
|
Other current assets
|
80
|
24
|
||||||
|
TOTAL CURRENT ASSETS
|
3,047
|
4,979
|
||||||
|
NON-CURRENT ASSETS:
|
||||||||
|
Restricted cash
|
-
|
25
|
||||||
|
Long-term deposit
|
5
|
5
|
||||||
|
Property and equipment, net
|
35
|
49
|
||||||
|
Operating lease right-of-use asset
|
-
|
198
|
||||||
|
TOTAL NON-CURRENT ASSETS
|
40
|
277
|
||||||
|
TOTAL ASSETS
|
$
|
3,087
|
$
|
5,256
|
||||
|
September 30,
|
December 31
|
|||||||
|
2024
|
2023
|
|||||||
|
U.S. dollars in thousands
|
||||||||
|
Liabilities and redeemable convertible preferred shares, net of capital deficiency
|
||||||||
|
CURRENT LIABILITIES:
|
||||||||
|
Trade payables
|
$
|
799
|
$
|
319
|
||||
|
Current maturities of operating lease liability
|
-
|
112
|
||||||
|
Warrants to preferred shares (including $0 and $186 due to related party, as of September 30, 2024 and December 31, 2023, respectively)
|
-
|
200
|
||||||
|
Employee related obligations
|
687
|
207
|
||||||
|
Accrued expenses and other account payable
|
1,858
|
1,358
|
||||||
|
Private warrants to purchase ordinary shares
|
10
|
-
|
||||||
|
Underwriters Promissory Note
|
229
|
-
|
||||||
|
TOTAL CURRENT LIABILITIES
|
3,583
|
2,196
|
||||||
|
NON-CURRENT LIABILITIES:
|
||||||||
|
Long-term operating lease liability
|
-
|
59
|
||||||
|
Underwriters Promissory Note
|
977
|
-
|
||||||
|
Promissory note - related party
|
3,106
|
-
|
||||||
|
TOTAL NON-CURRENT LIABILITIES
|
$
|
4,083
|
$
|
59
|
||||
|
TOTAL LIABILITIES
|
$
|
7,666
|
$
|
2,255
|
||||
|
COMMITMENTS AND CONTINGENT LIABILITIES
|
||||||||
|
REDEEMABLE CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERESTS:
|
||||||||
|
Convertible Series A Preferred Shares (NIS 0.09 par value, 0 and 56,667 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0 and 43,121
shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);
|
||||||||
|
Convertible Series A-1 Preferred Shares (NIS 0.09 par value per share, 0 and 13,334 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0
and 10,136 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);
|
||||||||
|
Convertible Series A-2 Preferred Shares (NIS 0.09 par value per share, 0 and 22,223 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0
and 5,051 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);
|
||||||||
|
Convertible Series A-3 Preferred Shares (NIS 0.09 par value per share, 0 and 8,889 shares authorized as of September 30, 2024 and December 31, 2023, respectively 0
and 7,037 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);
|
||||||||
|
Convertible Series A-4 Preferred Shares (NIS 0.09 par value per share, 0 and 90,556 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0
and 2,413** shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);
|
||||||||
|
TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES
|
-
|
15,057
|
||||||
|
CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS
|
-
|
3,420
|
||||||
|
TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS
|
$
|
-
|
$
|
18,477
|
||||
|
September 30,
|
December 31,
|
|||||||
|
2024
|
2023
|
|||||||
|
U.S. dollars in thousands
|
||||||||
|
CAPITAL DEFICIENCY:
|
||||||||
|
Ordinary shares ($0.0009 par value per share, 22,222,222 shares authorized as of September 30, 2024 and December 31, 2023;
1,242,267 and 97,120 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively)
|
1
|
*
|
||||||
|
Additional paid-in capital
|
37,003
|
11,335
|
||||||
|
Accumulated deficit
|
(41,583
|
)
|
(26,811
|
)
|
||||
|
TOTAL CAPITAL DEFICIENCY
|
$
|
(4,579
|
)
|
$
|
(15,476
|
)
|
||
|
TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY
|
$
|
(4,579
|
)
|
$
|
3,001
|
|||
|
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE
|
||||||||
|
PREFERRED SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY
|
$
|
3,087
|
$
|
5,256
|
||||
|
Nine months ended
September 30
|
Three months ended
September 30,
|
|||||||||||||||
|
2024
|
2023 |
2024
|
2023
|
|||||||||||||
|
U.S. dollars in
thousands
|
U.S. dollars in
thousands
|
U.S. dollars in
thousands
|
||||||||||||||
|
OPERATING EXPENSES:
|
||||||||||||||||
|
Research and development (including $1,796 and $51 from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including $1,762
and $17 from related party for the three months period ended September 30, 2024 and 2023, respectively)
|
$
|
4,944
|
$
|
2,451
|
$
|
3,217
|
$
|
535
|
||||||||
|
General and administrative (including $2,972 and $36 from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including
$2,948 and $12 from related party for the three months period ended September 30, 2024 and 2023, respectively)
|
5,727
|
502
|
4,819
|
196
|
||||||||||||
|
TOTAL OPERATING EXPENSES
|
10,671
|
2,953
|
8,036
|
731
|
||||||||||||
|
OPERATING LOSS
|
10,671
|
2,953
|
8,036
|
731
|
||||||||||||
|
Financial expenses (income), (including $(47) and $40 from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including
$(182) and $40 from related party for the three months period ended September 30, 2024 and 2023, respectively)
|
4,092
|
449
|
3,822
|
72
|
||||||||||||
|
LOSS BEFORE INCOME TAX
|
$
|
14,763
|
$
|
3,402
|
$
|
11,858
|
$
|
803
|
||||||||
|
INCOME TAX
|
9
|
26
|
2
|
6
|
||||||||||||
|
NET LOSS
|
$
|
14,772
|
$
|
3,428
|
$
|
11,860
|
$
|
809
|
||||||||
|
Attributable to:
|
||||||||||||||||
|
Equity holders of the Company
|
$
|
14,696
|
$
|
3,214
|
$
|
11,851
|
$
|
787
|
||||||||
|
Non-controlling interests
|
76
|
214
|
9
|
22
|
||||||||||||
|
$
|
14,772
|
$
|
3,428
|
$
|
11,860
|
$
|
809
|
|||||||||
|
LOSS PER SHARE, BASIC AND DILUTED
|
$
|
50.43
|
$
|
28.76
|
$
|
18.30
|
$
|
7.04
|
||||||||
|
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
|
291,407
|
111,726
|
647,568
|
111,726
|
||||||||||||
|
Redeemable Convertible Preferred Shares
|
Ordinary shares
|
Additional
paid-in Capital |
Accumulated deficit
|
Total capital deficiency
|
Total redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital deficiency
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Series A preferred shares
|
Series A-1 preferred shares
|
Series A-2 preferred shares
|
Series A-3 preferred shares
|
Series A-4 preferred shares
|
Contingently redeemable non-controlling
interests
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Shares
|
Amount
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE AT JANUARY 1, 2023
|
43,121
|
$
|
7,307
|
10,136
|
$
|
2,392
|
5,051
|
$
|
2,264
|
7,037
|
$
|
2,683
|
-
|
-
|
$
|
3,586
|
97,120
|
* |
$
|
11,204
|
$
|
(21,869
|
)
|
$
|
(10,665
|
)
|
$
|
7,567
|
||||||||||||||||||||||||||||||||||||||||
|
CHANGES DURING THE NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2023 (unaudited):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance of Preferred A-4 shares, net of issuance cost
|
2,413
|
$
|
411
|
1
|
1
|
412
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Share-based compensation
|
96
|
96
|
96
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Net loss
|
(214
|
)
|
(3,214
|
)
|
(3,214
|
)
|
(3,428
|
)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE AS OF SEPTEMBER 30, 2023
|
43,121
|
$
|
7,307
|
10,136
|
$
|
2,392
|
5,051
|
$
|
2,264
|
7,037
|
$
|
2,683
|
2,413
|
$
|
411
|
$
|
3,372
|
97,120
|
* |
$
|
11,301
|
$
|
(25,083
|
)
|
$
|
(13,782
|
)
|
$
|
4,647
|
|||||||||||||||||||||||||||||||||||||||
|
BALANCE AT JANUARY 1, 2024
|
43,121
|
$
|
7,307
|
10,136
|
$
|
2,392
|
5,051
|
$
|
2,264
|
7,037
|
$
|
2,683
|
2,413
|
$
|
411
|
$
|
3,420
|
97,120
|
* |
$
|
11,335
|
$
|
(26,811
|
)
|
$
|
(15,476
|
)
|
$
|
3,001
|
|||||||||||||||||||||||||||||||||||||||
|
CHANGES DURING THE NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2024 (unaudited):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exercise of options
|
13,780
|
**
|
* |
*
|
*
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Share-based compensation
|
78,650
|
* |
5,862
|
5,862
|
5,862
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance of convertible preferred shares upon net exercise of warrants
|
140
|
925
|
334
|
-
|
- |
-
|
334
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Net loss
|
(76
|
)
|
76
|
(14,772
|
)
|
(14,696
|
)
|
(14,772
|
)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Conversion of convertible preferred shares and noncontrolling interests upon the effectiveness of the SPAC Merger (see Note 1(d))
|
(43,121
|
)
|
$
|
(7,307
|
)
|
(10,276
|
)
|
$
|
(2,392
|
)
|
(5,051
|
)
|
$
|
(2,264
|
)
|
(7,037
|
)
|
$
|
(2,683
|
)
|
(3,338
|
)
|
$
|
(745
|
)
|
$
|
(3,344
|
)
|
478,073
|
1 |
18,734
|
18,735
|
-
|
|||||||||||||||||||||||||||||||||||
|
Issuance of ordinary shares upon Transactions (see Note 1(d))
|
417,375
|
* |
*
|
*
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance of ordinary shares for ELOC holders
|
157,269
|
*
|
996
|
996
|
996
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE AS OF SEPTEMBER 30, 2024
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1,242,267
|
$
|
1
|
$
|
37,003
|
$
|
(41,583
|
)
|
$
|
(4,579
|
)
|
$
|
(4,579
|
)
|
|||||||||||||||||||||||||||||||||||||||||||
|
Redeemable Convertible Preferred Shares
|
Ordinary shares
|
Additional
paid-in Capital |
Accumulated deficit
|
Total capital deficiency
|
Total redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital deficiency
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Series A preferred shares
|
Series A-1 preferred shares
|
Series A-2 preferred shares
|
Series A-3 preferred shares
|
Series A-4 preferred shares
|
Contingently redeemable non-controlling
interests
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Shares
|
Amount
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE AT JUNE 30, 2023
|
43,121
|
$
|
7,307
|
10,136
|
$
|
2,392
|
5,051
|
$
|
2,264
|
7,037
|
$
|
2,683
|
2,413
|
$
|
411
|
$
|
3,394
|
97,120
|
*
|
$
|
11,269
|
$
|
(24,296
|
)
|
$
|
(13,027
|
)
|
$
|
5,424
|
|||||||||||||||||||||||||||||||||||||||
|
CHANGES DURING THE THREE MONTHS PERIOD ENDED SEPTEMBER 30, 2023 (unaudited):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance of Preferred A-4 shares, net of issuance cost
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Share-based compensation
|
32
|
32
|
32
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Net loss
|
(22
|
)
|
(787
|
)
|
(787
|
)
|
(809
|
)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE AS OF SEPTEMBER 30, 2023
|
43,121
|
$
|
7,307
|
10,136
|
$
|
2,392
|
5,051
|
$
|
2,264
|
7,037
|
$
|
2,683
|
2,413
|
$
|
411
|
$
|
3,372
|
97,120
|
*
|
$
|
11,301
|
$
|
(25,083
|
)
|
$
|
(13,782
|
)
|
$
|
(4,647
|
)
|
||||||||||||||||||||||||||||||||||||||
|
BALANCE AT JUNE 30, 2024
|
43,121
|
$
|
7,307
|
10,136
|
$
|
2,392
|
5,051
|
$
|
2,264
|
7,037
|
$
|
2,683
|
2,413
|
$
|
411
|
$
|
3,353
|
110,900
|
* |
$
|
11,399
|
$
|
(29,656
|
)
|
$
|
(18,257
|
)
|
$
|
153
|
|||||||||||||||||||||||||||||||||||||||
|
CHANGES DURING THE THREE MONTHS PERIOD ENDED SEPTEMBER 30, 2024 (unaudited):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Share-based compensation
|
78,650
|
* |
5,798
|
5,798
|
5,798
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance of convertible preferred shares upon net exercise of warrants
|
140
|
925
|
334
|
-
|
-
|
334
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Net loss
|
(9
|
)
|
76
|
(11,927
|
)
|
(11,851
|
)
|
(11,860
|
)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Conversion of convertible preferred shares and noncontrolling interests upon the effectiveness of the SPAC Merger (see Note 1(d))
|
(43,121
|
)
|
$
|
(7,307
|
)
|
(10,276
|
)
|
$
|
(2,392
|
)
|
(5,051
|
)
|
$
|
(2,264
|
)
|
(7,037
|
)
|
$
|
(2,683
|
)
|
(3,338
|
)
|
$
|
(745
|
)
|
$
|
(3,344
|
)
|
478,073
|
1 |
18,734
|
18,735
|
-
|
|||||||||||||||||||||||||||||||||||
|
Issuance of ordinary shares upon Transactions (see Note 1(d))
|
417,375
|
* |
*
|
*
|
*
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance of ordinary shares for ELOC holders, net of issuance cost, see Note 3(d)
|
157,269
|
*
|
996
|
996
|
996
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE AS OF SEPTEMBER 30, 2024
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1,242,267
|
$
|
1
|
$
|
37,003
|
$
|
(41,583
|
)
|
$
|
(4,579
|
)
|
$
|
(4,579
|
)
|
|||||||||||||||||||||||||||||||||||||||||||
|
Nine months ended
September 30,
|
Three months ended
September 30
|
|||||||||||||||
|
2024
|
2023
|
2024
|
2023
|
|||||||||||||
|
U.S. dollars in thousands
|
U.S. dollars in thousands
|
|||||||||||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||||||||||
|
Net loss
|
$
|
(14,772
|
)
|
$
|
(3,428
|
)
|
$
|
(11,860
|
)
|
$
|
(809
|
)
|
||||
|
Adjustments required to reconcile loss to net cash used in operating activities:
|
||||||||||||||||
|
Depreciation
|
37
|
39
|
22
|
10
|
||||||||||||
|
Share-based compensation expenses
|
5,862
|
96
|
5,798
|
32
|
||||||||||||
|
Non-cash financial expenses
|
3,968
|
365
|
3,749
|
108
|
||||||||||||
|
Gain on disposal of property and equipment
|
-
|
(1
|
)
|
-
|
(1
|
)
|
||||||||||
|
Loss from lease termination
|
68
|
-
|
68
|
-
|
||||||||||||
|
Changes in operating assets and liabilities:
|
||||||||||||||||
|
Increase (decrease) in prepaid expenses
|
(609
|
)
|
(200
|
)
|
(417
|
)
|
(198
|
)
|
||||||||
|
Increase (decrease) in other receivables
|
(59
|
)
|
15
|
(17
|
)
|
24
|
||||||||||
|
Increase (decrease) in trade payable
|
479
|
74
|
517
|
131
|
||||||||||||
|
Net change in operating lease
|
(40
|
)
|
(7
|
)
|
(44
|
)
|
(2
|
)
|
||||||||
|
Increase (decrease) in employee related obligations
|
480
|
(75
|
)
|
436
|
(13
|
)
|
||||||||||
|
Increase (decrease) in accrued expenses
|
(884
|
)
|
(150
|
)
|
(905
|
)
|
33
|
|||||||||
|
Net cash used in operating activities
|
(5,470
|
)
|
(3,272
|
)
|
(2,653
|
)
|
(685
|
)
|
||||||||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||||||||||
|
Proceeds from short-term deposit
|
-
|
507
|
-
|
-
|
||||||||||||
|
Purchase of property and equipment
|
(22
|
)
|
(8
|
)
|
(16
|
)
|
(6
|
)
|
||||||||
|
Proceeds from Sale of property and equipment
|
-
|
78
|
-
|
78
|
||||||||||||
|
Net cash provided by (used in (investing activities
|
(22
|
)
|
577
|
(16
|
)
|
72
|
||||||||||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||||||||||
|
Proceeds from issuance of preferred shares and warrants, net of issuance costs
|
-
|
522
|
-
|
-
|
||||||||||||
|
Proceeds from issuance of ordinary shares (ELOC)
|
620
|
-
|
620
|
-
|
||||||||||||
|
Cash received from Transactions upon the effectiveness of the SPAC Merger
|
2,300
|
-
|
2,300
|
-
|
||||||||||||
|
Net cash provided by financing activities
|
2,920
|
522
|
2,920
|
-
|
||||||||||||
|
DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
|
(2,572
|
)
|
(2,173
|
)
|
251
|
(613
|
)
|
|||||||||
|
EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
|
(50
|
)
|
(324
|
)
|
25
|
(66
|
)
|
|||||||||
|
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD
|
4,645
|
8,309
|
1,747
|
6,491
|
||||||||||||
|
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD
|
2,023
|
$
|
5,812
|
2,023
|
5,812
|
|||||||||||
|
Nine months ended
September 30,
|
Three months ended
September 30
|
|||||||||||||||
| 2024 |
2023
|
2024 |
2023
|
|||||||||||||
|
U.S. dollars in thousands
|
U.S. dollars in thousands
|
|||||||||||||||
|
Appendix A – RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS:
|
||||||||||||||||
|
Cash and cash equivalents
|
1,973
|
5,764
|
1,973
|
5,764
|
||||||||||||
|
Restricted cash
|
50
|
48
|
50
|
48
|
||||||||||||
|
TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS
|
$
|
2023
|
$
|
5,812
|
$
|
2023
|
$
|
5,812
|
||||||||
|
Appendix B - SUPPLEMENTARY INFORMATION:
|
||||||||||||||||
|
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
|
||||||||||||||||
|
Operating lease termination
|
$
|
(55
|
)
|
$
|
-
|
$
|
(55
|
)
|
$
|
-
|
||||||
|
Conversion of preferred shares
|
$
|
15,058
|
$
|
-
|
$
|
15,058
|
$
|
-
|
||||||||
|
Conversion of warrants to preferred shares on a cashless basis
|
$
|
334
|
$
|
-
|
$
|
334
|
$
|
-
|
||||||||
|
Conversion of non-controlling interests
|
$
|
3,344
|
$
|
-
|
$
|
3,344
|
$
|
-
|
||||||||
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
|
||||||||||||||||
|
Interest received
|
$
|
25
|
$
|
120
|
$
|
-
|
$
|
42
|
||||||||
| a. |
Silexion Therapeutics Corp (“New Silexion”) (hereinafter -"the Company" or the “combined company”) is a newly formed entity that was formed for the purpose of effecting the Transactions (see below), and now serves as a publicly-traded
holding company of its subsidiaries — including Moringa Acquisition Corp (“Moringa” or “the SPAC”), a Cayman Islands exempted company and Silexion Therapeutics Ltd. (formerly known as Silenseed Ltd.) (“Silexion”), an Israeli limited
company— after the closing of the Transactions (the “Closing”).
|
| b. |
Financial Information Presented:
|
| c. |
Subsidiaries:
|
| 1. |
Silenseed (China) Ltd. On April 28, 2021, Silexion (as the predecessor entity to the Company) signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (“GIBF”) to establish a new company in China. On June 15, 2021 a
company was established in China, named Silenseed (China) Ltd. (hereinafter - the "Subsidiary"). As of September 30, 2024, following transfer of all interests in the Subsidiary to the Company as part of the Transactions, the Company owns
(directly or indirectly) 100% of the shares of the Subsidiary. The Subsidiary has no significant operations as of September 30, 2024 (see Note c).
|
| 2. |
Moringa. Prior to the Transactions, Moringa’s class A ordinary shares and warrants were listed for trading on the Nasdaq Capital Market (Nasdaq: MACA and MACAW). As part of the Transactions, Moringa merged with a wholly-owned
subsidiary of the Company and now serves as an inactive, wholly-owned subsidiary of the Company.
|
| 3. |
Silexion. Silexion was incorporated in Israel and began its operations on November 30, 2008. Since its incorporation, Silexion has been engaged in one operating segment - the research and development of innovative treatments for
pancreatic cancer based on siRNAs, aiming to stop the production of a specific pancreatic cancer-causing protein known as the KRAS mutation. Silexion’s long-lived assets are located in Israel.
|
| 4. |
The Company, the Subsidiary, Moringa and Silexion are together referred to hereinafter as “the Group”.
|
| d. |
On April 3, 2024, Silexion entered into an Amended and Restated Business Combination Agreement (hereinafter, “A&R BCA”) with the SPAC, New Silexion, August M.S. Ltd. an Israeli company and wholly-owned subsidiary of New Silexion
(“Merger Sub 1”), and Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and wholly-owned subsidiary of New Silexion (“Merger Sub 2”). Under the A&R BCA, both Silexion and the SPAC were toi become wholly-owned
subsidiaries of New Silexion, which was to become a publicly-held, Nasdaq-listed entity (the A&R BCA and related transactions: the “Transactions”).
|
| e. |
In connection with the closing of the Transactions, the ordinary shares and warrants of New Silexion are now listed on the Nasdaq Global Market and began trading under the symbols “SLXN” and “SLXNW”, respectively.
|
| f. |
For more information on instruments issued as part of the Transactions, see Note 3.
|
| g. |
The Transactions were accounted for as a reverse recapitalization in accordance with US GAAP. Under this method of accounting, Silexion was treated as the accounting acquirer and the SPAC was treated as the “acquired” company for
financial reporting purposes. Silexion was determined to be the accounting acquirer based on evaluation of the following facts and circumstances:
|
| h. |
In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack, Israel’s security cabinet declared war against Hamas and
commenced a military campaign against Hamas and other terrorist organizations.
|
| i. |
Going concern:
|
|
The Company expects to continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating various financing
alternatives, as the Company will need to finance future research and development activities, general and administrative expenses and working capital through fund raising. However, there is no assurance that the Company will be
successful in obtaining such funding.
Under these circumstances, in accordance with the requirements of ASC 205-40, management has concluded that there is substantial doubt about the
Company’s ability to continue as a going concern for at least 12 months from the date these financial statements are issued. The unaudited condensed consolidated financial statements do not include any adjustments that may be
necessary should the Company be unable to continue as a going concern (see Note 1 (d)).
|
| a. |
Unaudited Condensed Financial Statements
The accompanying condensed financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in
accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial statements and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim financial
reporting. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all
adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of September 30, 2024, and the consolidated results of operations, statements of changes in
redeemable convertible preferred shares and capital deficiency and cash flows for the nine-month and three-month periods ended September 30, 2024 and 2023.
The consolidated results for the nine-months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31,
2024.
These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of Silexion as of
and for the year ended December 31, 2023, which are included in a current report on Form 8-K and in a registration statement on Form S-1/A which the Company is filing with the SEC presently. The significant accounting policies adopted and
used in the preparation of the financial statements are consistent with those of the previous financial year.
|
| b. |
Use of estimates
The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the
financial statements and accompanying notes. As applicable to these financial statements, the most significant estimates and assumptions relate share-based compensation and to fair value of financial instruments. See Note 6 and Notes 4
and 7, respectively. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.
|
| c. |
Restricted cash
|
| d. |
Fair value measurement
|
| Level 1: |
Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
|
| Level 2: |
Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.
|
| Level 3 |
Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
|
| e. |
Concentration of credit risks
|
| f. |
Loss per share
|
| g. |
Contracts over Ordinary Shares
|
| h. |
Promissory Notes
|
| i. |
New accounting pronouncements:
|
| 1) |
In November 2023, the FASB issued ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily through enhanced disclosures about
significant segment expenses. The ASU also require that a public entity that has a single reportable segment to provide all the disclosures required by the amendments and all existing segment disclosures in Topic 280. The ASU is effective
for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating this ASU to determine its impact on the Company's segment disclosures.
|
| 2) |
In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate
reconciliation, and modifies other income tax-related disclosures. The ASU will be effective for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with a retrospective option. The Company is in the
process of assessing the impacts and method of adoption.
|
| 3) |
In November 2024, the FASB issued ASU No. 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures about a public business entity’s expenses and
provides more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of
inventory, employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, SG&A and research and development). The ASU is effective for fiscal years beginning after December 15,
2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating this ASU to determine its impact on the Company's disclosures.
|
| a. |
Underwriters Promissory Note
Prior to the Closing, Moringa reached agreement with EarlyBird Capital, Inc. (“EarlyBird”) on the reduction, to $1,600, in the aggregate, of the fee payable to EarlyBird under the
Marketing Agreement entered into by Moringa with EarlyBird at the time of Moringa’s initial public offering (“IPO”). At the Closing, Moringa paid $350 of cash to EarlyBird from its Trust Account and New Silexion issued to EarlyBird a
convertible promissory note, due December 31, 2025, in an amount of $1,250 to be paid by New Silexion to EarlyBird in cash or via conversion of outstanding amounts into ordinary shares of New Silexion (the “EarlyBird Convertible Note”).
The EarlyBird Convertible Note bears interest at a rate of 6% per annum and matures on December 31, 2025. If not repaid on or prior to that maturity date or such earlier date as to which
the repayment obligation may be accelerated under the note, or not converted in accordance with the terms thereof, the rate of interest applicable to the unpaid principal amount would be adjusted to (15%) per annum. New Silexion is
required to make mandatory prepayments on the note in amounts equal to 10% of the gross proceeds received by New Silexion from any equity financings consummated by it prior to the maturity date.
New Silexion is entitled to voluntarily prepay any additional part of, or all of, the principal and accrued interest, in one or more installments without penalty, prior to the maturity
date.
|
|
EarlyBird, in turn, may elect, at its sole discretion, at any time on or prior to the maturity date, to elect to convert all or part of the then outstanding principal and/or accrued interest under the
EarlyBird Convertible Note into New Silexion ordinary shares, at a per share conversion price equal to 95% of the volume weighted average price of a New Silexion ordinary share for the five trading days immediately prior to the date
of New Silexion’s receipt of a conversion notice.
As of the date of this report, the Company repaid $100 of the EarlyBird Convertible Note as a result of the share issuance under the ELOC Agreement; see Note 3(d).
|
| b. |
Sponsor Promissory Note
Effective as of the Closing, New Silexion issued to the Sponsor in replacement in their entirety of all previously existing promissory notes issued by Moringa to the
Sponsor from its IPO until the Closing, an amended and restated promissory note (the “A&R Sponsor Promissory Note”) in an amount of $3,433. This reflected the total amount owed by Moringa to the Sponsor through the Closing Date. The
maturity date of the A&R Sponsor Promissory Note is the 30-month anniversary of the Closing Date (i.e., February 15, 2027). Amounts outstanding under the A&R Sponsor Promissory Note may be repaid (unless otherwise decided by New
Silexion) only by way of conversion into New Silexion ordinary shares (“Note Shares”). New Silexion and the Sponsor may also convert amounts outstanding under the A&R Sponsor Promissory Note at the price per share at which New
Silexion conducts an equity financing following the Closing, subject to a minimum conversion amount of $100, in an amount of Note Shares constituting up to thirty percent (30%) of the number of New Silexion ordinary shares issued and sold
by New Silexion in such equity financing. The Sponsor may also elect to convert amounts of principal outstanding under the note into New Silexion ordinary shares at any time following the 24-month anniversary of the Closing Date, subject
to a minimum conversion of $10, at a price per share equal to the volume weighted average price of the New Silexion ordinary shares on the principal market on which they are traded during the 20 consecutive trading days prior to the
conversion date.
As of the date of this report, the Company has neither repaid, nor converted into New Silexion ordinary shares, any principal amounts outstanding under the Sponsor
Promissory Note.
|
| c. |
PIPE Financing
In connection with, and immediately prior to the Closing of the Transactions, Moringa raised $2,000 via a private investment in public entity financing (the “PIPE
Financing”), whereby Moringa sold to Greenstar, LP, an affiliate of the Moringa Sponsor (the “PIPE Investor”), 22,223 newly issued Moringa ordinary shares at a price of $90.00 per share, pursuant to a subscription agreement, dated as of
August 15, 2024, by and among Moringa, New Silexion and the PIPE Investor (the “PIPE Agreement”). Those 22,223 shares automatically converted upon the Closing of the Transactions into an equivalent number of New Silexion ordinary shares
(the “PIPE Shares”).
|
| d. |
ELOC Financing
In connection with the Closing, New Silexion entered into an ordinary share purchase agreement, effective as of the Closing Date (the “ELOC Agreement”), for an equity
line of credit (the “ELOC”) with White Lion Capital, LLC (the “ELOC Investor”), whereby New Silexion will be able to request to sell to the ELOC Investor, and the ELOC Investor will be required to purchase, via private placement
transactions, up to $15,000 of New Silexion ordinary shares from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated sooner), subject to certain limitations and conditions as described therein.
The number of New Silexion ordinary shares that New Silexion may require the ELOC Investor to purchase in any single sales notice will depend on a number of factors, including the type of purchase notice that New Silexion delivers.
Similarly, the purchase price to be paid by the ELOC Investor for any shares that New Silexion requires it to purchase will depend on the type of sales notice that New Silexion delivers.
|
|
Purchase price is determined with reference to either the lowest daily volume-weighted average price of the Company’s Ordinary Shares during a period of three
consecutive business days ending on the notice date times 97% or lowest traded price of the Company’s Ordinary Shares on the notice date.
Pursuant to the ELOC Agreement, New Silexion agreed, among other things, that if New Silexion’s sales to the ELOC Investor under the ELOC exceed 19.99% of New
Silexion’s total number of ordinary shares outstanding, New Silexion will seek the approval of its shareholders for the issuance of any New Silexion ordinary shares under the ELOC in excess of that amount, in accordance with the Nasdaq
Listing Rules, subject to certain exceptions based on the price of the New Silexion ordinary shares to be sold in excess of that limit.
In consideration for the commitments of the ELOC Investor, New Silexion agreed to issue to the ELOC Investor an aggregate of $337.5 of New Silexion ordinary shares
(the “ELOC Commitment Shares”). On September 18, 2024 the Company issued 40,602 ordinary shares to White Lion LLC as the Commitment Shares. Issuance expenses amounted to $52.
During the three months ended September 30, 2024, the Company sold 116,667 ordinary shares under the ELOC at an
average price of $6.255 per share, net of fees of approximately $20. The net proceeds from those sales were $620. For further information see Note 11.
|
| e. |
SPAC Warrants
On the Closing Date, Moringa, New Silexion and Continental Stock Transfer & Trust Company (“CST”) entered into a certain Assignment, Assumption and Amendment
Agreement (the “New Warrant Agreement”). The New Warrant Agreement amended Moringa’s Warrant Agreement, dated as of February 19, 2021, to provide for the assignment by Moringa of all its rights, title and interest in the warrants of
Moringa to New Silexion.
Upon Closing, New Silexion assumed 638,889 warrants sold by Moringa in its IPO (“Public Warrants”) and 21,112 warrants sold by Moringa to the Sponsor and EarlyBird concurrently with its IPO (the “Private
Warrants”, and together with the Public Warrants, the “Warrants”). Each such Warrant entitles the holder thereof to purchase one Ordinary Share of New Silexion of $103.50 per share, subject to adjustment. No fractional shares will be
issued upon exercise of the Warrants. Each Warrant became exercisable 30 days after the Closing and will expire after five years after the completion of the Closing or earlier upon redemption (only in the case of the Public Warrants) or
liquidation.
Once the Public Warrants became exercisable, the Company may redeem them in whole and not in part at a price of $0.09 per Warrant upon a minimum of 30 days’ prior
written notice of redemption, if and only if the last reported sale price of the Company’s ordinary shares equals or exceeds $162.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third
trading day prior to the date on which the Company sends the notice of redemption to the Public Warrant holders.
The Company recognized a net liability, measured at fair value through profit or loss, from the Transactions (see also Note 2). As such, transaction costs related to
the Transactions were expensed as incurred.
The Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBird or their respective affiliates, the
Private Warrants: (1) will not be redeemable by the Company; (2) could not (subject to certain limited exceptions), be transferred, assigned or sold by the holders thereof until 30 days after the Closing; (3) may be exercised by the
holders thereof on a cashless basis; and (4) are entitled to registration rights.
|
| a. |
Research and development expenses:
|
|
Nine months ended
September 30,
|
Three months ended
September 30,
|
|||||||||||||||
|
2024
|
2023
|
2024
|
2023
|
|||||||||||||
|
U.S. dollars in thousands
|
U.S. dollars in thousands
|
|||||||||||||||
|
Payroll and related expenses
|
$
|
928
|
$
|
729
|
$
|
453
|
$
|
198
|
||||||||
|
Share-based compensation expenses
|
2,424
|
57
|
2,385
|
19
|
||||||||||||
|
Subcontractors and consultants
|
1,425
|
1,444
|
297
|
236
|
||||||||||||
|
Materials
|
3
|
16
|
-
|
-
|
||||||||||||
|
Rent and maintenance
|
106
|
124
|
57
|
46
|
||||||||||||
|
Travel expenses
|
13
|
27
|
-
|
-
|
||||||||||||
|
Other
|
45
|
54
|
25
|
36
|
||||||||||||
|
$
|
4,944
|
$
|
2,451
|
$
|
3,217
|
$
|
535
|
|||||||||
| b. |
General and administrative expenses:
|
|
Payroll and related expenses
|
$
|
856
|
$
|
190
|
$
|
575
|
$
|
71
|
||||||||
|
Share-based compensation expenses
|
3,438
|
39
|
3,413
|
13
|
||||||||||||
|
Professional services
|
1,053
|
79
|
605
|
51
|
||||||||||||
|
Depreciation
|
37
|
39
|
22
|
10
|
||||||||||||
|
Rent and maintenance
|
90
|
67
|
18
|
25
|
||||||||||||
|
Patent registration
|
25
|
18
|
-
|
2
|
||||||||||||
|
Travel expenses
|
72
|
31
|
56
|
15
|
||||||||||||
|
Other
|
156
|
39
|
130
|
9
|
||||||||||||
|
$
|
5,727
|
$
|
502
|
$
|
4,819
|
$
|
196
|
| c. |
Financial expense, net:
|
|
Change in fair value of financial liabilities measured at fair value
|
$
|
(919
|
)
|
$
|
(3
|
)
|
$
|
(1,064
|
)
|
$
|
-
|
|||||
|
Issuance costs
|
52
|
47
|
52
|
44
|
||||||||||||
|
Loss upon entering Transactions
|
4,783
|
-
|
4,783
|
-
|
||||||||||||
|
Interest income
|
(25
|
)
|
(120
|
)
|
-
|
(42
|
)
|
|||||||||
|
Foreign currency exchange loss, net
|
196
|
520
|
48
|
69
|
||||||||||||
|
Other
|
5
|
5
|
3
|
1
|
||||||||||||
|
Total financial expense, net
|
$
|
4,092
|
$
|
449
|
$
|
3,822
|
$
|
72
|
| a. |
On August 15, 2024, the Company vacated its office spaces and facilities in Israel. On September 8, 2024, an early termination agreement for the operating lease was signed with the landlord, which included a termination penalty. As a
result, the Company derecognized the right-of-use asset and the lease liability in its financial statements, recording a loss of $68 from the lease termination and an additional $18 from the disposal of leasehold improvements.
|
| b. |
On September 26, 2024 the Company signed a new lease agreement for an office in Israel starting November 1, 2024 and ending on October 31, 2026. The Company will pay a monthly payment of $10 to the lessor.
|
|
On May 30, 2023, Silexion issued warrants to acquire 2,413 Series A-4 Preferred Shares to various investors, with an exercise price of $222.921 per share and an expiration date of May 30, 2025. Issuance
expenses amounted to $3. On August 6, 2024, all of these warrants were exercised via a ‘cashless’ manner for 913 Preferred A4 shares of Silexion.
Silexion classified the warrants for the purchase of shares of its convertible redeemable preferred shares as a liability in its consolidated balance sheets, as these warrants were freestanding financial
instruments which underlying shares were contingently redeemable and, therefore, may have obligated the Company to transfer assets at some point in the future. The warrant liability was initially recorded at fair value upon the date of
issuance and was subsequently remeasured at fair value at each reporting date. The Company (or Silexion, as applicable) recorded revaluation expenses amounting to $134 and $40 for the nine months periods ended September 30, 2024 and
September 30, 2023 , respectively, and revaluation (income) expenses amounting to $(11) and $43 for the three months periods ended September 30, 2024 and September 30, 2023 and accounted for such revaluation expenses as part of its
financial (income) expense, net, in the statements of operations (see Note 8).
For further information in respect of warrants granted to a service provider and exercised, see Note 7.
For cashless exercise of these warrants see Note 1(d).
|
|
The Company's (or Silexion’s, as applicable) share-based expenses amounted to a total of $5,862 and $96 in the nine months periods ended September 30, 2024 and 2023, respectively. As of September 30,
2024, 63,953 shares remain available for grant under the Company’s 2013, 2023 and 2024 Equity Incentive Plans.
On July 4, 2024, Silexion’s board of directors approved granting fully vested 78,650 RSUs to Silexion’s employees and directors amounting to a total of $5,578. For a description of the acceleration of the
Company’s options prior to the Closing of the Transactions, see Note 1(d).
The fair value for the RSUs granted is based on the following assumptions:
|
|
Expected volatility
|
74.82
|
%
|
||
|
Assumptions regarding the price of the underlying shares:
|
||||
|
Probability of an IPO scenario (including de-SPAC transaction)
|
67
|
%
|
||
|
Expected time to IPO (including de-SPAC transaction) (years)
|
0.137
|
|||
|
Probability of other liquidation events
|
33
|
%
|
||
|
Expected time to liquidation (years)
|
2.25
|
|||
|
Expected return on Equity
|
22
|
%
|
|
On August 6, 2024, a service provider exercised the warrants in a ‘cashless’ manner, resulting in the issuance of 140 Series A-1 Preferred Shares and 12 Series A-4 Preferred Shares of Silexion (see Note
11(1) to the audited financial statements of Silexion as of December 31, 2023, which were published on May 9, 2024).
|
|
Summary of outstanding and exercisable options:
Below is a summary of the Company's (or for periods prior to the Closing of the Transactions, Silexion’s) stock-based compensation activity and related information with
respect to options granted to employees and non-employees for the nine month period ended September 30, 2024:
|
|
Number of options
|
Weighted-average exercise price (in U.S. dollars)
|
Weighted- average remaining contractual term
(in years)
|
Aggregate
intrinsic
value
|
|||||||||||||
|
Outstanding at January 1, 2024
|
53,914
|
$
|
38.94
|
4.88
|
$
|
316
|
||||||||||
|
Granted
|
-
|
-
|
-
|
-
|
||||||||||||
|
Exercised
|
(13,780
|
)
|
$
|
0.03
|
(0.01
|
)
|
$
|
490
|
||||||||
|
Forfeited
|
(326
|
)
|
$
|
60.52
|
(6.02
|
)
|
-
|
|||||||||
|
Expired
|
(13,492
|
)
|
$
|
41.06
|
-
|
-
|
||||||||||
|
Outstanding at September 30, 2024
|
26,316
|
$
|
57.97
|
7.09
|
-
|
|||||||||||
|
Exercisable at September 30, 2024
|
26,316
|
$
|
57.97
|
7.09
|
-
|
|||||||||||
|
Vested and expected to vest at September 30, 2024
|
26,316
|
$
|
57.97
|
7.09
|
-
|
|||||||||||
|
Up to September 30, 2024 and for the year ended December 31, 2023 no options were granted.
The share-based compensation expense by line item in the accompanying consolidated statements of operations is summarized as follows:
|
|
Nine months ended
September 30,
|
Three months ended
September 30,
|
|||||||||||||||
|
2024
|
2023
|
2024
|
2023
|
|||||||||||||
|
Research and development
|
$
|
2,424
|
$
|
57
|
$
|
2,385
|
$
|
19
|
||||||||
|
General and administrative
|
3,438
|
39
|
3,413
|
13
|
||||||||||||
|
$
|
5,862
|
$
|
96
|
$
|
5,798
|
$
|
32
|
|||||||||
|
Financial instruments measured at fair value on a recurring basis
The Company’s (or, for periods prior to the Closing of the Transactions, Silexion’s) assets and liabilities that are measured at fair value as of September 30, 2024, and December 31, 2023, are
classified in the tables below in one of the three categories described in “Note 2 – Fair value measurement”:
|
|
September 30, 2024
|
||||||||
|
Level 3
|
Total
|
|||||||
|
Financial Liabilities
|
||||||||
|
Private Warrants to purchase ordinary shares
|
$
|
10
|
$
|
10
|
||||
|
Promissory Notes
|
$
|
4,312
|
$
|
4,312
|
||||
|
December 31, 2023
|
||||||||
|
Level 3
|
Total
|
|||||||
|
Financial Liabilities
|
||||||||
|
Warrants to preferred shares
|
$
|
200
|
$
|
200
|
||||
|
The following is a roll forward of the fair value of liabilities classified under Level 3:
|
|
Nine months ended September 30, 2024
|
Three months ended September 30, 2024
|
|||||||||||||||||||||||
|
Warrants to preferred shares
|
Warrants to Ordinary shares
|
Promissory Notes
|
Warrants to preferred shares
|
Warrants to Ordinary shares
|
Promissory
Notes
|
|||||||||||||||||||
|
Fair value at the beginning of the period
|
$
|
200
|
$
|
-
|
$
|
-
|
$
|
345
|
$
|
-
|
$
|
-
|
||||||||||||
|
Issuance
|
-
|
1,130
|
4,622
|
-
|
1,130
|
4,622
|
||||||||||||||||||
|
Change in fair value
|
134
|
(1,120
|
)
|
(310
|
)
|
(11
|
)
|
(1,120
|
)
|
(310
|
)
|
|||||||||||||
|
Conversion
|
(334
|
)
|
-
|
-
|
(334
|
)
|
-
|
-
|
||||||||||||||||
|
Fair value at the end of the period
|
$
|
-
|
$
|
10
|
$
|
4,312
|
$
|
-
|
$
|
10
|
$
|
4,312
|
||||||||||||
|
Nine months ended September 30, 2023
|
Three months ended September 30, 2023
|
|||||||
|
Warrants to preferred share
|
Warrants to preferred shares
|
|||||||
|
Fair value at the beginning of the period
|
$
|
3
|
$
|
111
|
||||
|
Issuance
|
111
|
-
|
||||||
|
Change in fair value
|
40
|
43
|
||||||
|
Fair value at the end of the period
|
$
|
154
|
$
|
154
|
||||
|
ELOC agreement
As the ELOC agreement is in substance a purchased call option over the Company’s own shares at a price mentioned in Note 3(d), the fair value of this agreement will generally be
approximately zero, until the Company sells shares under the agreement. Once the Company sells share under the agreement, the difference between cash raised (net of transaction costs) and the closing price of the
Ordinary Shares as of the date of their issuance is recognized as financing income or expenses.
Fair value gain and losses arising from ELOC agreement are measured with reference to the spot price of the Company’s shares sold less consideration receivable from the investor.
Warrant to preferred shares
The fair value of Silexion’s warrant to purchase preferred shares as of September 30, 2023 and December 31, 2023 was estimated using a hybrid model in order to reflect two scenarios: (1)
an IPO event (including de-SPAC transaction) and (2) other liquidation events. For further details see Note 12 in the annual consolidated financial statements.
The valuation under the ‘other liquidation events’ scenario was assessed using an option pricing model (OPM) by implementing a Monte Carlo Simulation, which treats the financial
instruments
in Silexion’s equity as contingent claims whose future payoff depends on Silexion’s future equity value. Silexion’s entire equity value in 2023 was calculated based, among others, on the
financing round closest to the valuation date.
Promissory Notes
In measuring the fair value of the Company’s Promissory Notes, a discount rate of 11.4%-13.1% was used, based on a B- rated US dollar zero-coupon discount curve, plus a credit spread of
6.67%. The expected timing of conversion or redemption of the notes was determined using the Company’s forecasts.
|
|
Warrants over ordinary shares
A Black-Scholes-Merton model with Level 3 inputs was used to calculate the warrants’ fair value. Inherent in a Black-Scholes-Merton model are assumptions related to expected life (term),
expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants based on implied volatility from the Company’s traded warrants and from historical
volatility of selected peer companies’ Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant
date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the
historical rate, which the Company anticipates remaining at zero.
The following table provides quantitative information regarding Level 3 fair value measurements inputs of the warrants:
|
|
September 30,
|
August 15,
|
|||||||
|
2024
|
2024
|
|||||||
|
Volatility
|
76.86
|
%
|
80.23
|
%
|
||||
|
Dividend yield
|
0
|
%
|
0
|
%
|
||||
|
Financial instruments not measured at fair value
The carrying amounts of cash and cash equivalents, restricted cash, receivables, trade payables and other liabilities approximate their fair value due to the short-term maturity of
such instruments.
|
|
The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented (USD in thousands, except per
share data):
|
|
Nine months ended
September 30,
|
Three months ended
September 30,
|
|||||||||||||||
|
2024
|
2023 |
2024
|
2023 | |||||||||||||
|
Numerator:
|
||||||||||||||||
|
Net loss
|
$
|
14,772
|
$
|
3,428
|
$
|
11,860
|
$
|
809
|
||||||||
|
Net loss attributable to ordinary shareholders, basic and diluted:
|
$
|
14,696
|
$
|
3,214
|
$
|
11,851
|
$
|
787
|
||||||||
|
Denominator:
|
||||||||||||||||
|
Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted
|
291,407
|
111,726
|
647,568
|
111,726
|
||||||||||||
|
Net loss per share attributable to ordinary shareholders, basic and diluted
|
$
|
50.43
|
$
|
28.76
|
$
|
18.30
|
$
|
7.04
|
||||||||
|
Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period,
including fully vested pre-funded options for the Company’s (or Silexion’s, as applicable) ordinary shares at an exercise price of $0.027 or 0.0063 NIS per share, as the Company (or Silexion, as
applicable) considers these shares to be exercised for little to no additional consideration.
As of September 30, 2024 and September 30, 2023, the basic loss per share calculation included a weighted average number of 133 and 14,652, respectively, of fully vested
pre-funded options. As the inclusion of other potential ordinary shares equivalents in the calculation would be anti-dilutive for all periods presented, diluted net loss per share is the same as basic net
loss per share.
|
|
The following instruments were not included in the computation of diluted earnings per share because of their anti-dilutive effect:
|
| - |
Redeemable convertible preferred shares;
|
| - |
Warrants to purchase redeemable convertible preferred shares;
|
| - |
Share-based compensation issuable at substantial consideration;
|
| - |
Private Warrants to purchase ordinary shares;
|
| - |
Promissory Notes.
|
|
Transactions with related parties which are shareholders and directors of the Company (or Silexion, for periods prior to the Closing of the Transactions):
|
| a. |
Transactions:
|
|
Nine months ended
September 30,
|
Three months ended
September 30
|
|||||||||||||||
|
2024
|
2023
|
2024
|
2023
|
|||||||||||||
|
Share-based compensation included in research and development expenses
|
$
|
1,796
|
$
|
51
|
$
|
1,762
|
$
|
17
|
||||||||
|
Share-based compensation included in general and administrative expenses
|
$
|
2,972
|
$
|
36
|
$
|
2,948
|
$
|
12
|
||||||||
|
Financial expenses
|
$
|
(47
|
)
|
$
|
40
|
$
|
(182
|
)
|
$
|
40
|
||||||
| b. |
Balances:
|
|
September 30, 2024
|
December 31, 2023
|
|||||||
|
Non-Current liabilities -
|
||||||||
|
Warrants to purchase preferred shares
|
$
|
-
|
$
|
186
|
||||
|
Private warrants to purchase ordinary shares
|
$
|
10
|
-
|
|||||
|
Promissory Note
|
$
|
3,106
|
$
|
-
|
||||
| a. |
On October 1, 2024, the Company completed an equity raise through the ELOC, issuing 293,777 ordinary shares for a total consideration of $1,658.
|
| b. |
On October 22, 2024, the Company completed an equity raise through the ELOC, issuing 66,667 ordinary shares for a total consideration of $200.
|
| c. |
On October 29, 2024, the Company received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days preceding
the letter, the closing bid price of the Company’s Ordinary Shares was below the minimum $1.00 per share required for continued listing on The Nasdaq Stock Market. The Company has been given 180 calendar days, or until April 28, 2025, to
regain compliance. If at any time before April 28, 2025, the bid price of the Ordinary Shares closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company
has achieved compliance.
|
| d. |
d. For information regarding the reverse share split, see Note 1 (g)
|
|
Page
|
|
|
F-67
|
|
|
CONSOLIDATED FINANCIAL STATEMENTS:
|
|
| F-68 - F-69 |
|
| F-70 |
|
|
F-71
|
|
| F-72 - F-73 |
|
| F-74 - F-99 |

|
/s/Kesselman & Kesselman
|
|
|
Certified Public Accountants (lsr.)
|
|
|
A member firm of PricewaterhouseCoopers International Limited
|
|
|
Tel-Aviv, Israel
|
|
|
May 9, 2024, except for the effects of the reverse share split discussed in note 1c, and except for the effects of the merger exchange ratio discussed in note 1c,
as to which the date is January 13, 2025
|
|
|
Kesselman & Kesselman, 146 Derech Menachem Begin, Tel-Aviv 6492103, Israel,
P.O Box 50005 Tel-Aviv 6150001, Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il
|
|
December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Assets
|
||||||||
|
CURRENT ASSETS:
|
||||||||
|
Cash and cash equivalents
|
$
|
4,595
|
$
|
8,259
|
||||
|
Restricted cash
|
25
|
25
|
||||||
|
Short term deposits
|
-
|
507
|
||||||
|
Prepaid expenses
|
335
|
6
|
||||||
|
Other current assets
|
24
|
42
|
||||||
|
TOTAL CURRENT ASSETS
|
4,979
|
8,839
|
||||||
|
NON-CURRENT ASSETS:
|
||||||||
|
Restricted cash
|
25
|
25
|
||||||
|
Long-term deposit
|
5
|
5
|
||||||
|
Property and equipment, net
|
49
|
159
|
||||||
|
Operating lease right-of-use asset
|
198
|
305
|
||||||
|
TOTAL NON-CURRENT ASSETS
|
277
|
494
|
||||||
|
TOTAL ASSETS
|
$
|
5,256
|
$
|
9,333
|
||||
|
December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Liabilities and redeemable convertible preferred shares, net of capital deficiency
|
||||||||
|
CURRENT LIABILITIES:
|
||||||||
|
Trade payables
|
$
|
319
|
$
|
240
|
||||
|
Current maturities of operating lease liability
|
112
|
115
|
||||||
|
Warrants to preferred shares (including $186 and $0 due to related party, respectively)
|
200
|
3
|
||||||
|
Employee related obligations
|
207
|
253
|
||||||
|
Accrued expenses
|
1,358
|
999
|
||||||
|
TOTAL CURRENT LIABILITIES
|
2,196
|
1,610
|
||||||
|
NON-CURRENT LIABILITIES:
|
||||||||
|
Long-term operating lease liability
|
59
|
156
|
||||||
|
TOTAL NON-CURRENT LIABILITIES
|
$
|
59
|
$
|
156
|
||||
|
TOTAL LIABILITIES
|
$
|
2,255
|
$
|
1,766
|
||||
|
COMMITMENTS AND CONTINGENT LIABILITIES (Note 6)
|
||||||||
|
REDEEMABLE CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERESTS:
|
||||||||
|
Convertible Series A Preferred Shares (NIS 0.09 par value, 56,667 shares authorized as of December 31, 2023 and 2022, 43,121 shares issued and outstanding as of
December 31, 2023 and 2022); aggregate liquidation preference of $8,162 as of December 31, 2023;
|
||||||||
|
Convertible Series A-1 Preferred Shares (NIS 0.09 par value per share, 13,334 shares authorized as of December 31, 2023 and 2022, 10,136 shares issued and
outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $2,443 as of December 31, 2023;
|
||||||||
|
Convertible Series A-2 Preferred Shares (NIS 0.09 par value per share, 22,223 shares authorized as of December 31, 2023 and 2022, 5,051 shares issued and
outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $2,763 as of December 31, 2023;
|
||||||||
|
Convertible Series A-3 Preferred Shares (NIS 0.09 par value per share, 8,889 shares authorized as of December 31, 2023 and 2022, 7,037 shares issued and
outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $2,887 as of December 31, 2023;
|
||||||||
|
Convertible Series A-4 Preferred Shares (NIS 0.09 par value per share, 90,556 and 0 shares authorized as of December 31, 2023 and 2022, respectively, 2,413** and 0
shares issued and outstanding as of December 31, 2023 and 2022, respectively); aggregate liquidation preference of $1,076 as of December 31, 2023;
|
||||||||
|
TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES
|
15,057
|
14,646
|
||||||
|
CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS
|
3,420
|
3,586
|
||||||
|
TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS
|
$
|
18,477
|
$
|
18,232
|
||||
|
CAPITAL DEFICIENCY:
Ordinary shares (($0.0009 par value per share, 22,222,222 shares authorized as of December 31, 2023 and 2022; 97,120
shares issued and outstanding as of December 31, 2023 and 2022)
|
*
|
*
|
||||||
|
Additional paid-in capital
|
11,335
|
11,204
|
||||||
|
Accumulated deficit
|
(26,811
|
)
|
(21,869
|
)
|
||||
|
TOTAL CAPITAL DEFICIENCY
|
$
|
(15,476
|
)
|
$
|
(10,665
|
)
|
||
|
TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY
|
$
|
3,001
|
$
|
7,567
|
||||
|
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE
PREFERRED SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY
|
$
|
5,256
|
$
|
9,333
|
||||
|
Year ended December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
OPERATING EXPENSES:
|
||||||||
|
Research and development, net (including $69 and $49 from related party, respectively)
|
$
|
3,708
|
$
|
3,226
|
||||
|
General and administrative (including $48 and $37 from related party, respectively)
|
973
|
634
|
||||||
|
TOTAL OPERATING EXPENSES
|
4,681
|
3,860
|
||||||
|
OPERATING LOSS
|
4,681
|
3,860
|
||||||
|
Financial expenses (income), net (including $83 and $0 from related party, respectively)
|
395
|
(396
|
)
|
|||||
|
LOSS BEFORE INCOME TAX
|
$
|
5,076
|
$
|
3,464
|
||||
|
INCOME TAX
|
32
|
24
|
||||||
|
NET LOSS FOR THE YEAR
|
$
|
5,108
|
$
|
3,488
|
||||
|
Attributable to:
|
||||||||
|
Equity holders of the Company
|
4,942
|
3,215
|
||||||
|
Non-controlling interests
|
166
|
273
|
||||||
|
$
|
5,108
|
$
|
3,488
|
|||||
|
LOSS PER SHARE, BASIC AND DILUTED
|
$
|
44.23
|
$
|
28.79
|
||||
|
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS
PER SHARE
|
111,726
|
111,686
|
||||||
|
Redeemable Convertible Preferred Shares
|
Ordinary shares
|
Additional
paid-in Capital |
Accumulated deficit
|
Total capital deficiency
|
Total redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital
deficiency
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Series A preferred shares
|
Series A-1 preferred shares
|
Series A-2 preferred shares
|
Series A-3 preferred shares
|
Series A-4 preferred shares
|
Contingently redeemable non-controlling
interests
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Shares
|
Amount
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE AT JANUARY 1, 2022
|
43,121
|
$
|
7,307
|
10,136
|
$
|
2,392
|
-
|
-
|
-
|
-
|
-
|
-
|
$
|
3,859
|
97,074
|
*
|
$
|
11,007
|
$
|
(18,654
|
)
|
$
|
(7,647
|
)
|
$
|
5,911
|
||||||||||||||||||||||||||||||||||||||||||
|
CHANGES DURING 2022:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance of Preferred A-2 shares, net of issuance cost, see Note 9(b)
|
5,051
|
2,264
|
2,264
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Conversion of simple agreements for future equity (SAFE) to Preferred A-3 shares, see Note 7
|
7,037
|
2,683
|
69
|
69
|
2,752
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exercise of options
|
46
|
*
|
3
|
3
|
3
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Share-based compensation
|
125
|
125
|
125
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Net loss
|
(273
|
)
|
(3,215
|
)
|
(3,215
|
)
|
(3,488
|
)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE AT DECEMBER 31, 2022
|
43,121
|
$
|
7,307
|
10,136
|
$
|
2,392
|
5,051
|
$
|
2,264
|
7,037
|
$
|
2,683
|
-
|
-
|
$
|
3,586
|
97,120
|
* |
$
|
11,204
|
$
|
(21,869
|
)
|
$
|
(10,665
|
)
|
$
|
7,567
|
||||||||||||||||||||||||||||||||||||||||
|
CHANGES DURING 2023:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Issuance of Preferred A-4 shares, net of issuance cost, see Note 9(b)
|
2,413
|
411
|
1
|
1
|
412
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Share-based compensation
|
130
|
130
|
130
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Net loss
|
(166
|
)
|
(4,942
|
)
|
(4,942
|
)
|
(5,108
|
)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BALANCE AT DECEMBER 31, 2023
|
43,121
|
$
|
7,307
|
10,136
|
$
|
2,392
|
5,051
|
$
|
2,264
|
7,037
|
$
|
2,683
|
2,413
|
$
|
411
|
$
|
3,420
|
97,120
|
* |
$
|
11,335
|
$
|
(26,811
|
)
|
$
|
(15,476
|
)
|
$
|
3,001
|
|||||||||||||||||||||||||||||||||||||||
|
Year ended December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
|
Net loss
|
$
|
(5,108
|
)
|
$
|
(3,488
|
)
|
||
|
Adjustments required to reconcile loss to net cash used in operating activities:
|
||||||||
|
Depreciation
|
45
|
57
|
||||||
|
Share-based compensation expenses
|
130
|
125
|
||||||
|
Non-cash financial expenses
|
318
|
(268
|
)
|
|||||
|
Gain on disposal of property and equipment
|
(1
|
)
|
-
|
|||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Increase (decrease) in prepaid expenses
|
(329
|
)
|
415
|
|||||
|
Increase (decrease) in other receivables
|
18
|
(40
|
)
|
|||||
|
Increase (decrease) in trade payable
|
79
|
(38
|
)
|
|||||
|
Net change in operating lease
|
6
|
(34
|
)
|
|||||
|
Increase (decrease) in employee related obligations
|
(46
|
)
|
(53
|
)
|
||||
|
Increase (decrease) in accrued expenses
|
359
|
(11
|
)
|
|||||
|
Net cash used in operating activities
|
(4,529
|
)
|
(3,335
|
)
|
||||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
|
Proceeds from long-term deposits
|
-
|
16
|
||||||
|
Investment in short-term deposit
|
-
|
(500
|
)
|
|||||
|
Proceeds from short-term deposit
|
507
|
-
|
||||||
|
Purchase of property and equipment
|
(12
|
)
|
(40
|
)
|
||||
|
Proceeds from sale of property and equipment
|
78
|
-
|
||||||
|
Net cash provided by (used in (investing activities
|
573
|
(524
|
)
|
|||||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
|
Proceeds from issuance of preferred shares and warrants, net of issuance costs
|
522
|
2,749
|
||||||
|
Exercise of options
|
-
|
3
|
||||||
|
Net cash provided by financing activities
|
522
|
2,752
|
||||||
|
DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
|
(3,434
|
)
|
(1,107
|
)
|
||||
|
EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
|
(230
|
)
|
(667
|
)
|
||||
|
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR
|
8,309
|
10,083
|
||||||
|
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR
|
$
|
4,645
|
$
|
8,309
|
||||
|
Year ended December 31
|
||||||||
|
2023
|
2022 | |||||||
|
Appendix A – RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS:
|
||||||||
|
Cash and cash equivalents
|
4,595
|
8,259
|
||||||
|
Restricted cash
|
50
|
50
|
||||||
|
TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS
|
$
|
4,645
|
$
|
8,309
|
||||
|
Appendix B -
SUPPLEMENTARY INFORMATION:
|
||||||||
|
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
|
||||||||
|
Transition to ASC 842 - recognition of operating right of use assets and operating lease liabilities
|
$
|
-
|
$
|
391
|
||||
|
Conversion of SAFEs to preferred shares and warrants
|
$
|
-
|
$
|
2,683
|
||||
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
|
||||||||
|
Interest received
|
$
|
153
|
$
|
114
|
||||
| a. |
Silexion Therapeutics Ltd. (formerly known as Silenseed Ltd.) (hereinafter -"the Company") was incorporated in Israel and began its operations on November 30, 2008. Since its
incorporation, the Company has been engaged in one operating segment – the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming to stop the production of a specific pancreatic cancer-causing
protein known as the KRAS mutation. The Company’s long-lived assets are located in Israel.
|
| b. |
On April 28, 2021, the Company signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (GIBF) to establish a new company in China. On June 15, 2021 a company was
established in China, named Silenseed (China) Ltd (hereinafter - the "Subsidiary"). The Company owns 51% of the shares of the Subsidiary. The Subsidiary has not yet started significant operations as of December 31, 2023. The Company and
Silenseed (China) Ltd., together - “the Group” (see Note 9d).
|
| c. |
On April 3, 2024, the Company entered into an Amended and Restated Business Combination Agreement (hereinafter, “A&R BCA”) with Moringa acquisition Corp (the “SPAC“), Biomotion
Sciences, August M.S. Ltd. and Moringa Acquisition Merger Sub Corp (hereinafter - the “Business Combination”) which replaced an earlier business combination agreement, for further information see Note 15(a) and (b). Subsequently,
Biomotion Sciences changed its name to Silexion Therapeutics Corp (“New Silexion”).
|
| d. |
In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack,
Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas and other terrorist organizations.
|
| e. |
Going concern:
|
| a. |
Basis of presentation
|
| b. |
Use of estimates
|
| c. |
Functional currency
|
| d. |
Principles of consolidation
|
| e. |
Cash and cash equivalents
|
| f. |
Restricted cash
|
| g. |
Property and equipment:
|
|
%
|
|||
|
Computers and software
|
33
|
||
|
Laboratory and electronic equipment
|
15
|
||
|
Leasehold improvements *
|
15-40
|
| h. |
Employee rights upon retirement
|
| i. |
Fair value measurement
|
| Level 1: |
Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1
inputs.
|
| Level 2: |
Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.
|
| Level 3 |
Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
|
| j. |
Financial instruments issued
|
| k. |
Redeemable Non-controlling Interest
|
| l. |
Research and development expenses
|
| m. |
Share-based compensation
|
| n. |
Leases
|
| o. |
Loss per share
|
| p. |
Income taxes:
|
| 1) |
Deferred taxes
|
| 2) |
Uncertainty in income tax
|
| q. |
Concentration of credit risks
|
| r. |
Operating segments and geographical information:
|
| s. |
New accounting pronouncements:
|
| 1) |
In June 2022, the FASB issued ASU 2022-03 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU clarifies that a contractual restriction on
the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring
|
| 2) |
its fair value. The ASU also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The ASU also introduces new
disclosure requirements for equity securities subject to contractual sale restrictions. As an Emerging Growth Company, the ASU is effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years.
Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the effect that ASU 2022-03 will have on its consolidated
financial statements and related disclosures.
|
| 3) |
In November 2023, the FASB issued ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU improves reportable segments disclosure
requirements, primarily through enhanced disclosures about significant segment expenses. The ASU also require that a public entity that has a single reportable segment to provide all the disclosures required by the amendments and all
existing segment disclosures in Topic 280. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating this ASU to
determine its impact on the Company's segment disclosures.
|
| 4) |
In December, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories
for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU will be effective for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with
a retrospective option. The Company is in the process of assessing the impacts and method of adoption.
|
|
December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Cost:
|
||||||||
|
Computers
|
$
|
75
|
$
|
67
|
||||
|
Laboratory and electronic equipment
|
-
|
274
|
||||||
|
Office furniture
|
2
|
2
|
||||||
|
Communication equipment
|
3
|
3
|
||||||
|
Leasehold improvements
|
56
|
52
|
||||||
|
$
|
136
|
$
|
398
|
|||||
|
Accumulated depreciation:
|
||||||||
|
Computers
|
55
|
41
|
||||||
|
Laboratory and electronic equipment
|
-
|
179
|
||||||
|
Office furniture
|
2
|
1
|
||||||
|
Communication equipment
|
3
|
3
|
||||||
|
Leasehold improvements
|
27
|
15
|
||||||
|
$
|
87
|
$
|
239
|
|||||
|
Property and equipment, net
|
$
|
49
|
$
|
159
|
||||
|
Year Ended December 31,
|
||||||||
|
2023
|
2022
|
|||||||
|
Fixed payments and variable payments that depend on an index or rate:
|
||||||||
|
Office and operational lease expenses
|
$
|
131
|
$
|
132
|
||||
|
Variable lease cost (included in the operating lease costs)
|
$
|
9
|
$
|
3
|
||||
|
Total operating lease costs
|
$
|
140
|
$
|
135
|
||||
|
Year Ended December 31,
|
||||||||
|
2023
|
2022
|
|||||||
|
Office and operational spaces lease expenses
|
$
|
101
|
$
|
119
|
||||
|
Year Ended December 31,
|
||||||||
|
2023
|
2022
|
|||||||
|
Operating lease right-of-use assets
|
$
|
198
|
$
|
305
|
||||
|
Operating lease liabilities
|
$
|
171
|
$
|
271
|
||||
|
Weighted average remaining lease term (years)
|
1.58
|
2.58
|
||||||
|
Weighted average discount rate
|
12.69
|
%
|
12.69
|
%
|
||||
|
Operating
lease liabilities
|
||||
|
2024
|
$
|
117
|
||
|
2025
|
68
|
|||
|
Total undiscounted lease payments
|
$
|
185
|
||
|
Less - imputed interest
|
$
|
14
|
||
|
Present value of lease liabilities
|
$
|
171
|
||
| a. |
Research and development expenses, net:
|
|
Year ended December 31,
|
||||||||
|
2023
|
2022
|
|||||||
|
Payroll and related expenses
|
$
|
973
|
$
|
1,192
|
||||
|
Subcontractors and consultants
|
2,467
|
1,595
|
||||||
|
Materials
|
13
|
191
|
||||||
|
Rent and maintenance
|
160
|
175
|
||||||
|
Travel expenses
|
37
|
42
|
||||||
|
Other
|
58
|
31
|
||||||
|
$
|
3,708
|
$
|
3,226
|
|||||
| b. |
General and administrative expenses:
|
|
Payroll and related expenses
|
$
|
356
|
$
|
219
|
||||
|
Professional services
|
386
|
197
|
||||||
|
Depreciation
|
45
|
57
|
||||||
|
Rent and maintenance
|
86
|
71
|
||||||
|
Patent registration
|
22
|
32
|
||||||
|
Travel expenses
|
31
|
-
|
||||||
|
Other
|
47
|
58
|
||||||
|
$
|
973
|
$
|
634
|
| c. |
Financial expense, net:
|
|
Change in fair value of financial liabilities measured at fair value
|
$
|
86
|
$
|
(1,017
|
)
|
|||
|
Issuance costs
|
3
|
84
|
||||||
|
Interest income
|
(153
|
)
|
(114
|
)
|
||||
|
Foreign currency exchange loss, net
|
453
|
650
|
||||||
|
Other
|
6
|
1
|
||||||
|
Total financial expense (income), net
|
$
|
395
|
$
|
(396
|
)
|
| a. |
In connection with the Series A-2 Preferred Shares (see Note 9(b)), the Company issued warrants to acquire 10,329 Series A-2 Preferred Shares to various investors, including 5,278
warrants issued as part of the converted SAFE (see Note 9(b)). These warrants feature an exercise price of $547.047 per share and expired during 2023. As of December 31, 2022, there are 10,329 outstanding warrants. As of December 31,
2023, all warrants are expired.
|
| b. |
Concerning the Series A-4 Preferred Shares (see Note 9(b)), the Company issued warrants to acquire 2,413 Series A-4 Preferred Shares to various investors, with an exercise price of
$222.921 per share and an expiration date of May 30, 2025. Issuance expenses amounted to $3. As of December 31, 2023, there are outstanding warrants of 2,413. Regarding the warrants issued to the subsidiary see Note 9(b)(2).
|
| a. |
As of December 31, 2023 and 2022, the share capital is composed of 0.09 NIS par value shares, as follows:
|
|
December 31, 2023
|
||||||||||||||||
|
Authorized
|
Issued and paid
|
Carrying
Value |
Liquidation
Preference |
|||||||||||||
|
Ordinary Shares
|
22,222,222
|
97,120
|
$
|
4,685
|
||||||||||||
|
Preferred A Shares
|
56,667
|
43,121
|
$
|
7,307
|
$
|
8,162
|
||||||||||
|
Preferred A-1 Shares
|
13,334
|
10,136
|
$
|
2,392
|
$
|
2,443
|
||||||||||
|
Preferred A-2 Shares
|
22,223
|
5,051
|
$
|
2,264
|
$
|
2,763
|
||||||||||
|
Preferred A-3 Shares
|
8,889
|
7,037
|
$
|
2,683
|
$
|
2,887
|
||||||||||
|
Preferred A-4 Shares
|
90,556
|
2,413
|
$
|
411
|
$
|
1,076
|
||||||||||
|
December 31, 2022
|
||||||||||||||||
|
Authorized
|
Issued and paid
|
Carrying
Value |
Liquidation
Preference |
|||||||||||||
|
Ordinary Shares
|
22,222,222
|
97,120
|
$
|
4,685
|
||||||||||||
|
Preferred A Shares
|
56,667
|
43,121
|
$
|
7,307
|
$
|
8,162
|
||||||||||
|
Preferred A-1 Shares
|
13,334
|
10,136
|
$
|
2,392
|
$
|
2,443
|
||||||||||
|
Preferred A-2 Shares
|
22,223
|
5,051
|
$
|
2,264
|
$
|
2,763
|
||||||||||
|
Preferred A-3 Shares
|
8,889
|
7,037
|
$
|
2,683
|
$
|
2,887
|
||||||||||
| b. |
Issuance of shares:
|
| 1) |
On January 14, 2022, the Company signed an agreement to issue shares in consideration for an investment in the amount of $2,763. In return for this investment, the Company issued
5,051 Series A-2 Preferred Shares with a par value of NIS 0.09. Issuance expenses amounted to $14.
|
| 2) |
On May 30, 2023, the Company entered into an agreement to receive an investment in a total amount of $538. In exchange for this investment, the Company issued 2,413 Series A-4
Preferred Shares with a par value of NIS 0.09. Issuance expenses amounted to $16.
|
| c. |
Shareholders rights:
|
| 1) |
The Ordinary shares confer upon their holders the right to participate and vote in general shareholders meetings of the Company and to share in the distribution of dividends, if any
declared by the Company.
|
| a) |
Distribution Preference
|
| b) |
Liquidation Preference:
|
| c) |
Dividend Preference:
|
| d) |
Conversion Rights:
|
| d. |
Silenseed China Minority Equityholder Rights:
|
| a. |
Conversion ("Put/Call") Option: Either GIBF or the Company may elect that the equity rights of GIBF in the Subsidiary shall be exchanged for the most senior shares (i.e., preferred
shares) of the Company, consequently turning the Subsidiary into a wholly-owned subsidiary of the Company. The number of shares to be issued to GIBF upon such exchange shall be calculated by converting the total cash amount invested by
GIBF in the Subsidiary (the "Contribution Amount"), into the most senior class of shares of the Company as of May 30, 2023, based on a pre-money valuation of the Company of US$20 million on a fully diluted basis as of September 1, 2023,
or later, as shall be mutually agreed between the parties.
|
| b. |
"Company Exit Event" means the consummation of: (i) an initial public offering of Company, in a stock exchange, directly or via a SPAC (or similar methods); (ii) the sale of all or
substantially all of the securities or assets of the Company (or an exclusive license with respect to all or substantially all of the assets of Company); (iii) a merger or acquisition of the Company (following which existing shareholders
as of immediately prior to such transaction hold less than 50% of the voting power of the surviving or acquiring entity); (iv) sale of at least 50% of the means of control or assets of the Company; (v) liquidation, dissolution or winding
up of the Company; or (vi) at any time upon a party’s written notice, provided, however that the exercise of such right by the Company shall be subject to GIBF’s written consent, which shall not be unreasonably withheld.
|
| 1) |
Anti-Dilution Protection: If the Subsidiary issues any additional equity rights in the Subsidiary to a third-party investor in the next two equity investment
rounds of the Subsidiary, reflecting a purchase price per equity right lower than the purchase price per equity right paid by GIBF, GIBF will be issued additional equity rights of the Subsidiary for no consideration, based on a broad
based weighted average formula.
|
| 2) |
Registration Rights: GIBF shall be entitled to the same rights to register its equity rights in the Subsidiary as part of an IPO of the Subsidiary, as granted to
Company, on a pro-rata basis.
|
| 3) |
Liquidation Preference: In the event of an IPO in which the Subsidiary's valuation is at least $200 million or an Exit Event (as defined in the Subsidiary’s
Articles), GIBF shall be entitled to be paid out of the assets legally available for distribution to equity holders of the Subsidiary (the "Distributable Proceeds"), prior to any payment made to any other equity holder, an amount in cash
equal to the Contribution Amount (the "Preference Amount"). Following payment of the Preference Amount, any remaining Distributable Proceeds shall be distributed among all holders of equity rights excluding GIBF, on a pro-rata basis,
provided that GIBF shall have the right to waive its right to receive the Preference Amount, in which case all Distributable Proceeds shall be distributed among all equity holders of the Subsidiary on a pari passu and pro rata basis.
|
| 4) |
Other rights, such as right of first refusal for GIBF to purchase the Company’s equity rights in the Subsidiary if the Company proposes to sell or receives an offer to sell its equity
rights; a right of co-sale for GIBF to participate in a proposed sale of the Company’s equity rights in the Subsidiary on a pro-rata basis; a preemptive right for both investors to participate in the issuance of new securities by the
Subsidiary until the consummation of an IPO or an Exit Event (as defined in the Subsidiary’s Articles).
|
| a. |
Corporate taxation in Israel
|
| b. |
Income taxes on non-Israeli subsidiary
|
| c. |
Tax loss carryforwards
|
|
Year ended December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Israel
|
$
|
4,769
|
$
|
2,929
|
||||
|
Subsidiary outside of Israel
|
307
|
535
|
||||||
|
Total
|
$
|
5,076
|
$
|
3,464
|
||||
| d. |
Uncertainty in income tax
|
| e. |
Tax rate reconciliation
|
|
Year ended December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Loss before income taxes
|
$
|
(5,076
|
)
|
$
|
(3,464
|
)
|
||
|
Statutory tax rate
|
23
|
%
|
23
|
%
|
||||
|
Computed “expected” tax income
|
(1,167
|
)
|
(797
|
)
|
||||
|
Exchange rate differences
|
120
|
588
|
||||||
|
Non-deductible share-based compensation
|
30
|
29
|
||||||
|
Non-deductible financial instruments valuation
|
21
|
(215
|
)
|
|||||
|
Effect of other non-deductible differences
|
112
|
162
|
||||||
|
Change in valuation allowance
|
922
|
268
|
||||||
|
Subsidiary tax rate differences
|
(6
|
)
|
(11
|
)
|
||||
|
Reported taxes on income
|
$
|
32
|
$
|
24
|
||||
| f. |
Deferred tax
|
|
December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Deferred tax assets
|
||||||||
|
Operating loss carryforwards
|
$
|
4,405
|
3,752
|
|||||
|
Research and development
|
780
|
592
|
||||||
|
Accrued expenses
|
304
|
219
|
||||||
|
Lease liability
|
39
|
62
|
||||||
|
Other
|
25
|
30
|
||||||
|
Total deferred tax assets
|
$
|
5,553
|
$
|
4,655
|
||||
|
Deferred tax liabilities
|
||||||||
|
Right of use asset
|
(46
|
)
|
(70
|
)
|
||||
|
Total deferred tax liabilities
|
$
|
(46
|
)
|
$
|
(70
|
)
|
||
|
Valuation allowance
|
$
|
(5,507
|
)
|
$
|
(4,585
|
)
|
||
|
Deferred tax assets, net of valuation allowance
|
$
|
-
|
$
|
-
|
||||
| g. |
Roll forward of valuation allowance:
|
|
Balance as of December 31, 2021
|
$
|
(4,317
|
)
|
|
|
Additions
|
(268
|
)
|
||
|
Balance as of December 31, 2022
|
$
|
(4,585
|
)
|
|
|
Additions
|
(922
|
)
|
||
|
Balance as of December 31, 2023
|
$
|
(5,507
|
)
|
| h. |
Income tax assessments
|
| 1) |
Warrants to service provider
|
| 2) |
Employee Stock Option Plan
|
|
Number of options
|
Weighted-average exercise price (in U.S. dollars)
|
Weighted- average remaining contractual term
(in years)
|
Aggregate
intrinsic
value
|
|||||||||||||
|
Outstanding at December 31, 2022
|
54,135
|
$
|
38.93
|
5.88
|
$
|
144
|
||||||||||
|
Granted
|
-
|
$
|
-
|
-
|
$
|
-
|
||||||||||
|
Exercised
|
-
|
$
|
-
|
-
|
$
|
-
|
||||||||||
|
Forfeited
|
-
|
$
|
-
|
-
|
$
|
-
|
||||||||||
|
Expired
|
(221
|
)
|
$
|
(38.41
|
)
|
-
|
$
|
-
|
||||||||
|
Outstanding at December 31, 2023
|
53,914
|
$
|
38.94
|
4.88
|
$
|
316
|
||||||||||
|
Exercisable at December 31, 2023
|
39,340
|
$
|
30.95
|
3.62
|
$
|
316
|
||||||||||
|
Vested and expected to vest at December 31, 2023
|
53,914
|
$
|
38.94
|
4.88
|
$
|
316
|
||||||||||
|
Number of options
|
Weighted-average exercise price (in U.S. dollars)
|
Weighted- average remaining contractual term
(in years)
|
Aggregate
intrinsic
value
|
|||||||||||||
|
Outstanding at December 31, 2021
|
31,897
|
$
|
23.88
|
4.46
|
$
|
493
|
||||||||||
|
Granted
|
24,119
|
$
|
60.51
|
9.98
|
$
|
-
|
||||||||||
|
Exercised
|
(46
|
)
|
$
|
60.49
|
(8.22
|
)
|
$
|
-
|
||||||||
|
Forfeited
|
(1,128
|
)
|
$
|
60.50
|
(9.18
|
)
|
$
|
-
|
||||||||
|
Expired
|
(707
|
)
|
$
|
(61.01
|
)
|
-
|
$
|
-
|
||||||||
|
Outstanding at December 31, 2022
|
54,135
|
$
|
38.93
|
5.88
|
$
|
144
|
||||||||||
|
Exercisable at December 31, 2022
|
30,677
|
$
|
22.46
|
3.29
|
$
|
144
|
||||||||||
|
Vested and expected to vest at December 31, 2022
|
54,135
|
$
|
38.93
|
5.88
|
$
|
144
|
||||||||||
|
Year ended December 31, 2022
|
|||
|
Employees
|
|||
|
Expected term (in years)
|
6.05 - 10.00
|
||
|
Expected volatility
|
82.97% - 88.45%
|
|
|
|
Risk-free interest rate
|
2.31% - 2.90%
|
|
|
|
Expected dividend yield
|
0.00%
|
||
|
Exercise price
|
$60.51
|
||
|
Non-Employees
|
|||
|
Expected term (in years)
|
9.78
|
||
|
Expected volatility
|
88.46%
|
|
|
|
Risk-free interest rate
|
2.31%
|
|
|
|
Expected dividend yield
|
0.00%
|
|
|
|
Exercise price
|
$60.51
|
|
Year ended December 31, 2022
|
||||||||||
|
Award amount
|
Exercise price
|
Vesting period
|
Expiration
|
|||||||
|
Employees
|
23,234
|
60.51
|
up to 4 years
|
10 years
|
||||||
|
Non-employees
|
886
|
60.51
|
Immediate
|
10 years
|
||||||
|
Total granted
|
24,120
|
|||||||||
|
Number of
options
|
Weighted-average grant-date fair
value price
|
|||||||
|
Outstanding at December 31, 2022
|
23,393
|
$
|
21.67
|
|||||
|
Granted
|
-
|
$
|
-
|
|||||
|
Vested
|
(8,827
|
)
|
$
|
21.60
|
||||
|
Forfeited
|
-
|
$
|
-
|
|||||
|
Outstanding at December 31, 2023
|
14,566
|
$
|
21.72
|
|||||
|
Outstanding at December 31, 2021
|
1,976
|
$
|
17.33
|
|||||
|
Granted
|
23,234
|
$
|
21.76
|
|||||
|
Vested
|
(690
|
)
|
$
|
16.04
|
||||
|
Forfeited
|
(1,127
|
)
|
$
|
19.34
|
||||
|
Outstanding at December 31, 2022
|
23,393
|
$
|
21.67
|
|||||
|
Number of
options
|
Weighted-average grant-date fair
value price
|
|||||||
|
Outstanding at December 31, 2022
|
59
|
$
|
11.21
|
|||||
|
Granted
|
-
|
$
|
-
|
|||||
|
Vested
|
(59
|
)
|
$
|
11.21
|
||||
|
Forfeited
|
-
|
$
|
-
|
|||||
|
Outstanding at December 31, 2023
|
-
|
$
|
-
|
|||||
|
Outstanding at December 31, 2021
|
135
|
$
|
11.09
|
|||||
|
Granted
|
886
|
$
|
26.96
|
|||||
|
Vested
|
(962
|
)
|
$
|
25.69
|
||||
|
Forfeited
|
-
|
$
|
-
|
|||||
|
Outstanding at December 31, 2022
|
59
|
$
|
11.21
|
|||||
|
Year ended December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Research and development
|
$
|
78
|
$
|
60
|
||||
|
General and administrative
|
52
|
65
|
||||||
|
$
|
130
|
$
|
125
|
|||||
|
December 31, 2023
|
||||||||
|
Level 3
|
Total
|
|||||||
|
Financial Liabilities
|
||||||||
|
Warrants to preferred shares
|
$
|
200
|
$
|
200
|
||||
|
December 31, 2022
|
||||||||
|
Level 3
|
Total
|
|||||||
|
Financial Liabilities
|
||||||||
|
Warrants to preferred shares
|
$
|
3
|
$
|
3
|
||||
|
2023
|
2022
|
|||||||||||
|
Warrants
|
Warrants
|
SAFE
|
||||||||||
|
Fair value at the beginning of the year
|
$
|
3
|
$
|
-
|
$
|
3,204
|
||||||
|
Issuance
|
111
|
1,020
|
-
|
|||||||||
|
Change in fair value
|
86
|
(1,017
|
)
|
-
|
||||||||
|
Conversion to equity
|
-
|
-
|
(3,204
|
) |
||||||||
|
Fair value at the end of the year
|
$
|
200
|
$
|
3
|
$
|
-
|
||||||
|
December 31
|
||||||||
|
|
2023
|
2022
|
||||||
|
Expected volatility
|
73.8
|
%
|
87.3
|
%
|
||||
|
Assumptions regarding the price of the underlying shares:
|
||||||||
|
Probability of an IPO scenario (including de-SPAC transaction)
|
25
|
%
|
-
|
|||||
|
Expected time to IPO (including de-SPAC transaction) (years)
|
0.414
|
-
|
||||||
|
Probability of other liquidation events
|
75
|
%
|
100
|
%
|
||||
|
Expected time to liquidation (years)
|
2.75
|
3.00
|
||||||
|
Expected return on Equity
|
22
|
%
|
23
|
%
|
||||
|
Year ended December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Numerator:
|
||||||||
|
Net loss for the year
|
$
|
5,108
|
$
|
3,488
|
||||
|
Net loss attributable to ordinary shareholders, basic and diluted:
|
$
|
4,942
|
$
|
3,215
|
||||
|
Denominator:
|
||||||||
|
Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted
|
111,726
|
111,686
|
||||||
|
Net loss per share attributable to ordinary shareholders, basic and diluted
|
$
|
44.23
|
$
|
28.79
|
||||
| - |
Redeemable convertible preferred shares (see Note 9);
|
| - |
Warrants to purchase redeemable convertible preferred shares (see Note 8);
|
| - |
Simple agreements for future equity (see Note 7);
|
| - |
Share-based compensation issuable at substantial consideration (see Note 11).
|
| a. |
Transactions:
|
|
Year ended December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Share-based compensation included in research and development expenses
|
$
|
69
|
$
|
49
|
||||
|
Share-based compensation included in general and administrative expenses
|
$
|
48
|
$
|
37
|
||||
|
Financial expenses
|
$
|
83
|
$
|
-
|
||||
| b. |
Balances:
|
|
December 31
|
||||||||
|
2023
|
2022
|
|||||||
|
Non-Current liabilities —
|
||||||||
|
Warrants to preferred shares
|
$
|
186
|
$
|
-
|
||||
| a. |
On February 21, 2024, the Company entered into a business combination agreement with Moringa Acquisition Corp. (the “SPAC”), an exempted company incorporated under the Laws of the
Cayman Islands whose class A ordinary shares (as well as other instruments) are listed for trade on the Nasdaq Global Market (NASDAQ:MACA), and April.M.G. Ltd. (the “April Merger Sub”), a limited liability company organized under the
laws of the State of Israel and a wholly-owned subsidiary of the SPAC (the “Original BCA”). According to the Original BCA, April Merger Sub would merge with and into the Company, with the
Company continuing as the surviving entity and a wholly-owned subsidiary of the SPAC, and with the SPAC continuing as a public company following the completion of the merger and with its securities continuing to be traded on Nasdaq.
|
| b. |
On April 3, 2024, the SPAC and the Company restructured the transactions contemplated under the Original BCA by entering into the A&R BCA by and among Biomotion Sciences, a
Cayman Islands exempted company (the “New Pubco”), August M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Pubco (the “Merger Sub 1”), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly
owned subsidiary of New Pubco (the “Merger Sub 2”), the SPAC and the Company. The A&R BCA amends and restates, in its entirety, the Original BCA.
|
| c. |
For information regarding the reverse share split, see Note 1 (c)
|